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Lipopolysaccharide (LPS), also known as endotoxin, is a constituent 
of the outer membrane of Gram -negative bacteria which is toxic for 
humans and other animals. LPS probably plays a key part in the 
pathogenesis of Gram -negative bacteraemia and sepsis syndrome in 
humans. Cross- reactive antibodies to LPS may play a part in natural 
host defences, and may also be useful in the treatment of Gram - 
negative bacteraemia and sepsis syndrome. The structure of LPS, its 
toxicity, its role in Gram -negative bacteraemia and sepsis syndrome 
in humans, and the potential value of cross -reactive antibodies to 
LPS are reviewed. 
The antibody response in recipients of typhoid vaccine was studied, 
with particular reference to the possibility that typhoid vaccine 
might induce the production of antibodies to the core region of LPS 
(LPS- core). In most recipients however the response observed was 
directed against specific antigens. 
Urine samples from patients with suspected UTI were tested for IgG 
antibodies to LPS -core. Such antibodies were found to be associated 
with the presence of bacteriuria, although the association was not 
strong enough for antibody assay to be useful as a diagnostic test. 
Total urinary IgG was equally strongly associated with bacteriuria. 
This suggested that the antibodies were probably present because of 
non -specific leakage of serum components into the urine as a result 
of inflammation. 
A large number of murine monoclonal antibodies (MAbs) to LPS -core had 
been produced by a collaborative group in Edinburgh and Basel, in the 
hope of producing a cross -reactive MAb which would be useful 
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therapeutically. The binding of some of these MAbs to a collection 
of blood- culture isolates of Gram -negative bacteria was studied. The 
principal method used was immunoblotting with LPS prepared by 
proteinase K digestion. These studies showed that, in general, the 
MAbs bound to E. coli but not to other Enterobacteriaceae commonly 
isolated from blood- cultures. 
There was a suggestion from initial studies with MAbs that some were 
specific for particular core types of E. coli. This was investigated 
by reacting 79 blood- culture isolates of E. coli, together with 
control strains, with 61 MAbs in an enzyme -linked immuvosorbent assay 
(ELISA). This allowed the identification of MAbs specific for E. coli 
core types R1, R2, and R3. The specificity of these MAbs for LPS -core 
was confirmed by imnunoblotting. The MAbs were used to determine the 
core -type of E. coli strains from blood, urine, and faeces. The 
association of core type with 0 type, K type, serum resistance, and 
susceptibility to rough -specific phage was studied. R1 was the 
commonest core type among E. coli from all sites, and was associated 
with the common 0 types. 
Some cross -reactive MAbs had been produced which, unexpectedly, did 
not react with LPS -core. Three of these MAbs were investigated. One 
appeared to react with enterobacterial common antigen. The other two 
reacted with a low- molecular weight protein, probably the Braun 
lipoprotein. 
Small quantities of HA -1A (Centoxin), a human MAb which is said to 
react with lipid A, became available towards the end of the project. 
The MAb bound to a variety of materials, including some Gram -positive 
bacteria, and could not be shown to react with LPS. 
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Lipopolysaccharide (LPS) is an essential component of the outer 
membrane of Gram -negative bacteria. It is a molecule which has 
attracted an enormous amount of scientific attention because of its 
toxicity to humans and other mammals, and in this context it is 
referred to as "endotoxin ". LPS (or endotoxin) may be an extremely 
important mediator in Gram -negative bacteraemia and sepsis syndrome, 
and for this reason may be a key target for therapies aimed at such 
diseases. 
This thesis is concerned with cross -reactive antibody to LPS. The 
experimental work consists of studies of the binding of antibodies to 
LPS. To put this work in perspective the introduction reviews the 
structure of LPS, its toxicity, the evidence that this toxicity may 
be important in Gram -negative bacteraemia and sepsis syndrome, and 
the evidence that cross -reactive antibodies to LPS may be beneficial. 
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LPs STRUCTURE 
LPS consists of three regions: lipid A, core oligosaccharide, and 0 
polysaccharide, as shown schematically in figure 1.1. Lipid A, which 
is the innermost part of the molecule, is the most conserved part, 
and the part most clearly associated with toxicity. The 0 
polysaccharide, which forms the outer part of the molecule, is the 
most variable and the most immunogenic. The core region, which is 
central to the molecule also lies metaphorically between lipid A and 
0 polysaccharide with regard to immunogenicity, variability and 
association with toxicity. Three major reviews of LPS structure have 
been published recently [29,142,193]. 
LIPID A 
Lipid A forms the inner -most part of the molecule and is inserted 
into the outer leaflet of the outer membrane of Gram -negative 
bacteria. Lipid A makes up a large proportion of the outer leaflet, 
and must be of structural and functional significance to Gram - 
negative bacteria. 
The chemical structure of lipid A from E. coli is shown in figure 
1.2. It has a hydrophilic backbone made up of a 1,4'- 
bisphosphorylated ß- 1 ,6- D- glucosaminyl- D- glucosamine disaccharide. 
Four acyl residues are attached directly to the glucosamine residues, 
and two of these acyl residues are themselves esterified with further 
acyl groups, forming acyloxyacyl residues. 
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Figure 1.2 Covalent structure of lipid A from E. coli (A) and 
Salmonella minnesota (B) [195]. Numbers in circles refer to the 
number of carbon atoms in the acyl chains. 
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Lipid A from other organisms shares the same overall structure. 
Among the endotoxic lipid A structures from enterobacteriaceae, 
structural variations concern the number of carbon atoms in the 
hydrocarbon chains, the type and distribution of the acyloxyacyl 
residues, and additional substitution of the phosphoryl residues. 
Salmonella lipid A, for example, has an additional 16 carbon acyl 
group forming a third acyloxyacyl group, and the two phosphoryl 
groups are substituted with phosphorylethanolamine and 4- deoxy -4- 
amino-L-arabinopyranose respectively (figure 1.2). Studies with 
synthetic lipid A suggest that the minimal structure for full 
endotoxic activity is the bisphosphorylated glucosamine disaccharide 
with 5 or 6 acyl residues including one acyloxyacyl residue [29]. 
Lipid A structures which have little or no endotoxic activity are 
found in some bacteria, particularly the photosynthetic 
Rhodospirillaceae (reviewed by Mayer et al [142,143]). Some of these 
lipid A structures share the 1,4'- bisphosphorylated 
glucosaminyl-D-glucosamine disaccharide backbone. They may have the 
amide- linked 3- hydroxy fatty acids replaced partially or completely 
by 3-oxo fatty acids, as is found in Rhodobacter spp.. 
Alternatively the glucosamine disaccharide may have an additional 
glucosamine residue attached, as in Rhodocyclus tenius. Bacteroides 
fragilis Lipid A, which is 100 to 1000 times less toxic than lipid A 
from Enterobacteriaceae, lacks one of the phosphate residues and has 
an average of only 5 fatty acid residues per glucosamine disaccharide 
[131]. 
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A further group of lipid A variants with a backbone containing one or 
two residues of diaminoglucose are referred to as lipid ADAG. Lipid 
ADAG has been found in at least 25 different species, including some 
pathogens such as Brucella abortus [160]. The disaccharide form of 
lipid ADAG, as found in Pseudomonas diminuta [107] has endotoxic 
properties, while the monosaccharide form, as found in 
Rhodopseudomonas viridis [77], does not. 
LPS--CORE 
Attached to the C6 hydroxy residue of the non- reducing glucosamine of 
lipid A is the core oligosaccharide or "LPS- core ". The structure of 
LPS -core can be subdivided into inner and outer regions. 
The inner core typically consists of two or three KDO (keto- deoxy- 
octulosonic acid, now known as 3- deoxy -D- manno -2- octulosonate) 
residues and two or three heptose residues. The KDO residues are 
linked together, one of them being directly linked to lipid A. The 
inner core is, like lipid A, highly conserved, at least among 
Enterobacteriaceae, and Pseudomonas. There is however variation in 
the inner core structures of widely divergent bacteria, as shown in 
figure 1.3. In some species, such as Acínetobacter calcoaceticus 
[111], a KDO analogue is thought to occupy the linking position 
between lipid A and the outer core, but KDO is present also. 
The outer core is typically made up of 3, 4 or 5 hexose and 
hexosamine residues, and is more variable than the inner core. There 
are 4 variants (termed R1 - R4) described in wild -type P. coli, and 
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Figure 1.3 Covalent structures of the inner core region [142]. 
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Figure 1.4 Covalent structures of LPS -cores of E. coli and 
Salmonella [101]. 
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other variants noted in "laboratory" strains of E. coli (cg E. coli 
K12 and J5) and in Salmonella [101], Citrobacter [197,198], Proteus 
[192] and Pseudomonas [200]. Examples of some core structures which 
show a constant inner region but variable outer region are shown in 
figure 1.4. In some non -enterobacterial species the outer core 
region may be completely missing [142]. 
The analytical techniques available to establish structures of LPS- 
core in intact LPS are difficult, indirect, and subject to artifacts. 
The core structures shown in figures 1.3 and 1.4 cannot therefore be 
regarded as definitive [193]. In particular, the presence or absence 
of the third KDO and the third heptose residue is difficult to 
establish. It should also be noted that the apparent conservation of 
LPS -core structure may in part be a reflection of the limited number 
of strains whose core structures have been determined. 
Mutants have been obtained from several bacteria (notably E. coli and 
Salmonella minnesota) which express LPS with lipid A and LPS -core 
but no 0 polysaccharide. These mutants are referred to as "rough" 
mutants, as distinct from "smooth" wild -type organisms which have 
complete LPS structures. Rough mutants which have a complete LPS- 
core structure are referred to as Ra mutants, and their LPS is termed 
Ra LPS. Mutants with progressively smaller LPS core structures are 
termed Rb, Rc, Rd, and Re, as shown for Salmonella in figure 1.5. Re 
LPS is the smallest LPS structure found in viable bacteria, and 
therefore presumably the minimal structure required to perform the 
essential functions of LPS. Re LPS always contain lipid A and either 
one (or more usually two) KDO residues, or occasionally, (as in 
Acinetobacter, [30]) a KDO- analogue. 
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Figure 1.5 Covalent structures of the LPS -core region of rough 
mutants of Salmonella [29]. 
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0 ANTIGEN 
The third component of LPS is the 0 antigen. 0 antigen is made up of 
a number of repeating units of sugar residues. The actual sugar 
residues involved varies considerably among strains of even a single 
species of bacterium. For example there are some 150 different 0 
types of E coli. The repeating unit of the 0 antigen typically 
consists of up to five sugar residues which may be arranged in a 
linear or branching pattern. Many unusual sugars are found in 0 
antigens which are rarely found elsewhere [142]. In some organisms 
the 0 polysaccharide is absent or consists of only one or two 
repeating units, in which case the molecule is called LOS (Lipo- 
oligosaccharide) rather than LPS. 
Classic studies of 0 antigens of Salmonella and E. coli [110] 
involved analysis of the carbohydrate constituents of LPS and 
antisera produced in rabbits. The cross -reactions between sera were 
studied, and related to the carbohydrate constituents of the 0 
antigen. Cross -absorption studies were used to remove antibodies to 
common antigens, and therefore to identify specific 0 "factors" 
within the 0 antigen. These factors form the basis of the Kauffman - 
White scheme for the classification of Salmonella. 
0 antigen is thought of as the immunodominant part of the LPS 
molecule, and indeed may be the dominant antigen of many Gram - 
negative bacteria. The term "immunodominant" sugar was first used 
[134] to refer to the best inhibitor of a factor -antifactor reaction. 
Cross -absorption experiments of the type used to prepare antifactor 
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sera would effectively remove antibody to less diverse antigens such 
as LPS -core. The concept was therefore not based on an objective 
comparison of the responses to 0 antigen and other components of the 
organism, such as LPS -core. 
MOLECULAR MODELLING OF LPS 
The likely three- dimensional structures of Re LPS from E. coli have 
been calculated by Kastowsky et al [109]. In all, 19 different 
models consistent with the insertion of Re LPS into a highly ordered 
membrane were obtained. In all cases the diglucosamine backbone was 
found to be tilted by 53 ± 7° from the membrane normal, while the two 
glucosamine residues were parallel to the membrane normal. The 
calculated conformation of the two KDO residues was sensitive to the 
presence of cations, and could be either rigid (in the presence of 
divalent cations) or mobile (in the presence of monovalent cations). 
Similar calculation for a whole LPS molecule [108] suggest that the 
conformation of LPS -core is stable and roughly cylindrical. Some 
groups (e.g. some of the KDO carboxyl groups) which may be exposed in 
Re LPS are buried within the molecule. The 0- specific chain, in 
contrast, has a very variable conformation. 
Three- dimensional structures have also been calculated for the 
various outer core structures of E. coli and Salmonella, based on the 
accepted primary structures [103]. These calculations tend to suggest 
that the different core structures assume a similar overall 
conformation, despite the variation in sugar content and linkages. 
This may point to the functional determinants of LPS -core structure. 
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Consideration of three- dimensional structures is helpful in 
considering the epitopes to which antibodies to LPS -core may bind, as 
discussed in chapter 6. Molecular modelling may help to clarify the 
function of LPS both as a structural element in the bacterium and as 
endotoxin in the mammalian host. 
INTRA -STRAIN VARIABILITY OF LPS 
As well as variation between species and strains, there may be 
variation in the structure of LPS obtained from a single bacterial 
isolate. LPS prepared from a single bacterial culture shows 
heterogeneity in the length of the 0 polysaccharide chain, and 
includes some molecules completely lacking in 0 polysaccharide . 
Electrophoresis of LPS preparations from a single smooth bacterium in 
a polyacrylamide gel (frontispiece) yields a typical "ladder" pattern 
representing this heterogeneity [180]. The fastest moving band (shown 
at the bottom of the gel) consists of lipid A and LPS -core with no 0 
antigen, while each successive band above that represents LPS with 
the addition of one more 0 antigen repeating unit. 
Within lipid A and core there may also be variation, or 
"microheterogeneity " in the structures, which causes additional 
problems in attempts to define structures [142]. This may consist of 
incomplete substitution of some of the branching groups such as 
phosphate. 
In Pseudomonas aeruginosa there are two distinct forms of LPS present 
in wild -type strains. These two forms differ in the nature of the 0 
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repeating unit. The 0 polysaccharide of form A is the same in most 
Pseudomonas aeruginosa, while the 0 polysaccharide of form B is 
variable and accounts for the 0 typing antigen [125]. 
Conditions of growth may also affect the nature of the LPS produced 
by an individual organism. Nutrient limitation may increase the 
proportion of LPS molecules which lack 0 polysaccharide [165]. 
Duration of culture (or growth phase) can also alter the antigenicity 
and toxicity of isolated LPS [153]. In Yersinia enterocolitica the 
nature of the LPS expressed depends on the growth temperature and 
calcium concentration [50]. Growth conditions may therefore be 
crucial to the laboratory production of LPS for use in experiments 
which attempt to model clinical infection. 
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TOXICITY OF LPS 
LPS, also known in this context as endotoxin, is toxic to humans and 
other animals. This toxicity was initially observed following 
injection into animals, and the manifestations observed were fever, 
shock, death. More complex manifestations, such as the Shwartzman 
reaction and induction of tolerance may also be observed in whole 
animals. Unlike classic protein exotoxins there is no single 
specific action, but many different mechanisms which have been 
demonstrated in a wide variety of in -vitro systems [201]. These 
actions include the activation of complement and coagulation factors, 
and the stimulation of platelets (in rabbits), macrophages, 
neutrophils [61], and endothelial cells [250]. Assessing the 
significance of these actions of endotoxin is complicated by the many 
secondary effects that are produced, for example by activated 
complement components. 
Lipid A appears to be the minimal LPS structure required for 
endotoxic effect [29,75,193]. Free lipid A is however insoluble and 
lacks biological activity, but can be made soluble and biologically 
active by removing the cations which neutralise the negatively 
charged groups. 0 antigen and LPS -core are not in themselves toxic, 
but they do render the molecule water soluble (at least as micelles) 
and thus modulate the biological activity of lipid A, for example 
increasing the circulating life of LPS [73]. 
Early research on endotoxin stressed the importance on mediators 
released from leukocytes [256]. Modern researchers have returned to 
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this view [51,82,83], despite the demonstration of other actions of 
endotoxin. The key cell is thought to be the macrophage, which is 
triggered by endotoxin to produce cytokines which in turn are 
responsible for the toxic effects. 
The importance of macrophages is strongly supported by studies of a 
strain of C3H /HeJ mice (LPSd) which are genetically resistant to LPS. 
Transfer of macrophages from the LPS sensitive LPS mice restore LPS 
sensitivity in the galactosamine- sensitised model of endotoxicity 
[74]. 
Evidence for the central role of cytokines has been reviewed in 
detail recently [83, 136, 240]. Experimental endotoxaemia in animals 
and man leads to the appearance of Tumour Necrosis Factor (TNF), 
Interleukin (IL) -1 and IL -6 in the circulation, and these cytokines 
may also be detected in the circulation of patients with sepsis. The 
major source of these cytokines is thought to be the macrophage. 
TNF, IL -1, and IL -6 have been produced by recombinant DNA technology 
and have all been shown to be pyrogenic in animals. High doses of 
TNF or IL -1 independently can produce shock, and act synergistically 
when given together, leading to all the pathological features typical 
of endotoxic shock. TNF has also been shown to produce endotoxin -like 
effects in human volunteers. Antibodies to either IL -1 or TNF can 
protect against the toxic effects of endotoxin, as can a variety of 
other agents which block the production or action of these cytokines. 
TNF, IL -1 and IL -6 appear to interact with one another in a variety 
of ways. TNF and IL -1 stimulate the production of each other and of 
IL -6, while IL -6 impairs endotoxin - induced TNF and IL -1 production. 
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These interactions may explain why blockage of either TNF or IL -1 
action is sufficient to block endotoxic effects. 
The stimulation of macrophages to release cytokines probably involves 
specific receptors (Reviewed by Wright [260]). Three classes of 
receptor on macrophages can recognise endotoxins. Two of these (CD18 
and the scavenger receptor) mediate uptake and catabolism of the LPS. 
The third receptor, CD14, recognises complexes of LPS with the serum 
protein lipopolysaccharide binding protein (LBP). Binding of the 
LPS /LBP complex to CD14 appears to trigger the synthesis and 
secretion of TNF. The existence of specific receptors is compatible 
with finding that some lipid A analogues [247,248] and natural non- 
toxic lipid A structures [84] can block the effects of endotoxin. 
The stimulation of macrophages to produce Interleukins and TNF 
cannot explain all the effects of endotoxin. For example, the 
finding that a monoclonal antibody can block the lethal effect of 
experimental challenge with E. coli in mice without altering the 
pattern of TNF and IL -6 levels [218] points to the existence of other 
significant pathways. Among the many possible targets most current 
interest relates to the release of nitric oxide from endothelial 
cells [250] and interactions with neutrophlis and endothelial cells 
in the lung [61]. 
Although conventionally thought of as a toxin, it is also possible to 
regard LPS as the primary signal which animals use to trigger a 
protective response to invasive Gram -negative infection [127]. From 
this viewpoint the host response to endotoxin is seen as a well- 
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adapted protective system with positive and negative feed -back loops 
which ensure a rapid but controlled and normally beneficial response. 
Harmful effects are seen as an overactive response occurring when 
bacterial invasion is not initially controlled, for example in 
experimental sepsis where large numbers of organisms are injected 
into an immunocompromised host. This viewpoint explains why 
evolution has favoured the retention of the response to endotoxin 
when single mutations [74] can lead to a greatly reduced response. 
Much has been learned about the mechanisms by which endotoxin may 
produce its effects. Much more remains to be learned about when 
particular mechanisms are triggered and about the possible benefits 
of medical interventions aimed at blocking these mechanisms. 
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ENDOTOXIN IN CRAM -NEGATIVE BACrERAErIIA AND THE SEPSIS SYNDROME. 
Endotoxin is thought to be the key microbial element in the causation 
of the systemic features of Gram -negative bacteraemia. Many other 
properties of the organisms involved may be important in colonising 
and invading the host, and in aiding microbial survival in the face 
of attack by the host defences. A few Gram -negative pathogens also 
produce protein exotoxins which are important in pathogenesis. It is 
endotoxin however which is thought to be the cause of the symptoms 
observed in most cases [261]. Gram -negative bacteraemia will be 
reviewed in some detail because of the doubt that has arisen over its 
significance [116,137], and therefore over the significance of 
endotoxin derived from bacteraemic organisms. 
Endotoxin absorbed from the gut may also be an important cause of 
illness [242]. This may occur in the presence or absence of 
bacteraemia. 
GRAM-NEGATIVE BACTERAffi1IA 
The role of Gram -negative bacteraemia in systemic disease has been 
studied principally in two overlapping groups of patients: patients 
with bacteraemia, and patients with clinically defined illness. 
Studies of series of patients with Gram -negative bacteraemia has shed 
useful light on which particular organisms are involved and (to a 
limited extent) why. The weakness in these studies is an underlying 
assumption that the organisms are clinically important, an assumption 
which is often not tested. Studies of patients who have sepsis 
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syndrome or septic shock (systemic illnesses of the type which could 
be produced by endotoxin) allow a broader view of the possible 
cans, and raise the question of whether the Gram -negative bacteria 
in the blood are important. 
Failure to appreciate the differences between the two groups of 
patients has led to some misinterpretation of the data. For example 
Glauser et al [83] refer to the series of patients reported by 
Ispahani et al [99] as a series of septic shock patients when in fact 
they are a series of cases of bacteraemia. This leads to the false 
impression that bacteraemia is present in most cases of septic shock. 
Gram -negative bacteraemia is a condition which is now common in 
hospitalised patients in Western countries. The frequency has 
increased and the spectrum of organisms has changed during this 
century. The organisms involved include some specific pathogens (eg 
Salmonella typhi, Haemophilus influenzae, and Neisseria 
meningitidis), but are now mostly gut commensals (particularly E. 
coli), acting as opportunist pathogens. 
In 1924 Bacillus coli (= E. coli) was "one of the least frequently 
encountered" organisms in blood cultures in septic disease [67]. 
Common organisms at that time were Gram -positive cocci and Salmonella 
typhi. The changes since then have not been widely recorded, but one 
major hospital (Boston City Hospital; [155]) has kept consistent and 
detailed records of Gram -negative bacteraemia over the period 1935 to 
1972 and observed an increasing trend. More recently attempts have 
been made in the USA to estimate the number of cases of septicaemia 
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(defined as "systemic disease associated with the presence and 
persistence of pathogenic microorganisms or their toxins in the 
blood ") diagnosed each year in hospitals in the USA. The numbers of 
cases more than doubled in the period 1979 -1987 [2], and although the 
organisms responsible were not reported in this study it seems likely 
that the number of Gram -negative bacteraemias must be continuing to 
rise. 
From 1935 to 1972 the proportion of Gram -negative bacteraemias which 
were due to E. coli fell, despite an increase in absolute numbers. 
The proportion of other organisms, notably Klebsiella spp., increased 
[155]. A review of large series of Gram -negative bacteraemia 
reported between 1965 and 1987 [261] showed that E. coli was still 
the commonest single isolate, with K1ebsiella spp. second and 
Pseudomonas aeruginosa third, and this pattern is maintained in more 
recent series [66,72,99,168]. A number of other genera are 
consistently reported, notably Enterobacter, Acinetobacter, Proteus 
and Ci trobacter. 
Table 1.1 shows figures from one series [168], which illustrate some 
further points about the organisms involved in Gram -negative 
bacteraemia. First, there is a difference between community-acquired 
infections and nosocomial (hospital acquired) infection, with a 
greater proportion of E. coli in the community -acquired cases and a 
greater proportion of Klebsiella spp., Enterobacter spp., P. 
aeruginosa and Acinetobacter spp. in the hospital -acquired cases. 
Second, this series contains a relatively large number of primary 
pathogens among the community- acquired cases. In the case of 
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Table 1.1 Gram -negative bacteria isolated from blood cultures in 
Columbia- Presbyterian Medical Centre, New York, in a 20 -month period 
in 1988 -89 [168]. 
Number 
Organism Community -acquired Nosocomial Total 
E. coli 148 56 204 
Kiebsiella spp. 62 65 127 
Pseudomonas aeruginosa 14 52 66 
Enterobacter spp. 14 33 47 
Acinetobacter spp. 6 40 46 
Haerrophilus influenzae 23 0 23 
Bacteroides spp. 13 9 22 
Proteus spp. 10 8 18 
Pseudomonas spp. 8 7 15 
Serratia spp. 4 4 8 
Ci trobacter spp . 1 5 6 
Salmonella typhi 5 0 5 
Haemophilus spp. 0 4 4 
Morganella spp. 2 2 4 
Achromobacter spp. 3 1 4 
Neisseria spp. 3 0 3 
Other 4 1 5 
Total 320 287 607 
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Salmonella typhi this must reflect a high prevalence of this organism 
in the population served. In the case of Haemophilus influenzae 
(presumably Pitmann type b) it probably reflects a large paediatric 
service in the hospital. This study [168] also found an increase in 
the proportion of Acinetobacter spp. between 1981 and 1988, 
indicating that change in the spectrum of organisms is continuing. 
It is likely therefore that there will continue to be differences 
between hospitals and over time in the range of organisms causing 
Gram -negative bacteraemia. 
E. coli, the commonest single cause of Gram -negative bacteraemia, has 
been studied in detail. A small proportion of the many O:K:H types 
described account for most cases of E. coli bacteraemia [39,52,177]. 
The 0 types involved are broadly the same as those commonly found in 
urinary infections and as faecal commensals [89,246], though there 
appear to be geographical and temporal variations. The 0 types found 
in bacteraemia are different from those recognised as 
enteropathogenic strains [178]. Most E. coli isolated from blood 
cultures are resistant to killing by fresh serum [52], a property 
which is clearly likely to favour the survival of extracellular 
bacteria in the blood. Serum resistance is itself associated with 
some 0 types and with the presence of K1 capsule, though K1 capsule 
is found no more commonly in bacteraemic strains than in faeces 
[196]. 
The organisms causing Gram -negative bacteraemia probably originate 
most commonly from the gut. These organisms can establish foci of 
infection in various sites, depending on the predisposition of the 
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patient. The most commonly identified foci of infection in the 
series cited above are in the urinary tract, the abdomen, or 
(following overgrowth of coliforms in the pharynx [104,138]) in the 
respiratory tract. The differences observed between organisms 
involved in community acquired and hospital- acquired infection are 
thought to be the result of a replacement of endogenous gut flora by 
bacteria in the hospital environment [186,215,243], as a result of 
antibiotic and other pressures. The predominance of E. coli in 
community- acquired Gram -negative bacteraemia therefore reflects its 
presence as the predominant aerobe in the normal gut flora, while the 
higher proportion of Kiebsiella and Pseudomonas spp. in hospital 
acquired infections reflects the replacement of gut flora by these 
organisms. Acinetobacter spp. may be an exception to this 
generalisation, however, since the commonest sites of infection 
identified for this organism are intravenous lines [168]. The 
Acinetobacter spp. as a cause of bacteraemia may 
therefore simply be a result of increased use of intravenous lines. 
Mortality in patients with Gram -negative bacteraemia has been 
variously reported at between 20 and 50% [261]. With the exception 
of cases caused by invasive pathogens such as Salmonella typhi, Gram - 
negative bacteraemia is a complication of an underlying disease 
process rather than a primary cause of disease, and the observed 
mortality is therefore in part a reflection of the underlying 
disease. In the meta -analysis of Young (1990), mortality rates were 
highest for P. aeruginosa, and second for Kiebsiella spp., with E. 
coli coming in fourth after the relatively infrequent Proteus spp.. 
Only P. aeruginosa bacteraemia has however been shown to be 
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independently associated with increased mortality [158], and even 
then the effect is weak. Most of the differences in mortality are 
explained by the association of P. aeruginosa and Kiebsiella spp. 
with more severe underlying disease [118]. This is related to the 
differences observed between community -acquired and nosocomial 
infection, since the patients with nosocomial infection tend to be 
those with more severe and complicated underlying illness, and 
therefore a higher mortality rate [72,99]. 
Among E. coli bacteraemias, serum resistance and 0 types 4, 6, and 8 
have been associated with higher mortality, but so have the absence 
of recognisable capsule and rough phenotype [151]. It is not clear 
whether these differences are due to increased virulence or 
association with more severe underlying illness. 
It appears therefore that the various Gram -negative organisms which 
commonly cause bacteraemia are all approximately equal in the harm 
which they cause. This is compatible with the idea that the harm is 
caused by endotoxin, which is common to them all. 
IS GRAM - NEGATIVE BAC ERA 1IA A CAUSE OF ILLNESS? 
It is possible to assume that Gram -negative bacteraemia is harmful. 
The patients involved have a high mortality, and there is ample 
evidence from studies of the action of endotoxin and from 
experimental infections in animals to conclude that the organisms 
could be responsible for the illness observed. There are two 
important inconsistent findings however. First, Gram -positive 
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bacteraemias, even those caused by coagulase- negative staphylococci, 
are associated with similar mortality rates to those associated with 
Gram -negative bacteraemias [72,99,139,252]. This calls into question 
the pre -eminent role of endotoxin as a bacterial virulence factor. 
Second, among patients with clinically defined sepsis syndrome, those 
with bacteraemia (Gram- negative or Gram -positive) fare no worse than 
those without bacteraemia [26,86,221,266]. The bacteraemia in these 
patients might therefore be just an epiphenomenon, with the real harm 
coming from some other stimulus to the cytokine release. The 
question of whether bacteria are important in sepsis syndrome has 
been the subject of a review [81], the key points of which are 
reproduced here. 
Sepsis syndrome and Septic shock 
The term "sepsis syndrome" has been used [23,24,83] to describe a 
condition of fever or hypothermia associated with tachypnoea, 
tachycardia, and evidence of inadequate tissue perfusion, in a 
patient with clinical evidence of infection. "Septic shock" is used 
to refer to a more severely ill group of patients who in addition to 
the features noted above, have signs of shock. These definitions 
could apply to a very wide range of patients, but are usually applied 
to patients in intensive care units in developed countries. Most such 
patients are suffering primarily from trauma, or from intra- abdominal 
infection which has not been eradicated surgically. 
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A consensus conference on the terminology to be used in this area 
[25] has recently suggested that a new and broader term, "Systemic 
Inflammatory Response Syndrome" is required to describe the clinical 
features of sepsis syndrome in patients who may or may not have 
underlying infection. The condition would be termed Sepsis "when the 
systemic inflammatory response syndrome is the result of a confirmed 
infectious process ". An infection is defined as "an inflammatory 
response to the presence of microorganisms or the invasion of 
normally sterile host tissues by those microorganisms ". This 
approach does seem to clarify the terminology, but it leaves 
unanswered the question of how to establish that an infectious 
process may cause the systemic inflammatory response. 
Bacteraemia in sepsis syndrome 
There have been four major prospective studies of patients with 
clinically defined sepsis syndrome [26,86,221,266] and one of septic 
shock [54]. Studies of subgroups of three of the sepsis syndrome 
series have been published separately, duplicating some of the data 
[27,232,259]. Two other studies [38,267] were prospective in design 
but appear to have included Gram -negative bacteraemia as one of the 
possible entry criteria, and cannot therefore be used to determine 
the frequency of bacteraemia in sepsis syndrome. In prospective 
series of sepsis syndrome patients, bacteraemia was found in 40 -47% 
[26,221] and Gram -negative bacteraemia was found in 21 -37% 
[26,86,221,266]. In the prospective study of septic shock, 39% had 
bacteraemia, of whom about half (19% of the total) had Gram- negative 
bacteraemia [54]. Full detail of the blood culturing protocol is not 
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given in any of these studies, and there may be false negatives in 
some series if inadequate volumes of blood were cultured before 
antibiotics were given [71]. Bacteraemia (Gram -positive or Gram - 
negative) was associated with the development of septic shock in one 
series of febrile patients [241] and in one series of sepsis syndrome 
patients [27], but not in the other series. Bacteraemia was not 
associated with a worse outcome in any of these series. 
Evidence that bacteremia is harmful. 
The ideal way to show that mortality or morbidity is attributable to 
Gram -negative bacteraemia would be to perform a case- control study. 
A study of this nature has demonstrated that bacteraemia due to 
coagulase- negative staphylococci results in increased mortality and 
prolonged hospital stay [139]. Such studies specifically dealing 
with Gram -negative bacteraemia do not exist, although mortality 
attributable to bacteraemia in general was demonstrated in neonates 
in a study where 70% of the bacteraemias were due to Gram -negative 
bacilli [234]. Other studies have attempted to distinguish, in a 
less formal way, mortality due to underlying disease from mortality 
due to infection [99,252]. 
Clinical studies of the effect of antibiotics do support the idea 
that bacteraemia is harmful. Since the demonstration that early 
antibiotic treatment led Lo greatly reduced mortality in Pseudomonas 
bacteraemia [205] antibiotics have been used empirically for 
patients in whom bacteraemia is suspected. It would be considered 
unethical now to withhold antibiotics as part of a double -blind study 
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to show their benefit, and therefore such definitive studies have not 
been done. More oblique approaches have been used however, including 
comparisons of different antibiotic regimens, and retrospective 
studies of the outcomes of individual patients. 
Comparisons of antibiotic regimens. 
Large studies in febrile neutropenic patients have compared different 
empirical antibiotic regimens [115,262], and have shown differences 
between outcome for the different regimens. These studies have also 
shown that in -vitro sensitivity tests on blood -culture isolates are 
good predictors of the effectiveness of treatment regimens. This 
implies that the differences in outcome observed are due to the 
antibiotic action of the drugs, and therefore that the living 
bacteria detected in the blood were important. However, in these 
patients, unlike sepsis syndrome patients, bacteraemia itself is a 
predictor of a worse outcome [115]. This difference is probably 
related to the much lower clinical threshold for admission of these 
patients to trials. These results therefore confirm that 
bacteraemia can be a cause of illness, but they are not necessarily 
applicable to sepsis syndrome patients in whom other more powerful 
insults may be responsible for the illness observed. 
Retrospective series of bacteraemic patients. 
Retrospective studies have looked at the difference in outcome for 
patients treated with appropriate antibiotics (antibiotics to which 
the organism isolated was sensitive) and those treated with 
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inappropriate antibiotics (to which the organism was not sensitive). 
Significantly lower mortality rates in patients receiving appropriate 
antibiotics were found in three large series of bacteraemic patients 
[119,185,252] and in several smaller series of patients bacteraemic 
with groups of organisms such as Ehterobacter [19] K1ebsiella [251] 
E. coli [85]. The relationship between appropriate antibiotic and 
outcome has been considered in one small study of sepsis syndrome 
patients [113], which confirmed that inappropriate antibiotics were 
associated with a significantly worse outcome. Delay in introduction 
of the appropriate antibiotic was also associated with a significant 
increase in hospital stay and with the development of acute organ 
failure, though not with increased mortality. This study considered 
appropriateness in relation to "the cultured pathogen ", which 
presumably means isolates from abscesses and other sites as well as 
blood cultures, but nevertheless supports the view that antibiotics 
can be effective in sepsis syndrome patients, and therefore that 
invading organisms, such as blood culture isolates, are important. 
Do antibiotics completely neutralise the deleterious effect of 
bacterial invasion? 
The apparent effectiveness of antibiotic treatment offers an 
explanation for the failure to observe a worse outcome in sepsis 
syndrome patients who have bacteraemia. Among sepsis syndrome 
patients, 90.5% to 98% [86,266,267] of those with Gram -negative 
bacteraemia, or 86% to 91% of all patients with significant positive 
cultures [113,232], received appropriate therapy. The lack of 
difference between bacteraemic and non -bacteraemic patients with 
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sepsis syndrome could therefore be because the deleterious effect of 
bacteraemia is largely neutralised by effective antibiotics. 
There does however seem to be room for further improvement in the 
outcome of sepsis syndrome patients, despite adequate antibiotics. 
Ziegler et al [266] showed that the human monoclonal IgM antibody HA- 
lA reduced the mortality rate from 49% to 30% in patients with sepsis 
syndrome who had Gram -negative bacteraemia, although the mortality 
rate rose from 40% to 45% [228] in those patients who did not have 
Gram -negative bacteraemia. The benefit was greatest in patients who 
had Gram -negative bacteraemia and shock. No benefit was reported in 
the group of patients who had Gram -negative infection (defined by 
culture from the site of infection) but no bacteraemia. There is 
some doubt about how exactly HA -1A might work [15,16], but the 
demonstration that it is only active in patients with Gram -negative 
bacteraemia suggests an 
important respect from other sepsis syndrome patients. This is true 
even after the beneficial effect of antibiotics has been taken into 
account. 
ANTIBIOTICS AND ENDO'l'OXIN RELEASE. 
The finding that antibiotics are of benefit in bacteraemia runs 
contrary to the idea that antibiotic treatment might lead to release 
of endotoxin and therefore to worsening of clinical progress [214]. 
The evidence that significant endotoxin release happens in vivo is 
however weak. 
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In brucellosis, treatment with tetracycline was followed 8 -12 hrs 
later in half of the patients by a spike of fever, sometimes 
accompanied by hypotension [220]. This was not however regarded as a 
serious toxic complication, and was in contrast to the "remarkable" 
immediate and lasting benefit of treatment. There are anecdotal 
reports of worsening of typhoid after chloramphenicol treatment [97] 
but such events have not occurred frequently enough in large series 
to deserve consideration in a recent review of typhoid treatment 
[96]. Both Salmonella typhi and Brucella melitensis are pathogens 
which multiply within macrophages, and which might therefore trigger 
macrophage responses in many ways. Chloramphenicol and tetracycline 
are both bacteriostatic antibiotics, and would therefore not be 
expected to cause endotoxin release [212]. 
Rabbit experiments have shown an increase in the ratio of endotoxin 
to bacteria in the blood following therapy with moxalactam [212] or 
gentamicin [214]. In these experiments bacteraemia was induced by 
injecting 20 ml of overnight broth culture of E. coli, with mucin, 
into the peritoneum. The reported rise in endotoxin:bacteria ratio 
in the treated animals can be explained largely by the fact that 
antibiotic caused a reduction in the number of viable bacteria in the 
blood, rather than any marked difference in the amount of endotoxin 
in the blood. The endotoxin level did continue to rise after 
antibiotic treatment, but was no greater in the treated animals than 
in the controls. Endotoxin may well have continued to be absorbed 
from the very large inoculum (109 -1010 c.f.u.) in the peritoneum. 
Recent studies in humans have clearly shown in meningococcal 
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infection that endotoxin levels in the blood decline consistently and 
rapidly following the introduction of antibiotic therapy [33]. 
Rising levels of endotoxaemia have been observed during the first few 
hours of antibiotic therapy in some patients with septic shock [54] 
or Gram -negative bacteraemia [213], but these rising levels have not 
been consistently associated with poor outcome. 
FLOW DOES BAC ERAS IA LEAD TO DISEASE? 
The triggering of cytokine release by endotoxin derived from the 
invading organisms is the best -known mechanism by which bacterial 
invasion may lead to clinical sepsis syndrome [83]. This possibility 
is supported by a vast body of knowledge of the effects of endotoxin. 
It is supported in the case of meningococcal infection by the 
demonstration that the LOS level is related to the severity and 
outcome of disease [33]. 
Endotoxin in the blood may be absorbed or "translocated" from the 
gut [242]. This is presumably the mechanism which leads to 
endotoxaemia in Gram -positive infection [213,241], but begs the 
question of how bacterial invasion leads to endotoxin translocation. 
Mechanisms other than the effects of endotoxin must be involved in 
sepsis caused by Gram -positive infection, and may well be involved in 
Gram -negative infections also. 
A group of protein toxins produced by Staphylococcus aureus, 
Streptococcus pyogenes and some other organisms are now recognised as 
"superantigens" which can interact with the Vß element of the T -cell 
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receptor and MHC class II antigens on monocytes [93,206]. This 
stimulates the release of TNFa and IL -1, and can produce systemic 
illness in animal models. Toxic Shock Syndrome is a well -recognised 
manifestation of this effect in humans and would in many cases 
satisfy the clinical criteria for sepsis syndrome. 
Other bacterial components are able to induce the features of sepsis 
syndrome, though with relatively low specific activity. Cell walls 
of Gram -positive bacteria are pyrogenic [199], and low molecular 
weight peptidoglycan is probably the active component. Muramyl 
Dipeptide (MDP) is a synthetic molecule which appears to be the 
minimum structure required to mimic the effect of low- molecular- 
weight peptidoglycan, and its activity has been studied in some 
detail [59]. MDP induced the production of endogenous pyrogen 
(interleukin -1) from rabbit white blood cells or human mononuclear 
cells in vitro. The action of MDP did not appear to be due to 
endotoxin contamination of the material, since LAL assays were 
negative, and cross -tolerance experiments suggest that the mechanism 
of action of MDP is different from that of endotoxin. 
Neither "superantigen" protein toxins nor peptidoglycan fragments can 
be readily detected in clinical samples. The importance of these 
factors in sepsis syndrome has therefore not been explored, but this 
does not mean that they are unimportant. 
35 
ENDO'1bXAEHIA IN THE ABSENCE OF BAGTERAEHIA 
Endotoxin assays based on Limulus Amoebocyte Lysate (LAL) were 
originally developed as a way of rapidly detecting the presence of 
Gram -negative bacteria, and positive results in the absence of 
bacteria were initially regarded as false- positives [226]. More 
recently it has been noted that endotoxaemia is an independent 
prognostic indicator, and indeed a better indicator for the 
development of shock [241] or death [54] than is bacteraemia. 
Absorption of endotoxin from the gut 
The commensal bacteria of the gut can be thought of as a large pool 
of endotoxin which may represent an important threat to the host. 
Endotoxin does not seem to be absorbed in health [242], but may be 
absorbed in disease, for example in patients undergoing surgery for 
ulcerative colitis [179]. Experimental intestinal ischaemia leads to 
absorption of endotoxin, via the portal vein [181] or lymphatics 
[171]. Endotoxaemia itself is a cause of increased gut permeability 
[175] leading to the absorption of whole bacteria into the lymphatic 
system [56]. 
The significance of endotoxin from the gut has been clearly 
established in heatstroke. Experimental heatstroke in monkeys causes 
endotoxaemia which can be prevented by pretreatment with oral 
kanamycin [80]. Prevention of endotoxaemia gives some protection 
against the cardiovascular effects of heat- stroke. Pretreatment with 
equine hyperimmune anti -LPS plasma also reduces endotoxaemia and 
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prolongs survival [79]. 
ENDOTOXAEMIA IN SEPSIS SYNDROME 
It is remarkable, in view of the central role which endotoxin is 
thought to play in sepsis syndrome [83], how few of the large studies 
of sepsis syndrome have reported the results of endotoxin assays. 
This is a reflection of the major practical difficulties in actually 
performing the assays [45], particularly in the multi- centre studies 
which have been required to collect large numbers of sepsis syndrome 
patients. Danner et al [54] measured endotoxaemia in septic shock 
and showed that it was associated with a poor prognosis. They also 
found that 57 of 100 patients with septic shock did not have 
endotoxaemia, despite performing an average of 9.6 endotoxin assays 
per patient. Either the assays were missing transient episodes of 
endotoxaemia, or some other mechanism is involved in these patients. 
This implies that although endotoxaemia is important it cannot be 
confidently regarded as the only cause of septic shock. This problem 
may be clarified by the concept of a systemic inflammatory response 
syndrome [25], which does not assume an infective etiology. 
Which endotoxins are involved in sepsis syndrome? 
There is some uncertainty over exactly which LPS structures are 
relevant in clinical sepsis. If Gram -negative blood culture 
isolates are the major source then the range of LPS from such 
organisms must be considered. If however LPS is largely derived from 
organisms in the gut then it is less clear which organisms are 
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relevant. The gut flora in health is complex and variable. 
Bacteroides out -number the enterobacteriaceae in the colon by 
approximately 1000 fold [62], so that although Bacteroides LPS is 
100- to 1000 -fold less endotoxic then enterobacterial LPS [131] it 
may contribute significantly to gut -derived endotoxicity. E. coli is 
the dominant Gram -negative aerobe in the colon of most healthy 
volunteers, but other enterobacteriaceae dominate in some 
individuals, particularly after antibiotic treatment [128]. The 
question of which LPS(s) are important in sepsis becomes crucially 
important when one goes on to think about antibody treatment aimed at 
LPS. 
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CROSS- REACTIVE ANTI -LPS ANTIBODIES. 
Several new forms of treatment aimed at blocking the effects of 
endotoxin are being developed, together with treatments aimed more 
broadly at blocking the events responsible for sepsis syndrome and 
septic shock [46,53,162]. 
Among the various possibilities are antibodies to LPS, both type - 
specific [53] and cross- reactive. Anti -LPS antibodies have the 
theoretical advantage of acting at the earliest point in the 
pathological cascade, but will be useful only in those cases where 
LPS is a key mediator. 
The idea that cross -reactive antibodies to LPS might be useful may be 
supported by five strands of evidence. 
1. Evidence that there are common structures in LPS. 
2. Evidence that antibodies to these structures exist, or can be 
produced. 
3. Evidence that the presence of such antibodies prior to sepsis is 
associated with a good prognosis. 
4. Animal experiments which show that such antibodies can be 
beneficial in experimental sepsis, and in vitro experiments which 
show that the antibodies have effects on the mechanisms of LPS 
toxicity. 
5. Clinical trials of potential therapeutic antibodies in humans with 
clinical sepsis. 
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CONt4ON STRUCTURES IN LPS 
The structure of LPS has been reviewed in the first part of this 
chapter, and it is clear that there are structures common to LPS from 
many bacterial species, particularly in the inner core and lipid A 
region. The terminal KDO residue in particular may be an accessible 
common epitope present in smooth LPS from enterobacteria and 
Pseudomonas [130]. 
EVIDENCE THAT CROSS- REACTIVE ANTIBODIES TO LPS EXIST 
Problems in demonstrating cross -reactive antibodies to LPS 
There is a lack of agreement about what constitutes a cross -reactive 
antibody, and how to demonstrate its presence. In polyclonal sera a 
major problem is in distinguishing cross -reactivity from the 
coincidental presence of several antibody specificities. This 
problem is avoided with MAbs, but difficulties remain in 
distinguishing specific from non -specific binding, and in determining 
what level of activity in any assay can be regarded as biologically 
significant. 
Most reports have used assays which simply detect binding of antibody 
to immobilised antigen. ELISA is now the most popular approach, 
having replaced the former standard of passive haemagglutination. 
Binding assays give results which vary according to the way the LPS 
is immobilised [94,210], and can give false -positive results with 
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lipid A [5]. The ideal must be to present the antigen in a condition 
which is "physiological ", but that is a currently a subjective 
judgment. Workers at Borstel have championed the use of passive 
haemolysis [29]. In this assay the LPS is inserted into a red -cell 
membrane (which is thought to result in a physiological conformation) 
and antibody is detected by triggering haemolysis, which is reasoned 
to be biologically significant. 
Absorption and competition have been widely used to demonstrate 
binding to particular antigens, but this can add to the problems. 
Absorption or competition with whole bacteria introduces a vast array 
of new antigens, while absorption or competition with apparently pure 
materials such as lipid A may also give non- specific results [31]. 
In more recent studies of the specificity of MAbs antibody 
competition [187] and competition with synthetic partial structures 
[32,122,130] have allowed great precision in analysing the 
specificity of MAbs. 
Immunoblotting is useful for demonstrating binding to particular 
molecular species separated by electrophoresis, though the effect on 
antigenicity of binding to nitrocellulose is not clear. The 
drawbacks with this technique are that it is cumbersome, relatively 
insensitive, and non -quantitative. An alternative and potentially 
quantitative way of demonstrating binding to particular molecular 
species is to fractionate the LPS before demonstrating binding [182]. 
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Cross -reactive antibodies as a response to immunisation 
The possibility of cross reactive anti -LPS antibodies was initially 
inferred from animal protection studies [40,148] using antisera to 
rough mutants of Salmonella and E. coli. 
Initial attempts to demonstrate cross -reactive antibodies in these 
sera were negative [229]. Subsequently antisera to Salmonella lipid 
A was shown to react with other glucosamine- containing lipid A 
preparations, but not with Re LPS. Antisera to lipid A and antisera 
to Re LPS did react with some heterologous smooth LPS or whole 
bacteria, but this was largely due to the presence of heterologous 
antibodies in the immune sera which were thought to represent a non- 
specific mitogenic response to the immunisation. The strongest 
evidence for presence of an anti -Re cross -reactive antibody in these 
sera was the demonstration that immunofluorescence with heterologous 
whole bacteria could be reduced by absorption of the serum with Re 
LPS [105]. 
The development of ELISA allowed more sensitive detection of antibody 
and led to a claim that cross -reactive antibodies could be 
demonstrated [17]. However, further work by the same researchers 
produced a more specific ELISA employing LPS complexed with high - 
density lipoprotein (HDL) which failed to demonstrate cross -reactive 
antibodies in the sera of humans or rabbits immunised with E. coli J5 
[14,17]. 
One of the difficulties encountered in demonstrating cross -reactive 
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antibodies in J5 antisera was the relatively large amount of J5- 
specific antibody [17]. An elegant solution to this problem is to 
affinity purify the cross -reactive antibody with a different rough 
LPS. This approach has been applied to serum from a J5-immunised 
calf [237]. The resulting IgG did bind to LPS from E. coli, 
Salmonella, Shigella, Pseudomonas aeruginosa and Serratia, and to 
Salmonella lipid A in a simple ELISA assay [238]. However, in view 
of the possibility of non- specific binding in this type of ELISA 
[94], and the absence of any comparison with positive -control sera, 
these results must be treated with caution. 
Naturally occurring cross -reactive antibodies in humans 
Naturally occurring cross -reactive antibodies may be qualitatively 
different from those produced by immunisation with rough bacteria or 
LPS, since naturally occurring antibodies may be produced in response 
to the core region of whole LPS. Thus the highly specific antibodies 
to J5, for example may not be encountered in sera from unimmunised 
individuals, and assays with rough LPS may detect truly cross - 
reactive antibody in these individuals. This view is supported by 
the finding that the specific activity of affinity purified anti -Re 
IgG from rabbits immunised with S. minnesota R595 was approximately 
10 times higher than affinity -purified anti -Re IgG from unimmunised 
humans [224], and by absorption studies discussed below [211]. 
Antibodies to lipi A can be detected in human sera, particularly in 
those from individuals who have had Gram -negative infection [140]. 
Lipid A has been shown to inhibit the binding of naturally- occurring 
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antibodies in human sera to rough LPS [36], but the ability of these 
antibodies to cross -react with whole bacteria or smooth LPS has not 
been defined. 
Barclay and colleagues have studied the specificity of naturally 
occurring antibodies to endotoxin (reviewed by Barclay [9]). They 
developed an ELISA using LPS complexed with polymyxin which gave more 
reliable results than standard ELISA. This assay was also able to 
detect some naturally- occurring antibodies to J5 LPS which were not 
detected by conventional LPS ELISA, perhaps because LPS complexed 
with polymyxin was locked into the conformation encountered naturally 
in the host [210]. ( Polymyxin has been shown to inhibit the binding 
of some anti -lipid A MAbs to LPS [65,163,189], and may therefore 
block some epitopes, but this does not seem to be a practical 
problem.) Using this assay Barclay and Scott [10] studied IgG 
antibodies to a variety of rough and smooth LPS chemotypes in 763 
blood donor sera. They found a strong correlation between antibody 
to Salmonella Rc LPS and antibody to Ra, Rb or smooth LPS. Antibody 
to Re LPS associated with antibody to Ra and smooth LPS in only 
about half of the sera. They concluded that Rc or Rb LPS would be 
the best antigen to use to screen blood donor sera for cross -reactive 
anti -LPS antibodies. This assay seems to be better at detecting 
cross -reactive antibodies than simple ELISA with J5 or R595 LPS, 
which both seem to detect more chemotype -specific antibody [225,244]. 
A cocktail of four rough LPSsof Rc or greater -sized chemotype (E. 
coli K12, Kiebsiella pneumoniae M10b, P. aeruginosa PAC605, 
Salmonella typhimurium 878) complexed with polymyxin was then used to 
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screen blood donor sera. IgG prepared from sera with high levels of 
antibody to this cocktail reacted with each of the individual 
components of the cocktail, and with a range of other Salmonella and 
E. coli LPS preparations. In three sera studied in detail most of 
the measured antibody could be removed by absorption with Salmonella 
bacteria expressing Re (2 cases) or Re (one case) LPS [211]. This 
was compatible with the concept of common cross -reactive antibodies 
directed against the structures present in Re LPS, and confirmed that 
the polymyxin -LPS -core cocktail assay was a potentially useful way of 
screening blood donor sera. 
Using the polymyxin -LPS -core cocktail assay, Jackson et al [100] 
measured the levels of anti -LPS -core antibody in children, and found 
predominantly IgG antibody. The antibody was deficient in premature 
infants, but was present (as maternal antibody) in term infants and 
normal children, and reached adult levels by about 15 years of age. 
Law and Marks [126], using an ELISA with J5 LPS as antigen, obtained 
broadly similar results except that they found predominantly IgM. 
This difference could be explained by difference in the relative 
potency of the IgG and IgM conjugates used. 
Nys et al [174], using an ELISA with R595 (Re) LPS, found that the 
anti -Re IgG in blood donors was predominantly of IgG2 subclass, while 
the IgG4 sublclass was found only in patients with bacteraemia. 
Levels of antibody to LPS -core antigens have been found to be greater 
in normal individuals from some third -world locations than in normal 
individuals from the USA [225]. These differences are related to, 
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but not completely explained by, differences in total immunoglobulin 
levels. 
Cross- reactive Monoclonal antibodies (MAbs) 
There have been numerous attempts to produce cross -reactive MAbs to 
endotoxin. Early reports of cross- reactivity were based on ELISA 
[63,65,163,203,230] which may detect non- specific binding, as 
discussed above. Binding to heterologous heat killed whole bacteria 
but not LPS was noted in several cases [8,163,189]. 
The range of organisms used to demonstrate cross -reactivity varied 
enormously. Nelles et al [163] used a total of 32 isolates, 
including Acinetobacter, Pseudomonas, Klebsiella and Serratia as well 
as clinical isolates of E. coli, although the degree of binding 
detected with many of these organisms was much less than that with 
the J5 immunising strain. Teng et al [230] used an even wider range 
of genera. Neither of these groups showed results for a negative 
control Gram- positive organism. Erich et al [65] used one Shigella, 
two Salmonella and one E. coli while Salles et al [203] used four E. 
coli and single strains of Klebsiella and Serratia. Both of these 
latter groups used enteropathogenic strains of E. coli rather than 
blood -culture strains. 
Many of the MAbs studied in detail recently [32,55,122,130,187] have 
been found to bind to epitopes found only on rough mutant LPS or 
isolated lipid A, or have been found to react with only one or two 
core types [41,133,170,245]. Two MAbs with well- defined epitopes 
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(8A1 and clone 20) do appear to be cross -reactive however, as do a 
number of other MAbs with less well defined epitopes. 
The murine IgG MAb 8A1 has been shown to recognise the 
bisphosphorylated backbone of lipid A [122], and is reported to be 
cross -reactive in solid -phase radioim unoassay (RIA) (with heat - 
killed bacteria) and immunoblotting with E. coli, K. pnezmk niae, P. 
aeruginosa and Salmonella minnesota but not Serratia marcescens [21]. 
Clone 20, a murine IgG, reacts with the terminal KDO residue [32], 
and has been found to be cross -reactive in ELISA with smooth LPS from 
one strain of K. pneumoniae and with heat -killed cells of one strain 
of P. aeruginosa, [5]. The data on clone 20 should be treated with 
caution however as it was also reported to bind in ELISA to lipid A 
despite evidence that its epitope is the terminal KDO. 
The murine IgM MAb 8 -2C1 [55] has a less well- defined epitope in the 
KDO -lipid A region, and is said to bind in ELISA to heat- killed E. 
coli, K. pneumoniae, P. aeruginosa, Enterobacter cloacae, Proteus 
mirabilis Morganella morganii and Serratia marcescens. 
A study of two human anti -LPS -core MAbs found two patterns of cross - 
reactivity in ELISA, one involving E. coli, K. pneumoniae and P. 
aeruginosa, and the other involving many enterobacteriaceae but not 
P. aeruginosa [255]. This underlines the need to establish in detail 
the range of cross -reactivity of particular MAbs. 
Studies of the binding of E5, a mouse MAb which has been the subject 
of two major clinical trials, have recently been published [182,257]. 
They show binding to lipid A, cross -reactivity with representatives 
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of six genera of enterobacteriaceae and with P. aeruginosa, and 
binding to both 0`substituted and unsubstituted LPS. The methods 
used to show binding to lipid A were principally ELISA and solid - 
phase RIA in which plates were coated with LPS dissolved in methanol. 
This was very similar to the method shown by Heumann et al [94] to 
produce false cross -reactions, although the E5 studies did include a 
negative control MAb as evidence of specificity. In addition a LAL 
antibody -capture assay was used in which LAL was used to detect LPS 
captured by immobilised E5 MAb. 
Peer -reviewed data on the epitope specificity and cross- reactivity of 
the HA -1A the other MAb which has been the subject of a major 
clinical trial, is scanty [20,230]. 
EVIDENCE THAT NATURALLY-OCCURRING ANTIBODIffi PREVENT SSPSIS 
Several workers have shown a relationship between naturally- occurring 
antibodies and the course of endotoxin -related disease. McCabe et al 
[152,268] showed that the presence of high titres of antibody to Re 
595 LPS was associated with a lower incidence of shock and death in 
Gram -negative bacteraemia. An interesting negative finding in this 
study was that antibody to enterobacterial common antigen (ECA) was 
not associated with a favourable outcome, suggesting that the Re 595 
result is not merely a reflection of greater previous exposure to 
Gram - dative infection. Pollack et al [188] similarly showed that 
antibody to E. coli J5 LPS, particularly IgM antibody, was associated 
with survival in P. aeruginosa septicaemia. A similar relationship 
might be expected in other conditions where endotoxin plays a part. 
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IgM antibody to E. coli J5 LPS has been shown to be associated with a 
reduced risk of graft- versus -host disease following bone- marrow 
transplantation [47]. 
A more complex hypothesis studied by Barclay et al [11] was that 
cross -reactive antibody would be consumed during endotoxaemia, and 
that symptoms would occur when the endogenous supply of antibody was 
no longer sufficient to neutralise the endotoxin. Detailed studies 
of three patients with septic shock supported this view, showing a 
drop in antibodies to polymyxin -complexed rough LPSs (ranging from Ra 
to Re) associated with endotoxaemia. Similar conclusions were 
reached by Nys et al [172,173] who found that a high or rising level 
of IgG antibody to R595 (Re) was associated with a favourable outcome 
in patients in surgical intensive care, while a falling level of 
anti -Re IgG was predictive of a poor outcome. 
ANIMAL EXPERIMENTS AND IN VITRO MODELS OF PATHOGENESIS 
The concept of cross- reactive antibodies to LPS for the treatment of 
sepsis was originally based on passive transfer of sera from rabbits 
immunised with E. coli J5 and Salmonella Re 595 [34,148]. These 
effects can be produced by the IgM fraction of serum [147]. In the 
light of research which has failed to repeat these experiments [88] 
and failed to find cross -reactive antibodies in these sera [94] the 
results are difficult, although not impossible [264] to explain. It 
is certainly clear that the results of animal experiments are 
extremely complex and subject to many variables, and must therefore 
be interpreted with caution. 
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Factors which may produce false -positive results include protective 
factors in the sera of pre - immune donor animals [87] non- specific B- 
cell mitogenicity, acute phase reactants [88], and endotoxin 
contamination of antibody preparations [42,258]. False- negative 
results (reviewed by Ziegler [264]) may be produced by use of the 
wrong animal model, excessive challenge inoculum, or unreasonable 
comparisons between cross -reactive sera and much more active 
homologous sera. 
In animal models some anti -LPS MAbs have been found to be protective 
[64], while others have not [6,159]. MAbs apparently sharing the 
same epitope even differed in their protective activity [6], but more 
detailed analysis revealed fine differences in epitope [32]. If the 
mechanisms of action of endotoxin were well understood it would be 
possible to differentiate these types of MAb in vitro. If TNF is the 
key mediator then testing MAbs for inhibition of LPS- induced TNF 
production in vitro may be a useful way of looking for protective 
MAbs [44]. However it has been shown that one MAb (clone 20, see 
above) can have protective effects in an animal model without 
influencing the levels of TNF and IL -6 [218], so that in vitro TNF 
suppression may not be essential for protective activity. Other 
possible in vitro approaches to identifying protective MAbs have been 
to examine antibody subclass or inhibition of binding by polymyxin 
[6], or inhibition of Limulus activation [154], but none of these has 
proved useful. Ability of antibodies to initiate complement- mediated 
bacterial killing (itself a function of antibody class) has been 
shown to be related to protection in an infection model with 0- 
specific MAbs [176]. This may not be relevant to cross -reactive 
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MAbs, however, and is unlikely to be a predictor of in vivo anti- 
toxic activity of MAbs. 
HUMAN CLINICAL TRIALS 
The ultimate test of an antibody treatment must be a clinical trial. 
Several large and carefully planned trials have been mounted, but as 
yet none have produced results good enough to support routine 
clinical use of any anti -LPS antibody treatment. 
The first large trial [267] involved a comparison of serum from J5- 
immunised donors with pre-immune serum from the same donors. These 
sera were given to patients with a clinical diagnosis of Gram - 
negative bacteraemia. There was a significant reduction in mortality 
in the bacteraemic patients, particularly those with shock. A 
similar comparison between J5- immunised and pre - immune serum (or 
plasma) as prophylaxis against Gram -negative infection in high -risk 
surgical patients [13] also showed beneficial effects, reducing the 
incidence of shock related to Gram -negative infection. (The 
statistical significance of the findings in this trial has since been 
questioned by its first author [12].) 
Treatment with whole serum or plasma has practical problems [38], 
including the increasing possibility of HIV transmission. IgG 
formulated for intravenous administration (IVIG) avoids these 
problems. Calandra et al [38] compared IVIG prepared from J5- 
immunised donors with standard IVIG in the treatment of Gram -negative 
infection and found no difference in outcome. This may indicate that 
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the beneficial effect of J5 antiserum was in the IgM fraction. 
Two IgM MAbs, HA-1A and E5 had by now become available and were 
entered into clinical trials. The results of the HA -1A trial [266] 
looked promising, and had met with an enthusiastic initial response 
[4]. There was a significant reduction in mortality in patients with 
Gram -negative bacteraemia, particularly when associated with hock, 
as had been found with J5 antiserum. Overall however there was no 
improvement in the outcome of the patients treated because of a small 
(not statistically significant) increase in mortality in the non- 
bacteraemic patients who received HA -1A [228]. More detailed re- 
examination of the available data [249] pointed to some inequalities 
beween the patient and control group (for example there were more 
patients in the control group who received inadequate antibiotics) 
and concluded that the value of HA -1A remained unproven. This re- 
examination also emphasised the lack of understanding of exactly how 
HA -1A worked and therefore the lack of any assay which could be used 
in quality control of production batches. 
The E5 trials were even less persuasive despite the apparently 
superior affinity of E5 for LPS [182,257]. It was beneficial in 
patients with Gram -negative infection, whether bacteraemic or not, 
only if they were not in septic shock. These beneficial results were 
not confirmed in a repeat trial ([253], cited by [249]). 
Running in parallel with the recent studies of MAbs have been further 
studies with immunoglobulins derived from blood donors. Dominioni et 
al [60] gave a total of 1g /Kg of IgG (Sandoglobulin) to 29 severely 
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ill septic patients and found a reduction in mortality compared to a 
control group of 33 patients given albumin. Schedel et al [204] 
studies the effects of a different immunoglobulin preparation 
(Pentaglobin) which contains IgM and IgA as well as IgG, and which 
was said to have 8 to 16 fold higher "specific antibody titres to 
different determinants of lipopolysaccharide" than a random -donor, 
normal human serum pool" (data attributed to personal communication 
from BJ Appelmelk). They gave a total of 74.4 g of this preparation 
to each of 27 patients with septic shock and detectable endotoxaemia, 
and found only one death compared to 9 deaths in a control group of 
28 similar patients given no immunoglobulin. Both of these results 
could be explained by beneficial effects of naturally- occurring 
antibodies to LPS, though these antibodies may be a mixture of very 
specific antibodies rather than cross -reactive antibodies. 
The latest twist to this tale comes from a study by Cometta et al 
[48] which compared standard IVIG to IVIG from donors found to have 
high levels of antibody to Re595 LPS, and to an albumin placebo. Up 
to four doses of 0.4 mg /Kg IVIG or albumin were given as prophylaxis 
to patients at high risk of post -surgical infection, using the same 
entry criteria as Baumgartner et al [13]. Unfortunately the number 
of cases of Gram -negative infection or septic shock was too small to 
evaluate any effect [217]. There was however a reduction in 
hospital -acquired infection in the group given standard IVIG, but no 
reduction in the group given selected anti -Re IVIG. The mechanism by 
which this reduction might occur is not clear, but it does suggest 
that serum selected for a high level of anti -Re antibody may be 
lacking in some other important antibody. 
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AIMS OF THIS THESIS 
The story of cross -reactive antibodies to LPS is complex. There is 
no certainty that antibodies really exist that are cross -reactive 
enough to be active against the range of LPS found in human sepsis, 
and there is no very clear demonstration of their efficacy in humans. 
There is however considerable evidence to suggest that such 
antibodies may be important in infection, and that beneficial 
antibodies could be produced (as MAbs) or selected from donor sera. 
I established links with a group of researchers active an this field 
and, within the limits of the techniques and materials available to 
me, tried to produce some useful results. I have presented in this 
thesis 5 chapters of results: 
Chapter 3: Antibody response in recipients of typhoid vaccine. This 
was an attempt to determine whether high levels of antibody detected 
by polymyxin /LPS -core cocktail ELISA could be explained by an 
association with typhoid vaccination. 
Chapter 4: IgG antibody in urine in patients with 
urinary tract infection. This was an application of the 
polymyxin /LPS -core cocktail ELISA to the diagnosis of urinary tract 
infection. 
Chapter 5: Studies on the interaction of MAb and human IgG 
preparations with blood -culture isolates of Gram -negative 
bacilli and rough mutants of E. coli. In this chapter I present the 
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results of studies done as part of the characterisation of a large 
panel of MAbs and some human IgG preparations. 
Chapter 6: Core- typing of E coli. This work arose from an 
observation made in the experiments described in chapter 5, that some 
of the MAbs produced could distinguish between different core types 
of wild -type E. coli. The aim was to determine the frequency of the 
different core types in clinical isolates of E. coli, with the 
further purpose that this information should be of value in assessing 
the ability of MAbs to interact with common clinical isolates. 
Chapter 7: Studies of some cross -reactive antibodies not specific for 
LPS -core. The experiments described in this chapter aimed to 
characterise three non -LPS MAbs which were produced, and also include 
some experiments with HA -1A. 
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CHAPTER 2 
GENERAL MATERIALS AND METHODS 
This chapter contains details of materials and methods used in more 
than one of the succeeding chapters of results. Materials and 
methods specific to one chapter are included in that chapter. 
BACTERIA AND BACTERIOPHAGE 
Many different bacteriOphage and bacterial strains, obtained from 
several different sources, have been used in the work described here. 
Tables of sources and reference numbers are included in the relevant 
section of results. There were two main sources of strains, as 
follows: 
1. Microbial Pathogenicity Research Laboratory (MPRL), Department of 
Medical Microbiology, Edinburgh University. All bacterial strains in 
this collection are assigned an MPRL reference number and stored in 
freeze -dried form. Bacteriophages are stored as suspensions in 
nutrient broth at 4 °C saturated with chloroform. 
2. Clinical Bacteriology Laboratory, Department of Medical 
Microbiology, Edinburgh University. All blood -culture isolates from 
patients in the Royal Infirmary, Edinburgh are kept. Strains are 
initially stored on nutrient agar slopes and subsequently freeze - 
dried in batches. Reference numbers for blood-culture strains 
contain a "b" (eg 8b281). Enteric pathogens from stool cultures are 
stored on nutrient agar slopes. Urine isolates were kept either 
freeze dried (in the case of the 6 strains used in chapter 4) or on 
agar slopes (in the case of the 80 strains used in chapter 6). 
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Bacterial Culture Media 
Nutrient Broth was Gibco nutrient broth, prepared and filter - 
sterilised at the Blood Transfusion Service Protein Fractionation 
Centre, Edinburgh. 
Solid media used were nutrient agar (Columbia agar base, Oxoid, 
Basingstoke) and Cysteine Lactose Electrolyte Depleted (CLED) agar 
(Oxoid), both prepared by the media kitchen of the Department of 
Medical Microbiology. 
Bacterial Culture 
All bacteria were cultured at 37 °C in air. Broth cultures of between 
10 ml and 100 ml were prepared by inoculating colonies from agar 
media into broth and incubating overnight at 37 °C in a Gallenkamp 
shaking incubator Larger volumes were seeded with 1% of starter 
culture prepared as above. Purity of all cultures was checked by 
streaking -out to single colonies on CLED agar. 
MONOCLONAL ANTIBODIES (NABS) 
All MAb preparations (except HA -1A) were produced as part of 
collaboration between Sandoz (Basle) and researchers in Edinburgh. 
BALB /c mice were immunised with bacteria or LPS immunogens both in 
Edinburgh and Basle. Several different protocols were used, the 
details of which are to be published elsewhere. Spleen cells from 
immunised mice were fused with NS-0 myeloma cells using standard 
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techniques [114] in the Department of Surgery, Edinburgh University, 
and by Sandoz. In Edinburgh, MAbs of interest were selected by Dr GR 
Barclay of the Blood Transfusion Service on the basis of reactivity 
with a range of rough LPS in polymyxin -LPS ELISA. The antigens used 
for screening included the ímmunogen(s) that had been used in that 
particular mouse together with other LPS selected to complement the 
immunogen(s). The clones produced in Basel were initially screened 
for reactivity with bacteria in ELISA. MAbs were then further 
characterised by LPS /polymyxin ELISA with a wider range of LPS and 
lipid A preparations, mainly from E. coli and Salmonella species. 
The LPS preparations used were obtained from commercial sources 
(Sigma and List Biologicals) or were produced in MPRL or by Dr H 
Brade at the Forschungsinstitut, Borstel, Germany, as listed in table 
2.1. 
MAbs preparations used in this thesis were either supernatants of 
hybridoma cell cultures (in RPMI 1640 medium supplemented with 5% 
fetal calf serum, antibody concentration 10 -50 pg /ml) or purified 
preparations containing 5 -10 mg /ml of antibody. 
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Table 2.1 LPS preparations used to characterise monoclonal antibodies 


























































































































































































ENZYME -LINKED IIrMUNOSORBENT ASSAYS ( ELISA) 
Buffers 
Phosphate buffered saline (PBS) was 50 MM phosphate, 0.15 M sodium 
chloride, pH 7.4. 
Coating buffer was 0.05 M sodium carbonate -bicarbonate pH 9.6 with 
0.05% sodium azide. 
Wash buffer was PBS with 0.05% sodium azide and 0.1% Tween -20. 
Post -coating buffer was PBS containing 5% bovine serum albumin and 
0.05% sodium azide. 
ELISA diluent was PBS with 0.05% Tween -20 , 0.5% bovine serum 
albumin, 4% polyethylene glycol 6000 (Sigma, formerly called 
polyethylene glycol 8000), and 0.05% sodium azide. For work with 
monoclonal antibodies the albumin was omitted. 
Polymyxin -LPS ELISA plates 
These plates were prepared by Linda Milne in the Microbial Antibodies 
Laboratory, Blood Transfusion Service. The LPS used was prepared by 
Frances McLoughlin in the Microbial Pathogenicity Research 
Laboratory, except where attributed to a commercial source. 
Smooth LPS were prepared by the aqueous phenol method of Westphal and 
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Luderitz [254], and rough LPS were prepared by the aqueous phenol, 
chloroform, petroleum ether method of Galanos et al [76] 
incorporating the diethyl ether, acetone precipitation of LPS 
described by Qureshi et al [191]. 
LPS was made up to a concentration of 0.2 mM in pyrogen -free sterile 
water and added to an equal volume of 0.4 mM polymyxin B (Sigma) then 
mixed with continuous stirring for 30 minutes at room temperature to 
allow LPS- polymyxin complexes to form, dialysed overnight at room 
temperature to remove excess unbound polymyxin [161], and stored at 
-20 °C. To coat plates, complexes were sonicated for 30 seconds, 
diluted 1 in 50 in coating buffer, and dispensed (100 pl per well) 
into Nunc polysorb plates. The plates were incubated overnight at 
room temperature, then washed four times with wash buffer. Post - 
coating buffer (100p1 per well) was then added and incubated 
overnight at room temperature, and washed as above. Plates were 
wrapped in plastic film and stored at -20 °C. 
Polymyxin -LPS -core cocktail ELISA plates 
Polymyxin -LPS -core cocktail ELISA plates were made up as above using 
equal molar quantities of rough LPS from E. coli K12, Kiebsiella 
pneunk niae M10b, Pseudomonas aeruginosa PAC605, Salmonella 
typhimurium 878. 
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Sermon anti -LPS -core assay 
ELISAs on serum using polymyxin -LPS -core cocktail plates were 
performed using a 1:400 dilution of serum in ELISA diluent with 0.5% 
bovine serum albumin. Dilute serum (100 pl) was added per well in 
triplicate, incubated at 37 °C for 60 min, and washed five times. 
Then 100 pl of urease- conjugated sheep -anti -human-IgG (Sera -lab, 
diluted 1 in 500 in ELISA diluent with 0.5% bovine serum albumin) was 
added, incubated for a further 60 min at 37 °C, then washed three 
times and rinsed five time in distilled water. Urease substrate (100 
pl: Sera -lab) was added and left at room temperature for 60 min, and 
OD read at 590 nm. Blank readings (obtained with wells which had no 
LPS- polymyxin complexes added but which had been post- coated) were 
subtracted. Results were expressed as percentage of a known positive 
control (chapter 3), or as median units where 100 was the median 
value determined from assays on 1,000 blood donor sera (chapter 4). 
POLYACRYLAMIDE GEL ELECTROPHORESIS AND IMMUNOBLO'1TING 
Sample buffer (single strength) was 0.0625 M Tris /HC1, 2% sodium 
dodecyl sulphate, 10% glycerol, 1% 2- mercaptoethanol, 0.001% 
bromophenol blue. Double- strength sample buffer was made up with 
concentrations of all constituents doubled to be mixed with an equal 
volume of an aqueous solution of LPS or protein. 
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Preparation of proteinase K digests [95] 
Bacteria were grown up overnight in nutrient broth in a shaking 
incubator. Broth was then centrifuged at 3000 g (5000 rpm) for 10 
minutes in a bench centrifuge. The pellet was resuspended in 10 ml 
PBS, centrifuged again and resuspended in PBS, and the concentration 
adjusted to give an optical density (OD) of 0.5 - 0.6 at 525 nm. 
Aliquots of 1.5 ml were placed in screw -capped Eppendorf tubes and 
centrifuged for 5 minutes at 10,000 g (13000 rpm) in an MSE 
Microcentaur centrifuge. Supernatant was poured off and the pellet 
resuspended in 50 pl of single- strength sample buffer. This 
suspension was then heated to 100 °C for 10 minutes in a boiling water 
bath. After allowing the suspension to cool, 10 pl of a 2.5 mg /ml 
solution of proteinase K (Protease type XI; Sigma) was added, and the 
mixture incubated at 60 °C for 1 hour. The preparation was then 
stored at -20 °C until required. 
For the production of larger quantities of proteinase K digest the 
method above was scaled up. A 15 ml volume of bacterial suspension 
prepared as above was centrifuged at 5000 rpm in the bench centrifuge 
in a universal container, resuspended in 500 pl of sample buffer, and 
then transferred to a screw - capped Eppendorf tube for heating and 
digestion with 100 pl of proteinase K solution. These preparations 
were then divided into 100p1 aliquots for storage. 
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Polyacrylamide gel electrophoresis and imuuunoblotting 
Proteinase K preparations (20p1 aliquots) or LPS (10 pg in 20p1 
sample buffer) were separated on 14% polyacrylamide gel [124] 
omitting SDS from stacking and separating buffers. Protein 
preparations (25pg) were separated on polyaccylamide gel with SDS. 
Gels were then silver stained (for LPS) [95], or stained with 
Coomassie blue (for protein) [190] or blotted [233] to nitrocellulose 
membrane (Schleicher & Schuell, Dassel, Germany: 0.2 pm pore size). 
Blots were blocked with 3% wt /vol gelatin in Tris buffered saline 
pH7.5 (TBS), incubated for 3 h in a dilution of antibody in 1% 
gelatin in TBS. Unless otherwise stated the dilutions used were 1 
in 10 (1 -5 pg /ml) for MAb supplied as culture supernatants or 1 in 
500 (10 -20 pg /ml) for purified MAb preparations. This was followed 
in the case of murine IgG MAbs by 1 hour incubation with horseradish 
peroxidase anti -mouse IgG conjugate (ICN, diluted 1 in 1000), and 
developed with HRP colour reagent (Bio-Rad). For IgA and IgM MAbs 
anti IgG /M /A conjugate (Zymed, diluted 1 in 500) was used. For human 
antibodies, anti -human-IgG (Miles, diluted 1 in 500) or anti -human- 
IgM (ICN, diluted 1 in 500) conjugates were used as appropriate. 
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CHAPTER 3 
ANTIBODY RESPONSES IN RECIPIENTS OF TYPHOID VACCINE 
65 
INTRODUCPION 
During the process of screening of blood donor sera for IgG antibody 
to LPS core with polymyxin /LPS -core ELISA [9,211] a subjective 
impression was gained by those involved that there was an association 
between high levels of antibody and history of travel to areas where 
malaria is endemic. (Information about travel to such areas is 
routinely recorded by the transfusion service because of the risk of 
malaria transmission, and blood from these individuals is not used 
therapeutically.) One possible explanation for this would be that 
the antibody was increased following typhoid vaccination. This was 
an interesting hypothesis because it could lead to the use of typhoid 
vaccine to boost anti -LPS -core antibody levels in blood donors or in 
individuals who might in future be at risk of endotoxaemia. The use 
of typhoid vaccine for this purpose would have the major practical 
advantage that it is already approved for use in humans, and has an 
accepted safety record. I therefore set out to investigate this 
possibility by looking at antibody levels in recipients of typhoid 
vaccine. 
MATERIALS AND METHODS 
Sera 
Sera were obtained from two groups of vaccine recipients. The first 
group consisted of 11 students who each received two doses of 
Wellcome monovalent killed typhoid vaccine. Sets of three sera were 
collected from each. In each case serum was obtained a) on the day 
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of the first dose of vaccine; b) on the day of the second dose of 
vaccine (around 4 weeks after the first dose); and c) 2 -4 weeks after 
the second dose of vaccine. All sera were obtained before any 
foreign travel. The second group were 9 soldiers on an induction 
course. They each received two doses of typhoid and paratyphoid A 
and B (TAB), together with tetanus toxoid. This vaccine was prepared 
for the army at Porton Down. Due to a misunderstanding over the 
desired timing, these samples were obtained a) 19 days after the 
first dose; b) 1 day after the second dose; and c) 10 weeks after the 
second dose. 
Widal assays 
These tests were carried out using Wellcome stained salmonella 
suspensions SSO1 (Salmonella typhi -H), SSO9 (Salmonella typhí -0) and 
SS13 (Salmonella paratyphi C -0). Heat- inactivated sera were diluted 
1 in 20 in saline, and serial doubling dilutions made to a maximum of 
1 in 640. The appropriate antigen dilution (10.1) was added to 250 
p1 of serum dilution in a narrow glass tube. This dilution is 
equivalent to the recommended 1 drop (40p1) in i ml of serum dilution 
recommended by the manufacturer. A control tube with no serum was 
prepared for each antigen. Tubes were mixed and heated at 50 °C for 
two hours for the 0 antigens, or four hours for the H antigens. The 
highest dilution of serum giving agglutination of the antigen was 
recorded as the titre of antibody. 
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RESULTS 
All sera were assayed by the Widal method for antibody to Salmonella 
typhi 0 and H antigen, and S. paratyphi -C 0 antigen. IgG antibody to 
polymyxin /LPS -core cocktail was measured by ELISA. Sera from 8 
individuals were then tested for antibody to a range of 23 individual 
LPS preparations in LPS- polymyxin ELISA. 
Among the students (figure 3.2) there was a rise in antibody to S. 
typhi H antigen in all cases, and a rise in antibody to S. typhi 0 
antigen in all but one. The individual who had no rise in antibody 
to S. typhi 0 was the only one to show a rise in antibody to LPS- 
core. None of the students had a rise in antibody to S. paratyphi -C 
0 antigen. 
Among the soldiers (figure 3.1) the initial S. typhi and S. 
paratyphi -C antibody titres were similar to, or lower than, those 
seen in the students. This suggested that the initial samples did 
represent pre -immunisation antibody levels, despite the delay in 
their collection. A rise in antibody to S. typhi H antigen was 
observed in all but one of the soldiers, and a rise in antibody to S. 
typhi 0 was observed in all but two. (In one individual there was no 
rise in antibody to S. typhi 0 or H antigens.) A small rise in 
antibody to LPS -core was observed in two soldiers. One of these two 
had a large rise in antibody to S. typhi 0 antigen, while the second 
had a small rise(from 1:20 to 1:40) in this antibody. None of the 




























% of control 
Serum No. 
Figure 3.1 Antibodies in sera from 9 army recruits immunised with 
killed typhoid /paratyphoid (TAB) vaccine and tetanus toxoid. Antigens 
are as follows: TO = typhoid 0; TH = typhoid H; CO = paratyphoid -C 0 
(all Widal assays); CORE = polymyxin -LPS -core cocktail IgG ELISA 
(expressed as % of control). Serum samples were taken as follows: 0 = 
19 days after first dose, 1 = 1 day after second dose, 2 = 10 weeks 





































Figure 3.2 Antibodies in sera from 11 students immunised with 
monovalent killed typhoid vaccine. Antigens are as follows: 
TO = typhoid 0; TH = typhoid H; CO = paratyhpoid -C 0 (all Widal 
assays); CORE = polymyxin -LPS -core cocktail IgG ELISA (expressed as 
96 of control). Serum samples were taken as follows: 0 = before 
first dose, 1 = before second dose, 2 = 2 - 4 weeks after second 
dose. 
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Sera from 8 individuals were selected for measurement of antibody to 
individual LPS chemotypes (figures 3.3 - 3.10). These included the 
three individuals with a rise in LPS -core antibody (figures 3.3, 3.4, 
3.9). Increases in antibody to several of the smooth Salmonella 
LPSs were seen in six individuals, including two of the three with 
increasing antibody to the LPS -core cocktail. The increases in 
antibody to the smooth Salmonella LPSs can largely be explained on 
the basis of 0 antigen factors common to S. typhi (factors 9,12) and 
either S. enteritidis, (factor 9), or S. abortus-equi and S. 
typhimuri tun, (both f actorl2) . 
There was however no consistent relationship between the Widal titre 
against S. typhi 0 antigen and antibody to the various smooth 
Salmonella LPSs as measured by ELISA. In some cases (eg AT, figure 
3.7, and PU, figure 3.8) the Widal titre and the ELISA OD rise 
together. In other cases, for example, in soldier RW (figure 3.9) 
the Widal titre increases, but there is no rise in ELISA OD to the 
various smooth Salmonella LPSs. 
In student AB (figure 3.3) there is no rise in Widal titre to S. 
typhi 0 antigen, but there is a rise in IgG antibody S. typhi and to 
the cross -reacting Salmonella serotypes (S. abortus -equi and S. 
enteritidis but not S. minnesota). This individual also showed a 
marked increase in antibody to the polymyxin- LPS -core cocktail. It 
is possible that the antibody measured with the smooth Salmonella 
LPSs is in fact anti -core antibody. This seems unlikely, however, 
since there is no increase seen with the Salmonella Ra LPSs, and the 
antibody to smooth Salmonella LPSs is restricted to those known to 
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cross -react with S. typhi. 
In the three individuals with a rising antibody to polymyxin -LPS -core 
cocktail (soldiers YG (figure 3.4), and RW (figure 3.9) and student 
AB (figure 3.3)) there is no detectable rise in antibody to the 
individual rough LPSs that go to make up the cocktail. The only 
rough LPS which detects a rise in antibody is E. coli R1, which is 
not part of the cocktail. Antibody to E. coli R1 also rises in 
soldier US (figure 3.6) despite a falling anti -LPS -core cocktail IgG 
in this case. 
No significant rises were observed in the rough LPSs that go to make 
up the LPS -core cocktail, nor was there any consistent increase in 
antibody to Ra core of Salmonella. There was therefore no consistent 
rise in cross -reactive antibody to LPS -core. 
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Table 3.1 
Abbreviations for LPS preparations used in figures 3.3 - 3.10 
Abbreviation Species LPS Prepared by 
SABORTUS Salmonella abortus -equi Sigma 
SENTRDSIG Salmonella enteritidis Sigma 
SMWT Salmonella minnesota MPRL 
STWTSIG Salmonella minnesota Sigma 
STWTSIG Salmonella typhimurium Sigma 
STYPHI Salmonella typhi Sigma 
SERMARSIG Serratia marcescens Sigma 
ECK12 E. coli K12 List 
ECO18R E. coli 18 rough mutant MPRL 
ECR1BR E. coli R1 HF4704 Borstel 
ECR2BR E. coli R2 F576 Borstel 
ECR3BR E. coli R3 F653 Borstel 
ECR4BR E. coli R4 F 2513 Borstel 
SMRA Salmonella minnesota R60 (Ra) List 
STRA Salmonella typhimuirium TV119 (Ra) Sigma 
KAM10B Klebsiella aerogenes M10b MPRL 
PAC605 Pseudomonas aeruginosa PAC 605 MPRL 
SMRC Salmonella minnesota R5 (Rc) List 
STRC Salmonella typhimurium 878 (Rc) MPRL 
SMRE Sa7monella minnessota R595 (Re) List 
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































The results from the two groups of vaccine recipients are similar, 
most individuals showing a rise in specific antibody. The levels of 
antibody detected in the soldiers were generally lower. This may 
reflect differences in the vaccine used, or may be due to the timing 
of specimens. The levels of antibody to S. typhi 0 antigen in either 
group are higher than those reported by others [18], while the H 
antibody titres are roughly comparable. 
There is a suggestion from these results that some individuals tend 
to respond to LPS -core rather than the 0 antigen. This was seen most 
clearly in the initial results from student AB, but results of the 
ELISA with individual LPSs was not consistent with this. An 
alternative explanation for the apparent lack of anti -0 response is 
that this individual responded to vaccine with IgG rather than IgM. 
Widal tests can detect IgG antibody [123], but probably detects IgM 
with greater sensitivity. There is no obvious explanation for the 
detection of antibody to the LPS -core cocktail but not to the 
individual LPS chemotypes which make up the cocktail. 
If typhoid vaccine was capable of boosting pre -existing levels of 
antibody to the LPS -core cocktail (as distinct from bringing about a 
new response) then an increase would be predicted to occur in those 
individuals with the highest starting levels of antibody. The 
initial levels of anti -LPS -core antibody were however no higher in 
those individuals who showed an increase in this antibody than in 
those who did not (figures 3.1 - 3.2). This is in agreement with the 
work of Demaria et al [57] and Ziegler [264], who found that the 
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antibody response to E. coli J5 or Salmonella minnesota Re 595 
immunisation was higher in individuals whose pre -immunisation titre 
was low. They used passive haemagglutination to measure the antibody 
response, and interpreted the lack of booster effect as indicating a 
T- independent and therefore primarily IgM response. Direct 
measurement of IgM levels to LPS -core following J5 or Re 595 or 
typhoid immunisation would be of interest. 
The antibody response to immunisation varies considerably among the 
individuals tested here. Similar variation is found with other 
vaccines, eg with hepatitis B vaccine [43] there is variation in the 
response related to age and sex, with weaker responses in older 
individuals, and slower responses in males. Since the individuals 
tested here were all in their late teens or early twenties, and 
included an excess of males (soldiers) the results may therefore be 
biased. It is possible that older individuals, with a greater chance 
of prior exposure to Gram -negative infection, may tend to respond 
with less specific and more cross -reactive antibody, including 
perhaps anti -LPS -core antibody. 
There is no overall increase in the level of antibody to LPS -core in 
the vaccine recipients reported here, and none of the individuals who 
show a rise reached the 400% of control level which was the cut -off 
point for selecting sera for the manufacture of anti -LPS -core IgG. 
There is therefore no evidence to support the idea that typhoid 
vaccine might be used to boost anti -LPS -core antibody levels in blood 
donors or in patients at risk of endotoxaemia. On the contrary, the 
data support the conventional view that the antibody response to a 
smooth LPS is dominated by antibodies to the 0 antigen. 
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CHAPTER 4 
STUDIES ON IGG ANTIBODY IN URINE 
84 
INTRODUCTION 
It has been suggested that measuring urinary antibody to a mixed 
heat -killed coliform antigen preparation could be used as an aid in 
the diagnosis of UTI [156]. I decided to test this hypothesis, and 
to investigate the nature of the antibody found in urine during UTI. 
An initial question, relating this work to the rest of this thesis, 
was to what extent the antibody detected was directed against LPS- 
core. 
Previous studies of antibody in the urine during UTI have focused 
mainly on specific responses to organisms isolated from individual 
patients [194,216,219,227], and have often had the aim of trying to 
distinguish between cystitis and pyelonephritis [194,219]. Other 
workers have measured total IgA and secretory IgA in the urine in 
patients with UTI [68,69]. It has been shown, at least in 
pyelonephritis, that the antibody found in the urine is part of a 
systemic immune response, and that there may be some local production 
of specific secretory IgA in the urinary tract [216,219]. Antibody 
response to antigens which are not strain specific, such as outer 
membrane proteins [169] lipid A [141] or pili [202] have been 
measured in the serum in relation to urinary infection. Serum 
antibodies to these non -strain -specific antigens have been found to 
be raised after pyelonephritis and, to a lesser extent, cystitis. 
It is not clear whether antibody in the urine plays a significant 
part in host defence against UTI. Attachment of bacteria to the 
urinary tract epithelium is a key step in the pathogenesis of UTI 
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which could be blocked by antibody, but antibodies to the pili which 
are thought to act as adhesins have not been found in the urine 
[202]. Deficiency of urinary antibody production does not appear to 
be an important factor in recurrent UTI in adults [69,216], though it 
may be important in children [68]. 
The main class of antibody detected in urine with the mixed heat - 
killed coliform ELISA was IgG [156]. I decided therefore to 
concentrate just on IgG, since the mechanism of production of IgA was 
probably different and would complicate the interpretation of 
results. 
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MATTRRTATS AND METHODS 
Urine samples 
Control samples were obtained from 16 asymptomatic students. Seventy 
two urine specimens were collected from students with symptoms of 
urinary infection attending general practitioners at the University 
of Edinburgh Students' Health Centre. None of these patients was 
thought to have pyelonephritis. One patient who was known to be 
taking an antibiotic at the time was excluded. Most of these 
patients were subsequently treated with antibiotics, and none 
returned because of persisting symptoms. The specimens were 
collected under the supervision of an experienced nurse, and were 
then brought directly to the clinical bacteriology laboratory in 
Department of Medical Microbiology by the patient. 
Microscopy was performed using an inverted microscope. Ten pus cells 
per field (equivalent to 20 per mm3) was scored as positive. 
Cultures (standard loop) containing > 105 cfu /ml of a single 
bacterial species were considered positive. Cultures containing 
between 104 and 105 cfu /ml would be considered doubtful in this group 
of patients. 
Urine samples from patients with Gram -positive infection were 
selected from among all specimens sent to the clinical bacteriology 
laboratory by general practitioners. 
Urine samples were stored at 4 °C overnight, then centrifuged at 4000g 
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for 10 minutes and the supernatant stored at -20 °C as three separate 
i ml volumes. 
Urine samples with simultaneously taken serum or plasma sangles 
Thes samples were obtained from patients attending the recurrent UTI 
clinic at the City Hospital, Edinburgh. Many of these patients were 
on continuous low -dose antibiotics. Diagnostic bacteriological 
testing of these samples was carried out at the City Hospital 
bacteriology laboratory. These samples were collected as two 
distinct groups: 
Group 1: Urine and serum samples from 44 unselected patients 
attending Dr JA Gray's out -patient clinic were collected in 1991. 
These urines were centrifuged and supernatants stored as above. Only 
three of these patients had microbiologically confirmed UTI. 
Group 2: Urine and plasma samples from 8 patients with 
microbiologically confirmed UTI and 14 patients without confirmed UTI 
were selected from a large number of specimens collected in 1983 and 
1984 by Dr CC Blackwell. In these cases the urines were not 
centrifuged before freezing. 
All urine and serum or plasma samples were stored at -20 °C. 
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Mixed Heat -killed Coliform ELISA plates 
The preparation of these plates was based on the method described by 
McKenzie and Young [156]. Six isolates of coliform organisms (four 
E. coli, one Kiebsiella pneumoniae, and one Proteus mirabilis) were 
obtained from urine samples submitted to the diagnostic laboratory of 
the Department of Medical Microbiology. (The organisms were 
deposited in the MPRL freeze -dried collection, reference numbers MPRL 
2287 - 2292). These organisms were chosen to represent the range of 
Gram -negative bacteria isolated from urine specimens. Each organisms 
was grown overnight in nutrient broth at 37 °C, then washed and 
resuspended in PBS. The concentration was adjusted so that a 1 in 10 
dilution had an OD of 0.25 at 540 nm, and heated at 100 °C for 30 min. 
The six preparations were mixed together in equal proportions. The 
mixture was diluted 1:10 in coating buffer, and 100p1 added per well 
to Nunc polysorb 8 -well ELISA strips. After overnight incubation at 
room temperature the strips were washed four times with wash buffer. 
Urine ELISA assay for anti -bacterial Iq3 
Assays were performed using polymyxin -LPS -core plates (see general 
materials and methods) or mixed heat -killed coliform plates as 
described above. Duplicate aliquots of urine (100p1) were dispensed 
into coated wells and incubated for 1 hour at 37 °C. Plates were then 
washed four times with wash buffer, 100p1 of alkaline phosphatase 
conjugated goat anti -human IgG (ICN, diluted 1 in 500 in ELISA 
diluent with 0.5% bovine serum albumin) added, incubated for a 
further hour at 37 °C, and again washed four times. P- nitrophenyl 
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phosphate (Sigma, 100 pl of a 1mg /m1 solution in 0.05M sodium 
carbonate, 1mM magnesium chloride, pH 9.8) was added and the OD read 
after 30 minutes at room temperature. Each assay included duplicate 
blank wells with no urine added. Wells without antigen but washed as 
above were used as negative controls. 
Absorption of antibody with LPS -core cocktail plates 
Samples (100p1) of antibody -positive urine were added in duplicate to 
wells coated with polymyxin -LPS -core cocktail antigen and incubated 
at 37 °C for one hour. Incubation and transfer were repeated twice so 
that each sample had been incubated for a total of 3 hours in three 
separate wells. Antibody was then measured by ELISA using plates 
coated with the mixed heat -killed coliform antigen preparation. 
Antibody results were compared with those for unabsorbed urine and 
for urine that had been absorbed in control wells (wells containing 
no polymyxin -LPS -core cocktail but washed and post- coated in the same 
way as coated wells). 
Urinary total IcG assay 
Nunc Maxisorb plates were coated with affinity purified goat anti - 
human-IgG (Zymed) (diluted 1 in 2000 in 0.05M carbonate /bicarbonate 
buffer, pH 9.6) by adding 100p1 to each well and incubating overnight 
at room temperature. Each well was then washed four times with wash 
buffer. Wells were then post- coated for 2 h at room temperature with 
100p1 per well of 5% bovine serum albumin in PBS. Plates were then 
washed four times in wash buffer and stored at -20 °C. Urine samples 
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were diluted 1 in 3 in PBS and duplicate 100p1 samples added to wells 
in the coated plate. Human serum protein calibrator (Dakopatts) was 
diluted in PBS to give concentrations of 100, 25, 6.3, 1.6, 0.4, 0.1, 
and 0.025 pg /ml, and 100 pl samples added in triplicate to each assay 
plate. Coated wells to which PBS alone was added were included as 
blanks. Plates were incubated for 1 hour at 37 °C, and then washed 
four times. Alkaline phosphatase labelled goat anti -human IgG (ICN) 
was diluted 1 in 500 in ELISA diluent with 0.5% bovine serum albumin 
and 100p1 added to each well, incubated for 1 h at 37 °C and washed 
four times. P- nitrophenyl phosphate (Sigma, 100 pl of a 1mg /m1 
solution in 0.05M sodium carbonate, 1mM magnesium chloride, pH 9.8) 
was added and the OD measured, after 120 minutes at room temperature, 
on an Anthos plate reader. IgG concentrations were calculated from 
the standard curve by the plate reader's on -board software, taking 
into account the dilution of the urine. 
Calculation of predictive value of antibody tests 
This calculation was performed in the same way as other comparable 
studies [112,135,157): 
Sensitivity = true positives /(true positives + false negatives) 
Specificity = true negatives /(true negatives + false positives) 
Positive predictive value = true positives /(true positives + false 
positives) 




IIG antibodies to mixed- heat -killed coliform antigen and polymYxi.n- 
LPS -core cocktail antigen in urine. 
For all but one of the asymptomatic controls both assays gave OD 
values of < 0.1. One male asymptomatic control did have consistently 
high titres of urinary antibody to both antigens, with OD values of > 
1.0. This individual did not have covert urinary tract infection, 
haematuria, proteinuria, hypertension, or any other evidence of renal 
or other disease. 
Of the 72 samples from symptomatic patients, 19 were culture 
positive, and the remaining 53 were culture negative. All the 
positive cultures were of coliform organisms, and in all cases they 
were present at > 105 cfu /ml. Pus cells were seen in 17 of the 19 
culture- positive specimens, and in one of the 53 culture -negative 
specimens. 
IgG antibody to both the LPS -core cocktail antigen and the mixed 
heat -killed coliform antigen was detected in most of the symptomatic 
patients (figure 4.1). Significantly more antibody was found in 
specimens which were culture positive than in those which were 
culture negative. For the LPS -core antigen, t = 3.65; p < 0.001, 
while for the mixed heat -killed coliform antigen t = 3.55; p < 0.001. 
The usefulness of antibody as a predictor of positive culture was, 
however, low. For the LPS -core antigen, an OD of > 0.6 had a 
sensitivity (defined as the proportion of the culture- positive 
92 
IgG antibody 














CD O O O 
%O. 





.4 .8 1.2 1.6 
IgG antibody to Mixed Heat -killed Coliform 
antigen (ELISA OD) 
Figure 4.1 Correlation between IgG antibodies (ELISA OD) to 
mixed heat -killed coliform antigen and LPS -core cocktail 
antigen in 72 urine samples from symptomatic patients. 
= culture positive; 0 = culture negative. 
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samples which were picked out by the ELISA test) of 15/19 (79 %) and a 
positive predictive value (defined as the number of samples picked 
out by the ELISA test which were culture positive) of 15/30 (50 %). 
For the mixed heat -killed coliform antigen an OD of > 0.4 had a 
sensitivity of 13/19 (68 %) and a positive predictive value of 13/21 
(62 %). 
There was a significant correlation between antibody to the two 
antigen preparations (r = 0.7633, 95% confidence limits 0.65 < r < 
0.85, p < 0.001). This suggested that the two assays might to some 
extent be measuring the same antibody. This was supported by the 
demonstration that the antibody measured by the mixed heat -killed 
coliform antigen could be reduced by absorption with LPS -core coated 
wells (figure 4.2). 
Eight antibody -positive and culture- positive specimens were tested 
for antibody to the individual components which went to make up the 
LPS -core cocktail antigen preparation. In each case antibody to all 
of the component parts of the antigen preparation could be detected. 
No one LPS preparation stood out as a particularly good antigen 
(table 4.1). 
Urine samples from which > 105 cfu /ml of a Gram -positive organism was 
isolated were selected (from those submitted to the clinical 
bacteriology laboratory by general practitioners) and tested for 
antibody to LPS -core and mixed heat -killed coliform antigens. These 
antibody levels in these samples (table 4.2) were similar to those 



















Figure 4.2 Reduction in IgG antibody (ELISA OD) to mixed 
heat -killed coliform antigen in four urine samples following 
absorption for three one -hour periods in wells coated with 
LPS -core cocktail antigen or blank plates. 
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Table 4.1 IgG antibody (ELISA OD) to polymyxin -LPS -core cocktail and 
individual polymyxin complexed rough LPS preparations in eight 
culture- positive urine samples. 
IgG antibody (ELISA OD) against 
Sample No Cocktail Klebsiella Pseudomonas E.coli Salmonella 
1 1.346 0.393 0.435 0.440 0.535 
2 1.310 1.087 1.135 1.077 1.012 
3 0.293 0.154 0.135 0.140 0.205 
4 0.992 0.758 0.719 0.587 0.722 
5 0.969 0.340 0.452 0.400 0.528 
6 0.888 0.507 0.480 0.513 0.473 
7 0.995 0.463 0.478 0.514 0.672 
8 1.302 0.358 0.256 0.300 0.676 
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Table 4.2 IgG antibody (ELISA OD) to mixed heat -killed coliform 
antigen and polymyxin -LPS -core cocktail antigen in six urine samples 
from which >105 cfu /ml of a Gram -positive organism was isolated. 
Sample 
IgG antibody (ELISA OD) 
detected with: 
Mixed heat -killed 
Organism isolated coliform 
LPS -core 
cocktail 
1 Enterococcus sp 0.256 0.571 
2 Enterococcus sp. 0.589 1.054 
3 Staphylococcus saprophyticus 0.265 0.584 
4 Staphylococcus saprophyticus 0.1 0.227 
5 Staphylococcus saprophyticus 0.688 1.235 
6 Group G Streptococcus 0.528 1.091 
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against the mixed heat -killed coliform antigen was 0.404 for the 
Gram -positive urines, and 0.458 for the Gram -negative urines. With 
the LPS -core cocktail antigen the mean OD for the Gram -positives was 
0.794 while for the Gram- negatives it was 0.708. The finding of 
antibody to Gram -negative bacterial antigens in Gram -positive 
infection implied that the antibody detected was not due to a 
specific immune response to the infecting organism. 
Total IqG levels in urine samples 
One possible explanation for the presence of antibody in urine is 
that it was simply the result of non- specific leakage of serum 
proteins into the urine as a result of inflammation. This would 
explain the finding of antibody to Gram -negative bacteria in Gram - 
positive infection. A capture assay for total IgG in urine was 
therefore developed, and applied to some of the urine samples. An 
example of a standard curve for this assay is shown in figure 4.3. 
Sixty -three of the original 72 urines from symptomatic patients were 
still available as frozen aliquots which had not been thawed. 
Eighteen of these were culture- positive specimens. IgG 
concentration (expressed as a logarithm) had a statistically 
significant correlation with IgG antibody to mixed heat -killed 
coliform antigen (r = 0.52, 95% confidence interval 0.32 - 0.68, p < 
0.001) and with IgG antibody to LPS -core cocktail antigen (r = 0.68, 
95% confidence limits 0.52 - 0.79, p < 0.001) (figure 4.4). Total 
IgG tended to be higher in culture positive specimens (Kruskal- Wallis 
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Figure 4.4 Relationship between IgG concentration and 
antibody to LPS -core (ELISA OD) in 63 urine specimens. 
= culture positive; O = culture negative. 
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pg /ml had a sensitivity for positive culture of 11/18 (61 %) and a 
positive predictive value of 11/17 (65 %), implying that it is roughly 
as good (as a predictor of positive culture) as measurements of 
antibody to either LPS -core or mixed heat -killed coliform antigens. 
The predictive value of the three measurements is summarised in table 
4.3. 
Comparison of Urine and Sema antibodies in patients attending a 
recurrent UTI clinic 
If the antibody detected in the urine was a result of non- specific 
leakage of IgG into the urine, then it should be an unselected sample 
of the antibody found in the serum. The ratio of anti -LPS -core 
antibody to total IgG should therefore be the same in the serum as in 
the urine. I therefore decided to try to collect some urine samples 
with simultaneously taken serum samples to investigate this 
possibility. Unfortunately the general practitioners at the 
University Health Centre were unwilling to subject their patients to 
venepuncture for this purpose. I therefore arranged to collect 
specimens from 44 patients attending Dr JA Gray's recurrent UTI 
clinic at the City Hospital Edinburgh. Only 3 of the 44 patients 
(group 1) had positive culture, and therefore some older samples and 
controls (group 2) were selected from a collection obtained from the 
same source by Dr CC Blackwell. 
The urine samples were first tested for anti -LPS -core and total IgG 
as before. The results are shown in figures 4.5 and 4.6. As in the 
samples from students with urinary symptoms, there was a correlation 
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Table 4.3 Comparisons of tests for the prediction of positive 
culture in 72 urine samples from students with symptoms of UTI. 
Predictive value 
for positive culture 
Test Sensitivity Specificity Positive Negative 
mixed heat -killed 
coliform ELISA 
OD > 0.4 
polymixyn -LPS -core 
cocktail ELISA 
68% 85% 62% 90% 
OD > 0.6 79% 72% 50% 93% 
IgGa >1 Pg/m1 61% 87% 65% 85% 
Pus cells 
> 20 /mm3 89% 98% 94% 96% 
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Figure 4.6 Relationship between IgG concentration and 
antibody to LPS -core cocktail antigen (ELISA OD) in urine 
specimens from recurrent UTI patients group 2 (n =22). 
= culture positive; C)= culture negative. 
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between antibody to LPS -core cocktail and total IgG in these samples. 
In the 44 urines which I collected (group 1), r = 0.58, P < 0.001, 
95% confidence interval 0.34 - 0.74. In the 22 urines obtained from 
Dr Blackwell (group 2) r = 0.75, P < 0.001, 95% confidence interval 
0.48 - 0.89. 
Unlike the samples from students with urinary symptoms there was no 
association between positive culture and either antibody to LPS -core 
cocktail or total IgG in either group. One reason for this may have 
been the fact that many of the patients were on long -term, low -dose 
antibiotic treatment. This would be expected to result in some false - 
negative culture results. Other indicators of the presence of 
infection were therefore examined in relation to the antibody 
results. 
Of the 44 patients in group 1, 14 were reported to have symptoms of 
urinary infection at the time of clinic attendance, 6 were found to 
have increased numbers of pus cells in the urine, and 27 were on 
antibiotics. Results of analysis of the IgG anti -LPS -core and total 
IgG assays on the urine for differences related to these factors are 
shown in table 4.4. The only statistically significant difference 
observed was that patients on long term antibiotics tended to have 
higher levels of urinary IgG. 
Serum IgG anti -LPS -core antibody was measured in 42 of the 44 sera 
from group 1. The antibody level was raised with a median value of 
247.95 compared to a median of 100 for the blood donor population. 
There was a tendency for the patients on long -term antibiotic 
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Table 4.4 Analysis of the results of urine antibody assays by 
clinical indices on group 1 of the recurrent UTI patients (n =44). 
P values derived from Wilcoxon two -sample test. 
Index 
Anti LPS -core IgG Total IgG 
Mean OD P Mean OD P 
Pus cells 
in urine: 
Increased 0.113 0.343 
0.97 0.52 
No increase 0.182 0.246 
Symptoms 
of UTI: 
Present 0.258 0.389 
0.36 0.34 
Absent 0.133 0.198 
Long term 
antibiotics: 
In use 0.219 0.329 
0.09 0.04 
Not in use 0.099 0.148 
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treatment to have higher levels of this antibody (median level 378) 
than those who were not on antibiotics (median level 256), but this 
difference did not reach statistical significance (Wilcoxon two- 
sample test gives P= 0.34). 
If anti -LPS -core antibody in the urine was simply a result of non- 
specific leakage of antibody into the urine it follows that the ratio 
of anti -LPS -core to total IgG antibody should be the same in both 
serum and urine. It was not however clear how the ratios should be 
calculated since the anti -LPS -core measurements were not on linear 
scales. The urinary anti -LPS -core IgG measurements were simply ELISA 
OD values, which probably bore a logarithmic relationship to the 
actual amount of antibody present. In addition to calculating simple 
ratios of the available data the results of some data transformations 
was therefore examined. The expected correlation between the urine 
and serum values of the ratio of anti -LPS -core IgG to total IgG could 
not however be demonstrated with either the basic data nor with any 
transformation. Figure 4.7 shows the result obtained with one data 
transformation, where an attempt was made to make the urine anti -LPS- 
core IgG data linear by expressing the results as the exponent of the 
OD value, e(OD). Other transformations examined consisted of using 
the log of the total IgG values and log of the serum anti -LPS -core 
IgG values. 
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Figure 4.7 Relationship between ratio of 
anti -LPS -core IgG to total IgG in serum and 
urine of 40 patients attending a recurrent UTI 
clinic. 




The "gold standard" used for the diagnosis of urinary tract infection 
is quantitative culture. Quantitative culture of bacteria in urine 
can be influenced by many factors other than the presence of UTI, 
notably contamination, overgrowth, and the effect of antibiotics. 
The interpretation of bacterial counts in urine even when these 
problems can be excluded is controversial, and the old standard of 
105 cfu /ml cannot be accepted blindly [222]. There is however no 
satisfactory alternative standard. Detailed and consistent 
clinical criteria would be required to yield information more 
reliable than culture [112,222]. I therefore concentrated where 
possible on freshly taken samples from patients not on antibiotics, 
as in the controls and the students attending the University of 
Edinburgh Students' Health Centre. The possibility that bacterial 
counts of 104 -105 cfu /ml are significant is covered by the approach 
used in the Clinical Bacteriology laboratory, but such counts are not 
common and were not encountered in the specimens I collected. Among 
the recurrent UTI patients studied the interpretation of culture 
results was complicated by the fact that many of these patients were 
on antibiotics. 
Urinary antibody is clearly associated with UTI in the symptomatic 
student group, but the predictive values for positive culture of the 
urinary antibody tests reported here are too low to be useful in 
diagnostic laboratories. Very similar conclusions have been reached 
by other workers [112,135,157]. 
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One reason for the poor predictive value of urinary antibody 
measurements is the raised antibody levels found in many culture - 
negative specimens from symptomatic patients. Similar results were 
obtained by McKenzie and Young [156]. Antibacterial substances in 
urine could account for some false- negative cultures, but previous 
studies in the Clinical Bacteriology laboratory have found such 
substances in less than 1% of urines from the Students' Health 
Centre. Urethritis, or urinary tract infection with < 104 cfu /ml 
might be present in some case, but the absence of large numbers of 
pus cells in all but one of the culture negative specimens is against 
this. There is no satisfactory explanation for acute urinary 
symptoms in many patients however [223], and the finding of raised 
levels of antibody in this group may be an indication of some as yet 
undefined physical basis for the symptoms. 
Antibody to LPS -core cocktail or mixed heat -killed coliform 
correlated with one another, and both had a similar association with 
positive culture in the symptomatic students. The assays could be 
measuring two quite separate antibodies which happen to occur 
together, or they could be measuring the same antibody. The 
demonstration that the coliform antibody can be reduced by absorption 
with LPS -core antigen suggests that antibody to LPS -core makes up a 
sizable proportion of the antibody detected by the coliform antigen. 
This may in part reflect the fact that other antigens in the coliform 
antigen will have been denatured by heat (in the case of proteins) or 
will be highly strain specific (in the case of 0 antigens). It 
might also indicate that antibody to LPS -core is an important part of 
the host immune response to UTI. 
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The assay used to measure urine IgG levels was fairly crude. An 
examination of the scatter of triplicates on the standard curve 
(figure 4.4) indicates an overlap between OD values obtained with 
some pairs of neighbouring standards. The cut -off value chosen to 
distinguish between culture- positive and culture- negative urines from 
the symptomatic patients is i pg /ml. Connel et al [49], using a 
similar assay, report 1 pg /ml as the median concentration of IgG 
found in urine samples from a group of genitourinary medicine 
patients and blood donors being tested for antibody to HIV. Lentner 
[1] quotes a median daily excretion of 1.93 mg of IgG in adults, 
equivalent to 1.6pg /ml for a mean daily urine volume of 1.2 1. The 
absolute values of urinary IgG reported here are therefore generally 
lower than those expected in asymptomatic controls. It is possible 
that the IgG concentration in patients with urinary infection would 
be low because of urine dilution. It is perhaps more likely that the 
crude assay employed is giving results which are too low. It would 
have been useful to measure urinary IgG in some asymptomatic 
controls, but this was not considered until the materials for the IgG 
assay had been exhausted. The assay might also have been improved by 
using urine spiked with purified IgG as the standard 
Despite the limitations of the assay, the total urinary IgG did 
correlate with the other antibody measurements. The simplest 
explanation for this would be that antibody was leaking into the 
urinary tract in association with inflammation. The antibody to LPS- 
core and coliform antigens would then simply reflect the prevalence 
of these antibodies in the general population. Antibody to LPS -core 
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is known to be common in blood donors [9]. 
The view that the antibody detected in urine in this and similar 
studies [112,135,156,157] is not part of a specific immune response 
is supported by the fact that it is present very early in the course 
of infection. It is further supported by the finding of antibody to 
Gram -negative bacteria in Gram -positive infection. It is possible 
that there is a specific immune response which results in the 
presence of IgG in the urinary tract, but this would probably be 
masked by non- specific leakage of antibody. 
If the antibody present is due to non- specific leakage it follows 
that there might well give false- positive results in patients with 
gonococcal or chlamydial urethritis. it is important that these 
infections are differentiated accurately from UTI, since they are 
managed quite differently. In response to this suggestion Thakker et 
al [231] reported negative findings with the "Uristat" test in 
patients with urethritis. This result may be due to the relatively 
small area of epithelium involved in urethritis, resulting in a much 
lower concentration of IgG leakage into the urine. Further studies 
of antibody in the urine in urethritis are required to clarify this 
point. 
In the recurrent UTI patients antibody was not associated with 
positive culture. This underlines the differences between the two 
groups of patients. Most of the recurrent UTI patients were 
asymptomatic, and symptoms, when present, were probably less severe 
in the recurrent UTI patients than in the students with acute urinary 
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symptoms. Many of the recurrent UTI patients were on long -term 
antibiotics, which may have resulted in some false -negative cultures. 
The association between long -term antibiotic treatment and raised 
levels of urinary IgG might be because patients on long -term 
antibiotics were those with the more severe problems of recurrent 
infection, associated with chronic inflammation in the urinary tract. 
The finding of raised levels of serum anti -LPS -core IgG in this same 
subgroup also suggests that these may be the patients who have had 
the larger number of Gram -negative infections. 
If the IgG antibody detected in urine is simply a result of non- 
specific leakage of serum components then the ratio of specific to 
total IgG should remain constant. It may appear unfortunate that the 
recurrent UTI patients were chosen for the comparison of serum and 
urine antibody levels, since the association of antibody with 
positive culture was not found in this group, but the hypothesis is 
still valid in this group as in symptomatic patients. The fact that 
the expected result was not obtained may be because of inaccuracies 
in the assays used, but may indicate that there is an alternative 
explanation for at least some of the IgG present in the urine. IgG 
may for example be produced locally in the urinary tract in some 
patients. 
Possible clues as to the alternative ways in which IgG might get into 
the urine were sought by considering the clinical background to the 
patients who had the greatest differences between the urine and serum 
ratio of specific to total IgG, but no associations were apparent. 
If this question were to be investigated further then a more accurate 
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assay of urinary IgG would be required, and it would also be useful 
to consider a range of different specific antibodies. 
Tne initial purpose of measuring urinary antibody to a mixture of 
common urinary pathogens was that it would permit rapid detection of 
UTI and it would be less susceptible to the problems of contamination 
and overgrowth than conventional bacteriology. In our hands IgG 
antibodies did not predict positive culture in fresh, carefully taken 
samples to a useful extent. Such antibody tests are therefore not 
likely to be useful in examining contaminated specimens or specimens 
where the patient has been on antibiotics. Other workers have come 
to similar conclusions using similar antigen preparations but 
measuring all antibody classes. It is possible that measuring 
urinary IgA or secretory IgA antibody to some shared bacterial 
antigen or combination of antigens would give some diagnostically 
useful information, but considerable further work is required to 
establish this. Measurement of IgG in urine might be a useful index 
of inflammation in the urinary tract. 
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CHAPTER 5 
INITIAL STUDIES ON THE INTERACTION OF MABS AND HUMAN IGG PREPARATIONS 
WITH BLOOD- CULTURE ISOLATES OF GRAM - NEGATIVE BACILLI 
AND WITH ROUGH MUTANTS OF E. COLI 
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INTRODUCTION 
When I first became involved with this work the production of MAbs to 
LPS had been under way for over 2 years, both in Edinburgh and in 
Basel. I set out to test the reactivity of some promising MAbs with 
LPS from a range of bacterial species selected from local blood 
culture isolates. As indicated in the general introduction, blood 
culture isolates may be the best available indication of the sort of 
LPS likely to be involved in sepsis syndrome patients, and therefore 
it was hoped that some of the MAbs might be widely cross- reactive 
with these strains. This work was then extended to examine the 
binding of selected MAbs to the known core types of E. coli, and to 
test some alternative methods of detecting the binding of antibody to 
LPS. In addition I examined the binding (by ininunoblotting) of some 
human IgG preparations to LPS from the same collection of bacteria 
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MATAIS AND METHODS 
Bacteria (table 5.1) 
Ten blood -culture isolates were selected to represent the range and 
relative frequency of Gram -negative bacilli isolated from blood 
cultures in the clinical bacteriology laboratory in Department of 
Medical Microbiology. Identification of these organisms was checked 
using API20E (Bio Merieux). One strain (8b 226) which had been 
labelled as a Kiebsiella was found to be an E. coli, and therefore a 
further Kiebsiella strain (9b26) was selected. When Polyacrylamide 
gel electrophoresis was performed the strain of Proteus was found to 
have an unusual pattern (see results) and therefore a second Proteus 
strain (9b24) was selected. 0 typing of the E. coli strains was 
subsequently performed by the Division of Enteric Pathogens, Central 
Public Health Laboratory, Colindale, London. The strains are listed 
in table 5.1 a. 
Rough strains of E. coli used in this chapter (table 5.1 b) were 
obtained from the MPRL collection. 
MAbs 
Most of the MAbs used in this chapter were bulk purified 
preparations. Their specificities (as determined by polymyxin -LPS 
ELISA) and concentration are listed in table 5.2. 
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Table 5.1 Bacteria used in chapter 5 
a: Blood culture isolates 
Number Reference letter 








E. coli 0:18 K5 
Proteus sp. 
Kriterobacter cloacae 
8b 273 d Serratia sp. 
8b 275 e E. coli 0:75 K5 
8b 281 f E. coli 0:18 K5 
8b 300 g Pseudomonas aeruginosa 
8b 305 h Pseudomonas aeruginosa 
8b 316 i K. coli 0:1 K1 
8b 317 j S. coli 0:6 
9b 24 k Proteus sp. 
9b 26 1 K1ebsiella pneunnoniae 
b: Standard core types of E. coli 
Reference numbers Origin 
R1 MPRL 1383 HF4704 Dr Nils Carlin, Sweden 
R2 MPRL 1908 F576 Dr G Schmidt, Germany 
R3 MPRL 1909 F653 Dr G Schmidt, Germany 
R4 MPRL 1382 F2513 Dr Nils Carlin, Sweden 
K12 MPRL 1303 2131 Dr Nils Carlin, Sweden 
B MPRL 1900 2156 Dr G Schmidt, Germany 
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Table 5.2 Characteristics of purified monoclonals used in chapter 5. 
MAb Name Isotype concentration 
(mg /ml) 
ELISA specificitya 
J5 4 45.6 IgG3 5.2 J5 
H5 13.23 IgG3 9.6 Rc 
SZ 27 150.3 IgG2a 8.9 Rc 
H1 61.1 IgG1 4.8 Rc 
SZ 27 19.16.7 IgG2a 10.3 Rc 
H4 351.18 IgG2a 10.3 Rc 
SZ 5 28.4.4 IgG2b 2.5 Rc 
H7 41.76 IgG1 8.1 Rc 
SZ 30 4.2.8 IgM 3.5 Lipid A 
SZ 27 193.3 IgM 4.5 Lipid A 
Rc 878 2.51.9 IgA 7.3 Rc 
SZ 43 27.7.3 IgG ? Ra 
a ELISA specificity defined as the smallest LPS chemotype of 




Whole -cell ELISA 
Overnight shaken broth cultures were washed and resuspended in normal 
saline. The concentration of bacteria was determined using an 
improved Neubauer counting chamber. A typical count was 2 x 109 /ml. 
The bacterial suspensions were then diluted in coating buffer to a 
concentration of 107 /ml, 100 pl per well added to NUNC polysorb 
strips, and the strips incubated at 4 °C overnight. The strips were 
then washed four times, and 100 pl per well of post -coating buffer 
added. After incubation overnight once more at 4 °C the plates were 
again washed four times and stored at -20 °C. 
Purified MAbs were diluted 1 in 2500 in ELISA diluent without 
albumin, and 100 pl volumes placed in duplicate wells and incubated 
for 1 h at 37 °C. Plates were then washed four times and 10Op1 of 
urease- conjugated sheep -anti -human-IgG (Sera -lab, diluted 1 in 500 in 
ELISA diluent without albumin) was added and incubated for a further 
60 min at 37 °C, then washed three times and rinsed five time in 
distilled water. Urease substrate (100 pl: Sera -lab) was added and 
left at room temperature for 60 minutes, and the OD read at 590 nm. 
Flow Cytometry 
Bacteria from overnight broth cultures were washed in PBS and 
resuspended to give an OD of 0.5 at 525nm. Using Eppendorf tubes, 1 
ml volumes were centrifuged and the bacteria resuspended in 1 ml PBS 
containing a 1 in 100 dilution (50 - 100 pg /ml) of purified MAb. 
After incubation for 1 hour at 37 °C the bacteria were washed twice 
in 
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PBS and resuspended in 1 ml of a i in 100 dilution of sheep FITC- 
conjugated anti -mouse IgG (ICN) in PBS and incubated for a further 
hour at 37 °C. The bacteria were then washed twice more and 
resuspended in 1 ml of PBS containing 0.5% formaldehyde. Prepared 
samples were diluted i in 50 in PBS and analysed using an EPICS "C" 
(Coulter Electronics) flow cytometer equipped with a 5 watt argon ion 
laser, operating at 500 mW and exciting and 488 nm. Cells were 
passed through the beam at approximately 500 per second from a 
standard 76 pm flow cell tip. Background noise and clumps of cells 
were excluded by a gate on the log forward angle light scatter. 
Cells stained with FITC conjugate, but with no primary antibody, 
provided a background staining level, set at 1% ± 0.5% by adjusting 
the voltage applied to the green fluorescence log (GFL) 
photomultiplier tube. A total of 50,000 cells were analysed from 
each sample and the percentage of cells exhibiting positive staining 
was calculated by the EPICS "Stat pack" programme. 
Co-Agglutination 
Calbiochem "Pansorbin" Staphylococcus aureus cells (lot 745004) were 
a gift from Dr H Young of the Department of Medical Microbiology. It 
consisted of a milky suspension of S. aureus cells. Following the 
manufacturers instructions, 1 ml volumes were washed 3 times in co- 
agglutination buffer (PBS containing 0.1% sodium azide, pH8). The 
cells were then resuspended in the same buffer containing 2 mg /ml of 
MAb, mixed, and incubated at room temperature for 15 minutes. Cells 
were then washed a further 3 times in co- agglutination buffer. A 
control suspension treated in the same way but with no added MAb was 
also prepared. 
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To test binding to bacteria, a colony from a nutrient agar plates was 
suspended in a drop of PBS on a dark tile. A drop (40 pill of co- 
agglutination reagent was added, mixed by rotation, and inspected for 
the development of agglutination. 
rPHAST" system 
The "PHAST" system is a commercial SDS -PAGE and immunoblotting method 
using small (usable area 2 inch square) factory made gels. Because 
the gels are mass -produced they are said to give more reproducible 
results and, because they are small, running the gel takes about 1 
hour. The whole process including blotting, reacting with antibody 
and staining can easily be completed within one day. The washing and 
staining of gels and blots can be run automatically, further 
improving reproducibility and reducing hands -on time. A " HAS°r." 
system was obtained on loan from Pharmacia for a trial.. 
Gels of various concentrations, including gradient gels, are 
available. The gel contains no buffer, and strips containing of 
buffer (with or without SDS) are used . The gel lies horizontally in 
the apparatus, and the samples of material to be separated are placed 
on the surface of the gel, instead of being placed in wells. There 
is considerable literature on the use of this system for analysis of 




INTERACTION OF NABS AND BACTERIA IN IMMUNOBLOTS AND WHOLE -CELL ELISA 
Silver stain of LPS from blood culture isolates of Gram- negative 
bacilli. 
Figure 5.1 shows a silver stained polyacrylamide gel of LPS prepared 
by proteinase K digestion from the first 10 isolates chosen. All 
but one produced a "ladder" pattern, as expected from wild -type Gram - 
negative bacilli. Strain 8b 239 (lane b; Proteus sp.) had material 
in the region where high molecular weight bands of LPS would be 
expected, but these did not resolve into distinct bands. The two 
strains of E. coli 0:18 (lanes a and f) produced almost identical 
ladder patterns, consistent with the idea that the repeating 0- 
antigen unit was the same in these two isolates. The two strains of 
Pseudomonas aeruginosa (lanes g and h) also produced patterns that 
were similar to one another. Two further isolates were then chosen, 
as discussed above, and a silver -stained gel of the series of 12 
strains made (frontispiece). The second Proteus sp. gave a similar 
pattern to the first, with no distinct ladder pattern, and therefore 
it was concluded that this appearance must be usual, or at least 
quite common, in Proteus isolates. The Klebsiella pneumoniae 
isolate 
did give a typical ladder pattern, though this is not well 
seen in 
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Figure 5.1 Silver -stained polyacrylamide gel of LPS (proteinase K 
digests) from 10 blood- culture. Lane a = 8b226 (E. coli); b = 8b239 
(Proteus sp); c = 8b257 (Enterobacter cloacae); d = 8b273 (Serratia 
sp.); e = 8b275 (E. coli); f = 8b281 (E. coli); g = 8b300 
(Pseudomonas aeruginosa); h = 8b305 (Pseudomonas aeruginosa); i = 
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Figure 5.2 Reactivity in ELISA of 4 MAbs with panel of 10 blood 
culture isolates. A = 8b226; B = 8b239; C = 8b257; D = 8b273; E = 
8b275 F= 8b281; G = 8b300; J = 8b317; K = 9b24; L = 9b26. 
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Figure 5.3 Reactivity in ELISA of 4 MAbs with panel of 10 blood 
culture isolates. A = 8b226; B = 8b239; C = 8b257; D = 8b273; E = 
8b275 F= 8b281; G = 8b300; J = 8b317; K = 9b24; L = 9b26. 




Whole cell ELISA 
Whole -cell ELISA was performed with 10 of the 12 isolates (omitting 
one of the P. aeruginosa strains and one of the E. coli strains) and 
a panel of purified MAbs. The ELISA was performed only at a single 
dilution of each antibody. Results are shown in figures 5.2 and 5.3. 
Most of the MAbs bound best to the E.coli strains. This pattern was 
particularly marked with MAb SZ 27 150.3, SZ 27 19.16.7, H5 13.23, 
and H1 61.1. The only MAb that appeared to be cross -reactive on this 
assay was H7 41.76. 
Immunoblots with MAbs tested in ELISA 
The first immunoblots performed were with MAb SZ 27 150.3, against 
the panel of 10 blood- culture isolates. Figure 5.4 shows the first 
successful blot. It shows reactivity of SZ 27 150.3 and both core and 
ladder patterns of all the E. coli strains, but none of the others. 
In order to establish a reasonable working concentration of MAb, the 
purified preparation of SZ 27 150.3 was blotted against three of the 
E. coli strains, at dilutions of 1 in 200 (as used above), 1 in 400, 
and 1 in 800. As shown in figure 5.5, the blot gave a much darker 
result on this occasion. It was apparent however that the bands 
produced with the 1 in 800 dilution were less dark than those 
produced at i in 400, and that the background was darker at 1 in 
200. 
It was decided to use a 1 in 500 dilution of purified MAb (equivalent 
to approximately 18 pg /ml) for future experiments. 
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a b c d e f g h i j 
Figure 5.4 Immunoblot of MAb SZ 27 150.3 against proteinase K 
digests of 10 blood culture isolates. The antibody was purified 
preparation, diluted 1 in 200, = 44 pg /ml. Lane a = 8b226 (E. coli); 
b = 8b239 (Proteus sp); c = 8b257 (Enterobacter cloacae); d = 8b273 
(Serratia sp.); e = 8b275 (E. coli); f = 8b281 (E. coli); g = 8b300 
( Pseudomonas aeruginosa); h = 8b305 (Pseudomonas aeruginosa); i = 
8b316 (E. coli); j = 8b317 (E. coli). 
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1 in 200 
(44 ug/ml) 
1 in 400 
(22 pg/ml) 
1 in 800 
(11 Kg/ml) 
a j a a f j 
Figure 5.5 Immunoblot of MAb SZ 27 150.3 (purified preparation) 
against proteinase K digests of three E.coli strains at three 
dilutions of MAb. Lane a = 8b 226; f = 8b 281, and j = 8b 317. 
Dilutions (approximate concentration) of MAb shown above. 
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Immunoblots were made with of each of the antibodies tested in the 
ELISA against LPS extracted by proteinase K digestion of the panel of 
12 organisms. Examples are shown in figures 5.6 - 5.8. H5 13.23 
(figure 5.6) and SZ 27 19.16.7 (not shown) gave similar patterns to 
that produced by SZ 27 150.3 (figure 5.4), with ladder patterns for 
the E.coli strains but no reactivity with the other species. The only 
apparent difference was that H5 13.23 produced a weaker reaction with 
8b 317 (E. coli 0:6) than did the other two. H4 351.18 (figure 5.7) 
and H7 41.76 (figure 5.8) reacted only with the fastest moving band 
of some of the E. coli strains (strains 8b 226, 8b 275, and 8b281: 
lanes a, e, and f). J5 4 45.6 , H1 16.1 & SZ 5 28.4.4 produced 
completely negative blots. Blots with these last three were repeated 
for three of the E. coli strains alone, with SZ 27 19.16.7 as a 
control. A single gel with four sets of bands was blotted and the 
blot cut into four pieces which were reacted simultaneously with one 
of the four MAbs. SZ 29 19.16.7 produced a ladder pattern as before, 
but the other three MAbs again produced negative results (not shown). 
Imtoblots with other MAbs against the panel of 12 clinical isolates 
Four other MAbs which were being considered for larger -scale 
production and more detailed investigation by Sandoz were blotted 
against the panel of 12 clinical isolates. 
SZ 27 193.3 was an IgM MAb which bound to most of the LPS chemotypes 
used in LPS- polymyxin ELISA, including lipid A, and was therefore 
thought provisionally to be an anti -lipid A antibody. In the 
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Figure 5.6 Immunoblot of H5 13.23 against proteinase K digests of 12 
blood culture isolates. Lane a = 8b226 (E. coli); b = 8b239 ( Proteus 
sp); c = 8b257 (Enterobacter cloacae); d = 8b273 (Serratia sp.); e = 
8b275 (E. coli); f = 8b281 (E. coli); g = 8b300 ( Pseudomonas 
aeruginosa); h = 8b305 (Pseudomonas aeruginosa); i = 8b316 (E. coli); 
j = 8b317 (E. coli); k = 9b24 (Proteus sp.); i = 9b 26 (Klebsiella 
pneumoniae). 
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Figure 5.7 Immunoblot of H4 351.18 against proteinase K digests of 
12 blood culture isolates. Lane a = 8b226 (E. coli); b = 8b239 
(Proteus sp); c = 8b257 (Enterobacter cloacae); d = 8b273 (Serratia 
sp.); e = 8b275 (E. coli); f = 8b281 (E. coli); g = 8b300 
( Pseudomonas aeruginosa); h = 8b305 (Pseudomonas aeruginosa); i = 
8b316 (E. coli); j = 8b317 (E. coli); k = 9b24 ( Proteus sp.); i = 9b 
26 (Klebsiella pneumoniae). 
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Figure 5.8 Immunoblot of H7 41.76 against proteinase K digests of 12 
blood culture isolates. Lane a = 8b226 (E. coli); b = 8b239 (Proteus 
sp); c = 8b257 (Enterobacter cloacae); d = 8b273 (Serratia sp.); e = 
8b275 (E. coli); f = 8b281 (E. coli); g = 8b300 (Pseudomonas 
aeruginosa); h = 8b305 ( Pseudomonas aeruginosa); i = 8b316 (E. coli); 
j = 8b317 (E. coli); k = 9b24 (Proteus sp.); 1 = 9b 26 (Klebsiella 
pneumoniae). 
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Figure 5.9 Immunoblot of SZ 27 193.3 against proteinase K digests of 
12 blood culture isolates. Lane a = 8b226 (E. coli); b = 8b239 
( Proteus sp); c = 8b257 (Enterobacter cloacae); d = 8b273 (Serratia 
sp.); e = 8b275 (E. coli); f = 8b281 (E. coli); g = 8b300 
(Pseudomonas aeruginosa); h = 8b305 (Pseudomonas aeruginosa); i = 
8b316 (E. coli); j = 8b317 (E. coli); k = 9b24 ( Proteus sp.); i = 9b 
26 (Klebsiella pneumoniae). 
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immunoblot (figure 5.9) it bound to material in a regular band across 
all the tracks which corresponded to the interface between the 
stacking and separating gel. No clear band could be seen in the 
region where bands containing LPS (and therefore lipid A) were 
expected. 
SZ 30 4.2.8, like SZ 27 193.3, was an IgM which bound to a wide range 
of LPS and to lipid A in LPS -polymyxin ELISA. Particularly strong 
binding to E. coli 0:18 strains had been noted. In the im unoblot 
(figure 5.10) it bound to material at the top of the separating gel, 
as seen with SZ 27 193.3. It also reacted with the upper part of the 
"ladder" pattern of both the E. coli 0:18 strains. 
Rc 878 2.51.9 was an IgA MAb which bound with a limited range of 
rough and smooth LPS in polymyxin -LPS ELISA. In the immunoblot 
(figure 5.11) it bound to the leading band of the E. coli isolates, 
and to the material at the top of the stacking gel. 
SZ 43 27.7.3 was an IgG which bound to a wide range of LPS, but 
particularly to E. coli R1 and some smooth E. coli in LPS -polymyxin 
ELISA. In the immunoblot (figure 5.12) it bound to the leading band 
of all the E. coli strains, but not to the other species. 
Binding to the "ladder" pattern versus binding to a single band in 
itomunoblots . 
The fastest moving band seen in the silver stain is thought to 
consist of the complete LPS -core structure, including Lipid A, but 
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Figure 5.10 Immunoblot of SZ 30 4.2.8 against proteinase K digests 
of 12 blood culture isolates. Lane a = 8b226 (E. coli); b = 8b239 
( Proteus sp); c = 8b257 (Enterobacter cloacae); d = 8b273 (Serratia 
sp.); e = 8b275 (E. coli); f = 8b281 (E. coli); g = 8b300 
(Pseudomonas aeruginosa); h = 8b305 (Pseudomonas aeruginosa); i = 
8b316 (E. co/í); j = 8b317 (E. coli); k = 9b24 (Proteus sp.); 1 = 9b 
26 (Klebsiella pneumoniae). 
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Figure 5.11 Immunoblot of Rc 878 2.51.9 against proteinase K digests 
of 12 blood culture isolates. Lane a = 8b226 (E. coli); b = 8b239 
(Proteus sp); c = 8b257 (Enterobacter cloacae); d = 8b273 (Serratia 
sp.); e = 8b275 (E. coli); f = 8b281 (E. coli); g = 8b300 
(Pseudomonas aeruginosa); h = 8b305 (Pseudomonas aeruginosa); i = 
8b316 (E. coli); j = 8b317 (E. coli); k = 9b24 (Proteus sp.); 1 = 9b 
26 (Klebsiella pneumoniae). 
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Figure 5.12 Immunoblot of SZ 43 27.7.3 against proteinase K digests 
of 12 blood culture isolates. Lane a = 8b226 (E. coli); b = 8b239 
(Proteus sp); c = 8b257 (Enterobacter cloacae); d = 8b273 (Serratia 
sp.); e = 8b275 (E. coli); f = 8b281 (E. coli); g = 8b300 
(Pseudomonas aeruginosa); h = 8b305 (Pseudomonas aeruginosa); i = 
8b316 (E. coli); j = 8b317 (E. coli); k = 9b24 (Proteus sp.); 1 = 9b 
26 (Klebsiella pneumoniae). 
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with no 0 antigen substitution. The next band is thought to consist 
of LPS with only a single 0- antigen unit, and each subsequent band 
consists of molecules with one more 0- antigen repeating unit[180]. 
The two different patterns of binding to individual E. coli LPS could 
therefore be explained by some of the MAbs (eg H4 351.18) binding 
only to unsubstituted core, while others (eg SZ 27 150.3) bind both 
to unsubstituted core and to core that is substituted with 0 antigen. 
To compare the patterns of binding more clearly a gel was prepared 
using a single broad track of LPS (proteinase K digest) from 8b 281 
(E. coli 0:18). Half of this gel was blotted onto nitrocellulose and 
cut into strips which were then reacted with SZ 27 150.3, H5 13.23, 
SZ 43 27.7.3, and an 0:18 specific monoclonal ES 184.4.1. This 
confirmed (figure 5.13) that the fastest moving band seen on the 
silver -stained gel corresponds to the single positive band seen in 
the immunoblot with SZ 43 27.7.3, and that this band does not react 
with the 0- specific MAb. SZ 27 150.3 and H5 13.23 react with this 
fast moving band and also with some of the slower -moving bands which 
are seen in the silver stain and which react with the 0- specific MAb. 
SZ 27 150.3 and H5 13.23 react preferentially with the lower part of 
the ladder, while the 0:18 specific MAb reacts more with the higher 
bands. This difference presumably reflects the greater proportion of 
0 antigen in the higher bands and the greater proportion of core 
material in the lower bands. 
Immunoblots with standard R types 
Slight but consistent differences in binding to different E. coli 
isolates were observed in both ELISA and immunoblots. One possible 
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Figure 5.13 Silver stain and immunoblots of proteinase K 
preparations of LPS from E. coli 0:18 (strain 8b281). Lanes: 
1 = silver stain; 2 -5 show immunoblots obtained with MAbs ES 184.4.1 
(0:18 specific), H4 351.8, H5 13.23, and SZ 27/150.3. 
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explanation for this would be that the LPS -core of the wild -type 
strains used differed. I therefore decided to examine the binding 
of some MAbs to the range of known core -types of E. coli and 
Salmonella in immunoblots, together with two of the blood culture 
isolates of E. coli which served as positive controls. .ig figure 
5.13 
In the first of these experiments (figures 5.14 and 5.15) the strain 
thought to be K12 was found subsequently to be a Salmonella Ra 
mutant. Note also that track h of the silver -stained gel (figure 
5.14) contained LPS from E. coli 8b316, while E. coli 8b317 LPS was 
used at the equivalent position in the subsequent blots (figure 
5.15). 
The silver stain (figure 5.14) of the rough LPSs showed, as expected, 
bands corresponding to the leading ( unsubstituted core) band of the 
smooth LPSs. In addition however the silver showed slower 
moving material which did not resolve clearly into bands. On some 
occasions, particularly in some of the blots, discrete bands could be 
seen in this material. 
SZ 27 150.3 (figure 5.15) and SZ 27 19.16.7 (not shown) reacted with 
all the rough LPSs, and with both unsubstituted and substituted core 
of the two blood culture isolates. H5 13.23 reacted with substituted 
and unsubstituted core of the blood culture isolates, and with E. 
coli R1, R2 and K12, and with the Salmonella rough mutant. H4 351.18 
and H7 41.76 both reacted with E. coli R2 and with the Salmonella 
rough mutant, and with the unsubstituted core band from E. coli 
8b226 
but not 8b317. Binding to the diffuse slow -moving material 
seen in 
the silver stain corresponded with binding to the core band 
of the 
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Figure 5.14 Silver -stained polyacrylamide gel of LPS (proteinase K 
digests) from rough and smooth E. coli or Salmonella. a = 8b 226; b = 
R1; c = R2; d = R3; e = R4; f = Salmonella; g = B; h = 8b 316. 
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Figure 5.15 Immunoblot of four MAbs against LPS (proteinase K 
digests) from rough and smooth E. coli or Salmonella. Lane a = E. 
coli 8b226; b = R1; c = R2; d = R3; e = R4; f = Salmonella rough 
mutant; g = E. colf B; h = E. coli 8b317. 
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appropriate track. 
These blots were repeated, using a strain confirmed to be K12 on 
biochemical and phage testing. E. coli B was omitted from these 
blots in order that the four blots could be run simultaneously on the 
two available gel tanks, each set of bands occupying half of one gel. 
Results (Figure 5.16) were consistent with the previous experiment. 
K12 reacted in these blots an identical way to the Salmonella rough 
mutant in the previous blots. 
The blots of SZ 27 150.3, H5 13.23 and H7 41.76 were then repeated 
using rough LPS preparations extracted by the phenol, chloroform, 
petroleum ether method by Dr H. Brade at the Forschungsinstitut 
Borstel, Germany. The results (figure 5.17) again agreed with the 
previous findings. 
Table 5.3 summarises the results of immunoblotting with MAbs SZ 27 
150.3, SZ 27 19.16.7, H5 13.23, H4 351.18, and H7 41.76. 
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Figure 5.16 Immunoblot of four MAbs against LPS (proteinase K 
digests) from rough and smooth E. coli. Lane a = 8b 226; b = R1; c = 
R2; d = R3; e = R4; f = K12; g = 8b 317. 
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Figure 5.17 Immunoblots of three MAbs against rough E. coli LPS. 
The LPS was prepared by phenol, chloroform, petroleum ether method by 
Dr H. Brade at the Forschungsinstitut Borstel, Germany. LPS 
chemotypes were: 1 = R1; 2 =R2; 3 = R3; 4 = R4;. 
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Table 5.3 Summary of reactivity of purified MAbs with LPS in 
imtmmoblots 
MAb Reactivity with LPS from: 
B. soli Salmonella 
Smooth R1 R2 R3 R4 K12 
SZ 27 150.3 ladder + + + + + + 
SZ 27 19.16.7 ladder + + + + + + 
H5 13.23 ladder + ++ - - ++ ++ 
H4 351.18 Core - ++ - - ++ ++ 
H7 41.76 Core - ++ - - ++ ++ 
Notes. + = weak band; ++ = strong band; ND = not done. 
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INTgRACPION OF MAB AND BACTERIA IN OTHER SYSTEMS 
Co-agglutination 
Co-agglutination might be a useful rapid way to test the ability of 
MAbs to bind to bacteria. This approach might be useful either for 
screening of a large collection of organisms, or for quickly testing 
clinical isolates to aid in identification or to direct therapy. An 
attempt was therefore made to produce co- agglutination reagents with 
MAbs SZ 27 150.3, H5 13.23, and H7 41.76. 
The reagent made with H7 41.76 was clumped (auto-agglutinated) and 
therefore unusable. The H5 13.23 and SZ 27 150.3 reagents were 
usable initially, and were tested against a small number of E. coli 
strains immediately after production. The preparations were both 
clumped by suspension of E. coli R1, R2, R3, 8b 273, and 8b 281. 
Clumping occurred within 10 seconds with the rough strains, and was 
coarse, while with the smooth strains fine clumping was observed 
after 1 -2 minutes. Heating the organisms to 100 °C for 15 minutes did 
not alter the character of the clumping observed. Unfortunately no 
good negative control organism was tested on that day. Three days 
later, when suitable negative controls were available, both the 
remaining preparations had also auto -agglutinated, and could not be 
tested further. 
It was decided not to pursue this approach. It would have been 
possible to make up co- agglutinating reagents quickly for immediate 
use, but this would require large quantities of MAb. 
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Table 5.4 Binding of MAbs to whole E. coli as measured in flow 
cytometry. 
E. coli strain Number ( %) of bacteria exhibiting fluorescence 
above background level with MAb given: 
SZ 27 150.3 H5 13.23 H7 41.76 
R1 40.7 49.8 55.7 
R2 25.5 60.6 81.5 
R3 21.0 31.0 63.4 
R4 29.3 20.2 31.0 
8b 281 Oa o o 
8b 317 0 0 0 
Note a 0 = less than background. 
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Flow Cytometry 
The binding of MAbs SZ 27 150.3, H5 13.23 and H7 41.76 to E. coli 
strains R1, R2, R3, R4, 8b 281, and 8b 317 was examined. As shown in 
table 5.4, all of the MAbs bound to all the rough mutants, in a way 
that showed less discrimination between the different core types than 
did the immunoblot. There was no detectable binding to either of the 
smooth strains. 
Other work in progress in the laboratory [165] confirmed that none of 
these MAbs bound (as determined by flow cytometry) to smooth E. coli 
grown in nutrient broth. Since it appeared that flow cytometry was 
not immediately useful for studying the binding of MAbs to a wide 
range of wild -type organisms, nor for discriminating between the 
different core -types of E. coli, I did not pursue it further. 
"PHAST" system 
Gels were run on the PHAST system with LPS (prepared by aqueous 
phenol extraction) from E. coli 8b 281 (0:18). Tracks containing 2 
pg, 0.4 pg, and 0.2 pg LPS were run on 4 -15% gradient gels and 12.5% 
gels, both with SDS -free and with SDS containing buffer, and were 
silver stained using the standard method for large gels, and using 
the faster method described by Fomsgaard et al [70]. The SDS - 
containing buffer strips resulted in completely blank silver stains. 
SDS -free buffer resulted silver stains with apparently non- specific 
staining of the front half of the gel, with no bands seen in the 
expected regions. 
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An immunoblot was performed using a 12.5% gel and SDS -free buffer. 
The resulting blot was reacted with MAb SZ 184 2.5.5 (0:18 specific). 
The result is shown in figure 5.18. Most of the staining is seen in 
the region where the LPS samples were originally applied, and there 
is no resolution into bands. It was concluded that LPS had failed to 
enter the gel, thus explaining the negative silver stains. 
IMMUNOBLOTS WITH HUMAN I0G PREPARATIONS 
Three human IgG preparations were available for study: a) "Normal" 
IgG preparation for intravenous injection, prepared from unselected 
blood donors; b) "Anti -CGL" IgG , prepared in the same way, but from 
blood donors selected because of high levels of IgG antibody to LPS- 
core (core glycolipid, CGL) in the polymyxin -LPS -core cocktail ELISA 
[9], c) "J5" IgG provided by Dr T Calandra [38], prepared from donors 
immunised with E. coli J5. 
A polyacrylamide gel was prepared with a single wide track of LPS 
(prepared by aqueous phenol extraction) from E. coli strain 8b 281. 
A 400 pg sample of LPS was used for the complete gel which is 
equivalent to 20 normal tracks plus spacers. The gel was run and 
blotted, and the blot cut into strips which were reacted with varying 
concentrations of the three IgG preparations as shown in figure 5.19. 
This showed reactivity with the upper part of the ladder pattern, 
representing 0 antigen, by both the "J5" and the "anti -CGL" 
preparations at the lowest concentration used. "Normal" IgG produced 
detectable bands in this region only at the highest concentration 
used. The "anti -CGL" preparation also produced a distinct band 
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Figure 5.18 Immunoblot of MAb SZ 184 2.5.5 (0:18 specific) against 
LPS from E. coli 8b 281 (0:18) separated and blotted using the 
"PHAST" system. The loading of the tracks are a = 2pg; b = 0.4 pg, 
c = 0.2 pg. The arrow indicates the direction of electrophoresis. 
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Figure 5.19 Immunoblot of human IgG preparations at three different 
concentrations, and MAb H5 13.23, against LPS (aqueous phenol 
preparation) from E. coli 8b 281 (0:18). Lanes were blotted 
separately with the antibodies shown above. Concentrations of human 
IgG preparations used were: 1 = 25 pg /ml; 2 = 250 pg /ml; 3 = 2500 
pg /ml. MAb H5 13.23 was at a concentration of 19 pg /ml. 
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Figure 5.20 Immunoblot of human IgG preparations, (500pg /ml) against 
proteinase K digests of 12 blood culture isolates. Lane a = 8b226 
(E. coli); b = 8b239 (Proteus sp); c = 8b257 (Enterobacter cloacae); 
d* 8b273 (Serratia sp.); e = 8b275 (Ek coli); f = 8b281 (E. coli); 
g = 8b300 (Psgudomonas aeruginosa)i h 8b305 (Pseudomonas 
aeruginosa); i = 8b316 (E. coli) j = 8b316 (E. ¡oli); k = 9b24 
(Proteus sp.); 1 = 9b26 (Klebsiella pneumoniae). In the top print 
( "Normal" IgG) the two Pseudomonas strains are in lanes i and j , and 
E. coli strains 8b316 and 8b317 are in lanes g and h . 
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corresponding to the leading band of unsubstituted LPS core (as shown 
by the H5 13.23 control) while the "J5" preparation produced a barely 
visible band in this position. 
The three IgG preparations were then reacted with the panel of 12 
blood -culture isolates. All three gels were run simultaneously in 
order to produce comparable results. An IgG concentration of 500 
pg /ml was used, which was between the two higher concentrations used 
above. The results are shown in figure 5.20. Note that in the blot 
of the "normal" IgG the order of lanes has been changed: E. coli 
strains 8b316 and 8b317 have been swapped with P. aeruginosa strains 
8b300 and 8b305. 
Binding of all three preparations to the higher part of the ladders 
of E. coli and P. aeruginosa is seen. For the "Normal" IgG and the 
"J5" IgG this is strongest with the two 0:18 E. coli strains, while 
the "anti -CGL" IgG produced dense bands in this region with many of 
the strains. The leading bands are not strikingly different between 
the different IgG preparations, though it is difficult to locate them 
with confidence in the absence of a suitable control. Also visible 
is a set of narrow bands running ahead of the strongly -staining part 
of the 0 antigen ladders. These bands are seen in all lanes except 
those containing P. aeruginosa LPS, and seem to be identical in size 
and spacing in all lanes. These bands do not correspond to anything 
seen on the silver stains of the proteinase K preparations, and are 
thought to represent the enterobacterial common antigen. 
155 
DISCUSSION 
The results presented here must be seen in their context as a small 
part of a much bigger project aimed at producing MAbs which could be 
used in therapy. I started from the point of trying to assess the 
binding of these MAbs to a wide range of clinically relevant 
bacteria. ELISA might have been the best approach, but at that time 
I did not have easy access to ELISA equipment within the department. 
After a brief attempt to examine the binding of MAbs to bacteria in 
ELISA I therefore concentrated on immvnoblotting, which was available 
in the department, and briefly examined some other possible 
approaches. Plans were made for a more extensive ELISA -based 
investigation of MAbs and bacteria to be carried out later. When it 
became apparent that the MAbs shared the property of being limited in 
their specificity largely to E. coli I began to explore the 
possibility that some of them might be specific for particular core 
types of E. coli. 
The ELISA results are limited, but did point to the major conclusion 
that, within the panel of organisms tested, most of the MAbs only 
recognised E. coli LPS. The antibodies tested were all known to react 
with purified LPS and therefore any reaction observed was likely to 
be with the LPS. The results suffer from the disadvantage that they 
were only performed at a single concentration of each MAb, and that 
they were not repeated. In the case of H7 41.76, the results appear 
to be wrong, in the sense that the broad cross- reactivity observed is 
incompatible with subsequent irrlrromoblotting results reported in this 
chapter, and with ELISA results reported in chapter 6, and with the 
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results from other collaborators. This may result from some 
technical error in performing this ELISA assay, or from too high a 
concentration of MAb being used. 
Immunoblotting is a cumbersome technique, not well suited to looking 
at the interaction of large numbers of bacteria and MAbs, but has 
produced some useful results. It has the advantage of showing 
graphically which a rent of a complex mixture is able to interact 
with the antibody, and in particular has been able to distinguish 
between binding to unsubstituted LPS core, substituted LPS core, and 
specific 0 antigen. 
Immunoblotting was also able to indicate specificity of binding to 
particular core type of E. coli in a way that had not been suspected 
from previous ELISA data. This raised the possibility of using MAbs 
to determine the frequency of the known core types in a collection of 
wild -type E. coli, though the MAbs used in this chapter do not have 
the specificities required to do this. It is of interest to note at 
this point that the original reason for investigating the specificity- 
of MAbs for different core types was the observation that MAbs bound 
different wild -type E. coli cores in a consistently different way, in 
particular the consistently poorer binding by 8b 317 of MAbs H4 
1351.18 and H7 41.76. It was thought that this might be due to 
differential binding to different core types. Later results (chapter 
6) found that all the wild -type E. coli strains used in these 
e= =priments were ;t the R1 core group, and therefore the differences 
observed here may be an artifact, or may indicate some heterogeneity 
within the R1 core group as subsequently defined with MAbs 
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Binding in immunoblots to a band corresponding to the interface 
between the stacking and separating gel was noted with some of the 
human IgG preparations (figure 5.20) and several MAbs (eg figures 
5.5, 5.9, 5.10, 5.12). This band did not always occur, for example 
in the case of MAb H5 13.23, it is very strong in figure 5.15, but 
not in figure 5.6. When present tended to be present in all tracks, 
whether the antibody bound to LPS bands in the track or not. This 
band is thought to represent non- specific binding to proteinase K or 
to aggregates of LPS. It was clearly distinct from the diffuse slow - 
moving material seen in some of the silver -stains and blots of rough 
LPS. This latter material only reacted with antibody when reaction 
with the leading band was seen, and therefore can be interpreted as 
specific binding to non -covalent polymers of rough LPS [184]. 
The binding of SZ 30 4.2.8 to the slow -moving bands of 0:18 LPS in 
addition to its binding to the fast -moving band of the other strains 
tested implies some cross -reactivity between the 0- specific 
polysaccharide and core or lipid A. SZ 30 4.2.8 was a cross -reactive 
MAb which resulted from of an immunisation with lipid A and therefore 
was expected to react with lipid A. The only obvious similarity 
between the structure of lipid A and the 0:18 antigen [90] is the 
presence of two glucosamine residues. These residues are however N- 
acetylated in the 0:18 antigen, unlike those in lipid A. One of the 
glucosamine residues in the 0:18 antigen is 13-1 linked to another 
sugar and may form an epitope similar to similar to that described by 
Kuhn et al [122] as specificity "f" on lipid A. 
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None of the other methods used here proved useful in examining the 
binding of MAbs to a LPS from a wide range of species. Co- 
agglutination and PHAST system gels failed on simple technical 
grounds since the co-agglutination reagent was auto-agglutinated, and 
LPS failed to enter the PHAST system gel. Flow cytometry was 
rejected for more complex and important reasons, however. The 
failure of the MAbs tested to bind whole bacteria when they have been 
shown to bind LPS from those bacteria clearly indicates that the 
appropriate epitopes are not exposed on these bacteria. This is 
relevant to therapy with such antibodies as well as to in vitro 
studies. The situation in the infected host may however not be 
reflected in these experiments. This question has been studied 
further by Nelson et al [165,166] who have shown that the conditions 
of bacterial growth markedly affect the binding of MAbs to live 
bacteria. 
The results obtained with human IgG preparations underline the non- 
quantitative nature of immunoblotting. Major differences can be 
demonstrated in the amount of anti -LPS -core antibody in these 
preparations (GR Barclay: personal communication) but these are not 
clearly represented in the immunoblot. 
The immunoblot with human IgG preparations also demonstrated the 
presence in the proteinase K preparations of a set of bands which 
were not detected in the silver stain. Their survival after 
proteinase treatment suggests that they are carbohydrate in nature, 
and their presence and identical size in all of the enterobacterial 
preparations together with their absence from the P. aeruginosa 
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preparations suggests that they represent the enterobacterial common 
antigen (ECA) [121]. The failure to visualise ECA in the silver 
stain and nature of the bands seen in the immunoblot is consistent 
with the results reported by Peters et al [183]. 
Overall, the work described in this chapter gave me practical 
experience of some of the methods available to study cross- reactive 
antibodies to LPS, and led to the application of some of these 
antibodies to the characterisation of core types in clinical isolates 
of E. coli, as described in the next chapter. 
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CHAPTER 6 
FREQUENCIES OF LPS -CORE TYPES 
AMONG CLINICAL ISOLATES OF E. COLI 
DEFINED WITH MONOCLONAL ANTIBODIES 
161 
INTRODUCPION 
In wild -type smooth E. coli the core region can occur in at least 4 
different forms, known as R1, R2, R3, and R4 [207 -209]. The 
naturally rough strain K12 has another different core region [102]. 
These core types were defined by a combination of phage- typing and 
serological methods, and their chemical structure subsequently 
determined [110]. The 0 antigen of smooth LPS may mask some of the 
epitopes and phage attachment sites in the core region, and may 
contain some of the same carbohydrate residues as the core region. 
The serological phage- typing and chemical methods which were used to 
define the different core types are therefore not directly applicable 
to wild -type smooth strains. The frequency with which these 
different core types occur in wild -type E. coli is therefore not 
known. 
Little is known about the association between core types and 0- 
serotypes of E. coli, except that the original R1 and R2 rough 
mutants were both derived from 08 strains [209], and that the 
original R3 mutant was derived from an 0111 strain [207]. There was 
no published evidence at the time this work was done on the 
relationship of LPS -core types with capsular types, or with 
virulence. Information about the distribution of 0 and K antigens 
has proved to be useful, for example in identifying and understanding 
enteropathogenic strains [178], and in defining the range of 
antibodies for O- or K- specific antisera for treatment of bacteraemia 
[52,53]. Information about core types might be equally interesting. 
We therefore set out to select, from the available MAbs, a panel 
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which would react with specific LPS -core types of E. coli. We wished 
to use these MAbs as a means of determining the LPS -core types of a 
collection of wild -type E. coli. 
It was decided to use heat -killed cells were used as antigen, since 
it had been found by others [41,164] that the binding of core - 
specific MAbs in ELISA was increased when heat -killed cells were used 
instead of unheated cells. Only a single dilution of MAb could be 
used, since the experiment would otherwise have become unmanageably 
large. 
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MATERIALS AND METHODS 
MAbs 
A panel of 61 MAbs was selected from a total pool of 300 produced 
jointly in Basel and Edinburgh. The selection was based on the 
results of LPS- polymyxin ELISA against the panel of purified LPS 
antigens listed in table 2.1. The data from these studies was sorted 
by the correlation method devised by Dr GR Barclay (described below) 
to identify MAbs with similar profiles of reactivity with the panel 
of LPS. Where several MAbs had very similar profiles, only a single 
representative was chosen. Concentrations were not known for every 
MAb preparation, but were in the range of 10 -50 pg /mL. 
Two batches of MAb were used. Batch 1 MAbs were used in the first 
large ELISA experiment with the blood -culture isolates. Batch 2 MAbs 
were used for the immunoblots and for experiments with the urine and 
faecal strains. 
Bacteria and Bacteriopbaae 
E. coli R1 (F470), R2 (F576), R3 (F653), R4 (2513) and K12 (2131) 
were provided by Dr H. Brade, Forschungsinstitut, Borstel, Germany. 
These had been distributed in 1990 to all the laboratories 
collaborating with Sandoz because of some discrepancies between the 
strains previously used in the different laboratories. In addition 
the E. coli R1, R2, R4 and K12 strains from the MPRL collection 
(listed in table 5.1) were used. 
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E. coli 0:1, 0:2, 0:4, 0:6, 0:8, 0:12, 0:15, 0:16, 0:18, 0:75 and 
0:86 were obtained from Dr A S Cross, Walter Reed Army Institute, 
Washington. Five strains of E. coli 0:18 were obtained from this 
source: 0:18 Kl, its isogenic mutants 0:18K1- (non -capsulate) and 0:18 
Krf (rough mutant); 0:18 K5, and its non -capsulate mutant 0:18K5 -. 
Rough -specific phages FO, Br10, C21, 6SR and T4 [208,209], and their 
bacterial hosts were obtained from Dr. G Schmidt, Forschungsinstitut, 
Borstel, Germany. Phage specific for E. coli capsular types K1 
(0K1GS) and K5 (95K5DG) were obtained from Dr AP Roberts, Charing 
Cross and Westminster Medical School, London, UK. 
Blood -culture isolates and urine isolates were obtained from the 
Clinical Bacteriology Laboratory, Department of Medical Microbiology, 
Edinburgh University, Edinburgh, UK, from routine clinical specimens. 
The blood -culture isolates were all the Gram -negative organisms 
isolated in a one -year period. Twenty -one faecal isolates of E. coli 
were obtained, each from a separate healthy volunteer. 
Rough mutants of Salmonella minnesota (R60), Salmonella typhimurium 
(1542), Klebsiella pneumoniae (M10B), and Pseudomonas aeruginosa 
(PAC608), and wild -type smooth Shigella sonne) (colicin types 4/2 
and 2/i) and Shigella flexneri (serotypes la and 3) were freeze -dried 
stock cultures held in the laboratory. Shigella dysenteriae and 
enteropathogenic E. coli were stock cultures or clinical isolates 
held on agar slopes. Three isolates of E. coli 0:157 were provided 
by Dr M Hanson, Central Microbiological Laboratories, Western General 
Hospital, Edinburgh. The 0 type of all Shigella and enteropathogenic 
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E. coli strains was confirmed by slide agglutination with appropriate 
antisera before use. 
Heat -killed bacterial ELISA used with monoclonal antibodies 
Overnight nutrient broth cultures of bacteria were washed and 
resuspended in saline to give an E525 of 0.5, and heated for 30 min 
at 100 °C. Cells were then diluted 1 in 20 in coating buffer (sodium 
carbonate /bicarbonate pH 9.6 with 0.05% sodium azide) and 100 pl 
added per well to NUNC (Roskilde, Denmark) polysorb strips. After 
overnight incubation at room temperature plates were washed three 
times with wash buffer (0.05% Tween 20 and 0.05% sodium aside in PBS 
pH 7.4) and post- coated with 5% wt /vol bovine serum albumin in 
coating buffer overnight at room temperature. Plates were then 
washed and stored at -20 °C. 
MAbs were diluted 1 in 250 in dilution buffer (4% wt /vol polyethylene 
glycol, 0.05% sodium aside, and 0.05% Tween 20 in PBS pH 7.4). 
Diluted MAb (100 pl) was added to wells and incubated for 90 min at 
37 °C. Plates were washed three times and urease- conjugated anti - 
mouse Ig (Zymed, Cambridge, UK; diluted 1 in 500 in dilution buffer 
with 0.5% bovine serum albumin, 100 pl per well) was added and 
incubated for a further 90 min. Plates were then washed three times 
in wash buffer and three times in distilled water, urease substrate 
solution (Seralab, Crawley Down, Sussex, UK; 100 pl per well) added, 
incubated for 90 min at room temperature, and read at 590 nm. Blank 
readings from wells which contained no antigen was subtracted. 
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Serum sensitivity of bacteria 
Serum from one donor (APG) was stored at -70 °C. This serum had IgG 
antibodies to LPS core at a level equal to the 65th centile of the 
normal population [211]. Overnight broth cultures were washed and 
resuspended in Complement Fixation Test (cn) buffer (Oxoid, 
Basingstoke, UK) at room temperature to an E525 of 0.5. This 
suspension was then diluted 1 in 5000 in CFT buffer, and 10 pl added 
to 70 pl CFT buffer and 20 pl freshly thawed serum or heated (56 °C, 
30 min) serum. After 1 h at 37 °C duplicate 20 pl samples were spread 
on the surface of nutrient agar plates and colonies counted after 
overnight incubation. If the number of cfu in the fresh serum was 
less than 10% of the number in the heated serum the organism was 
considered to be serum sensitive. 
0 typing 
E. coli strains from blood and urine cultures were screened for 
common 0 antigens, by ELISA, with absorbed 0 typing sera (Difco, 
Detroit, Michigan) to 0:1, 0:2, 0:4, 0:6, 0:7, 0:12, 0:15, 0:18, 0:22 
and 0:75 (diluted 1 in 1000), and by tube agglutination at a final 
dilution of 1 in 80 with unabsorbed sera to 0:8 and 0:9 (Statens 
Seruminstitut, Copenhagen, Denmark). 0 types were confirmed by 
conventional tube agglutination [177]. This method is discussed in 
more detail in the Note at the end of this chapter. 
167 
Phage typing 
Overnight broth culture was inoculated as a lawn on nutrient agar and 
allowed to dry. Phage suspension (10 pl) was dropped onto the agar 
and incubated overnight. A clear zone of lysis was scored as 
sensitive. 
Correlation sorting of ELISA data 
This method for analysing data from ELISA experiments involving very 
large numbers of antibodies and antigens was devised and implemented 
by Dr GR Barclay. 
For any pair of antibodies which have both been reacted in ELISA with 
an identical large panel of antigens the pairs of OD results for each 
antigen can be used to calculate Pearson's correlation coefficient as 
a measure of the similarity between the overall pattern of results. 
A similar calculation can be made for any pair of antigens which have 
both been reacted with reacted with an identical large panel of 
antibodies. 
A programme was written by Dr Barclay which calculated the 
correlation coefficient for each possible antibody pair, and for each 
possible antigen pair. The antibodies and antigens were then 
rearranged by the programme so that pairs with high correlation 
coefficients were placed together. The result of this manipulation 




Reaction of batch i MA bs with blood culture isolates of E. coli 
A single large ELISA was designed involving the 61 MAbs and 111 
bacteria., in-I:lading SO blood culture isolates said to be B. ccli, and 
28 standard strains (Also included were three isolates from sheep 
with watery nouth: these will be ignored). This had two aims: It 
w:.7_11f. :lye an indication of the degree of cross-reactivity of the 
XA:DEi with the strains being studied, and, in audition, since some of 
X2bs OM'S known to be selective for particular core types, it was 
n2ped to identify the core type of some or all of the wild-type 
The res...lts obtained with the bIood-culture isolates of E. 
anj, :ton'trols are in finure 6.1. MAbs which reacted with a 
restricted range of E types and also with sone smooth strains of Z. 
crai wre Lfentified 1.11.1E these results in m =1 
core type of wildtype smooth strains. Four 
to teríre the 
distinct patterns 
of reactivity MEre cbserved, eact a group of MAbs which were 
placed tcgether ty the correlation-sorting process. 
a)mt-specifiem MAbs 43 3.4.8, VW2 423.10, and SZ 43 27.11.2) 
reacted with ith E. cod/ 0:1, 0:2, 0:4, 0:6, 0:8, 0:16, 
0:1z 0:75, and with many of the wild-type strains. 
Wr4r-specifie Nabs (UE4 361.23, F6 724.02)) reacted with E2 and 
0:12, and with ,a. different grcup Of wild-type streams. 




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































reacted with R3, 0:15 and 0:86, and with a third group of wild -type 
strains. 
d) "all E. coli" MAb SZ 27 150.3 and WN1 222.5 reacted with all the E. 
coli rough and smooth strainsl and with the Salmonella rough mutants 
but not with the Klebsiella or Pseudomonas rough mutants. 
Other patterns were observed, including a group of MAbs which reacted 
with R2 and K12 or with R2 and the Salmonella rough mutants, or with 
all of these strains. However no MAb was found which reacted with K12 
or R4 but not with other rough mutants. Neither MAb SZ 27 150.3 
nor WN1 222.05 nor any of the core -specific MAbs mentioned above 
reacted with the Klebsiella or Pseudomonas rough mutants which were 
tested. 
Figure 6.2 shows the OD values obtained with three of the core -type- 
specific MAbs against the 79 E. coli strains. Most of the strains 
show strong reactivity with one of the three MAbs. The order in 
which the strains are presented is that determined by correlation - 
sorting of the data, and this has resulted in the ordering of most of 
the strains into four groups. The first group consisted of 47 
strains (10b182 - 10b340) which reacted almost exclusively with the 
R1 MAb, and these were classed as R1 strains. Two smaller groups of 6 
strains (9b346 - 9b357) and 11 strains (10b352 - 10b037) react with 
the R2 MAb and the R3 MAb respectively, and are classed as R2 and R3. 
1. MAbs SZ 27 150.3 and WN1 222.5 failed to bind to one of the blood - 
culture isolates, strain 10b300. This strain was re- identified and 
found to be a Citrobacter. 10b300 was one of two isolates from a 
single blood culture. The second of these two isolates, 10b301, was 
recorded as being a Citrobacter, but was in fact an E. coli. It was 


















































































SZ 43 3.4.8 (R1) 
H4 361.23 (R2) 
434.07 (R3) W4 
.4 .8 1.2 1.6 2 
Figure 6.2 Binding (ELISA OD) of three core -type- specific 
MAbs (batch 1) to 79 blood -culture isolates of E. coli. 
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The fourth group consists of 12 strains (10b73 - 10b230) which do not 
react strongly with any of the MAbs, which are referred to as RNC 
(not classified). 
Those MAbs which had reacted with R2, K12 and Salmonella rough 
mutants reacted with all of the R2 group of wild -type strains, but 
also reacted with variable numbers of the RNC strains. This showed 
that the RNC group was heterogeneous, but did not permit clear 
subdivision of this group. 
Some strains did not fit into the above groups, however. Strains 
10b31 and 10b159 react with both the R3 and the R1 antibody. In 
addition, strains 10b120 and 9b191 react with the R1 MAb but have 
been sorted separately from the rest of that group. Strain 10b118 
appeared to be in the RNC group, but bound H4 361.23 to a small 
extent. These five strains, together with representatives of the 
four groups described above, and standard strains were grown up 
again from single colonies from stock cultures (in case there had 
been any mixed cultures) and retested in ELISA with three of the 
core -type -specific MAbs. (The MAbs used for this experiment were 
preparations of confirmed specificity from batch 2 - see below.) The 
results are shown in figure 6.3. On the basis of this data all the 
blood -culture strains could be assigned to one of the four mutually - 




core -type groups 
Strains which 
did not initially 
fit into 


















SZ 43 3.4.8 (R1) 
Ilg H4 361.23 (R2) 





0 .2 .4 .6 .8 1 
Figure 6.3 Binding (ELISA OD) of three core -type- specific 
MAbs (batch 2) to selected E. coli strains. 
174 
Urine and Faecal strains of E. coli: Batch 2 MAbs 
The collection of 80 E. coli strains from urine cultures was tested 
in a ELISA with a panel of MAbs including core- type -specific and "all 
E. coli" MAbs. The MAb preparations used were a new batch obtained 
from Sandoz in Basel or (in the case of the MAbs prefixed "SZ ") from 
local production in Edinburgh. These MAbs are referred to as the 
batch 2, to distinguish them from the batch 1 used in the ELISA with 
the E. coli from blood -cultures. No standard strains were included 
in this assay, but examples from each of the core -types identified 
among the blood culture strains were included together with some 
strains that had not been assigned to a particular core type by the 
initial assay. These strains served as useful controls, as discussed 
below. The 21 E. coli strains isolated from the faeces of healthy 
volunteers were tested in a third assay which also included a group 
of bacteria other than E. coli isolated from blood cultures. 
The "all E. coli" MAb reacted with all of these strains except for 
two of the urine isolates, U36 and U44. These strains are 
discussed in detail later. 
The R1-specific MAbs and the "all E. coli" MAbs of batch 2 bound to 
the control strains as before. There were however some major 
differences noted in the reactions of some of the R2 and R3 
core -type -specific MAbs of batch 2 with control strains. This seemed 
to relate particularly to MAbs which had been received from Basel, 
and could be explained by misidentification of some MAbs. 
175 
R2- specific HAbs in batch 2 
H4 361.23 (R2 specific in batch 1) bound to four of the faecal 
isolates, none of which reacted with the R1 antibody. These four 
strains were identified provisionally as R2 strains. MAb H4 361.23 
was however of very low activity in the assay of the urine strains. 
MAb F6 724.02 (also R2 specific in batch 1) bound to two faecal 
strains which were neither in the R1 group nor in the provisional R2 
group of faecal strains. It also bound to four of the urine 
strains,and to the control strains of R3 core -type. It appeared 
therefore that batch 2 of MAb F6 724.02 was R3 specific. 
The MAb of batch 2 which appeared to react most clearly with the R2 
control strains tested was H4 422.17. This MAb also reacted strongly 
with the four provisionally identified R2 strains among the faecal 
isolates and with four of the urine strains. Batch 1 of MAb H4 
422.17 had reacted most strongly with the R2 strains in the original 
assay of E. coli from blood cultures but had also reacted weakly with 
some other strains. The difference between the two batches might be 
explained by differences in antibody concentration. Results obtained 
with H4 422.17 (batch 2) were used to identify provisionally a group 
of R2 strains among the strains from urine. 
R3- specific MAbs in batch 2 
MAb H4 250.7 (R3 specific batch 1) was found to be widely cross - 
reactive with organisms other than E. coli, and is discussed further 
in chapter 7. H4 351.05b (R3 specific in batch 1) reacted with the 
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R2 control strains, and W4 39.11 (R3 specific in batch 1) was no 
longer available. W4 434.07 (R3 specific in batch 1) did react with 
the R3 control strains as expected, and also reacted with four urine 
strains and two faecal strains which were not in the R1 group nor in 
the provisional R2 group. The activity of MAb W4 434.07 of batch 2 
was therefore consistent with its activity in batch one, and it was 
used to identify the R3 group of urine and faecal strains. 
Confirmation of the specificity of batch 2 MAbs 
A sufficient volume of seven of the MAbs from batch 2 discussed above 
was available for more detailed testing. Repeat testing of these 
preparations with the control organisms confirmed that the correct 
conclusions had been drawn above about the specificity of these MAbs. 
(table 6.1). MAbs F6 724.02 and H4 250.7 of batch 2 clearly had 
different specificities from the batch 1 MAbs with the same reference 
number. Batch 2 did however contain one R3- specific MAb (W4 434.07) 
one R2- specific MAb (H4 361.23) and three R1 specific MAbs (SZ 43 
3.4.8, SZ 43 27.11.2 and VN2 423.10) which had the specificities 
expected from batch one. This latter group of five MAbs were used in 
further experiments. 
Confirmation of the classification of the E. coli strains from faeces 
and urine 
The faecal strains (with the possible exception of strain F1) could 
be easily be assigned to mutually exclusive groups of strains, based 




























































































































































































































































































































































































































































































































































































































































361.23 (R2 specific) and W4 434.07 (R3 specific) (figure 6.4). The 
other R1- specific MAbs (VN2 423.10 and SZ 43 27.11.2), and the other 
batch 2 MAbs identified as R2 or R3 specific gave consistent results. 
The validity of these conclusions was confirmed in a repeat 
experiment retesting the binding of these three MAbs to examples from 
each group together with the rough mutants R1, R2, and R3, and with 
the smooth strains 0:12 0:15 and 0:18 (figure 6.5). Strain F1, which 
had reacted weakly with the R1-specific MAbs, was included in this 
assay and subsequently assigned to the RNC group. 
Most of the urine strains could also be assigned to R1, R2, R3 or RNC 
groups based on their reactions with SZ 43 3.4.8 (R1 specific), H4 
422.17 (provisionally R2 specific) and W4 434.07 (R3 specific), as 
shown in figure 6.6. As with the blood- culture strains, strains 
which did not fall clearly into one group were re- tested. In 
addition, all the strains provisionally identified as belonging to 
the R2 group were re- tested with the confirmed R2- specific batch 2 
MAb H4 361.23. As shown in figure 6.7, the group of strains 
provisionally identified as R2 did react with H4 361.23, and the 
other strains could all be placed in one of the four mutually - 
exclusive groups R1, R2, R3 or RNC. 
Urinary strains which did not react with the "all -E. coli" MAbs 
Strains U36 and U44, the urine isolates which had not reacted with 
the "all E. coli" MAbs, were retested in ELISA, and the lack of 
reactivity with these MAbs under the standard conditions used was 
confirmed. The identification of U36 was checked by API 20E, and 
179 
F1 iaii 
SZ 43 3.4.8 (R1) 
F2 '4 H4 361.23 (R2) 
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Figure 6.4 Binding (ELISA OD) of three core -specific MAbs 

















SZ 43 3.4.8 (R1) 
H4 361.23 (R2) 
W4 434.07 (R3) 
1 
0 .3 .6 .9 1.2 1.5 
Figure 6.5 Repeat assay of binding (ELISA OD) of 



















































































SZ 43 3.4.8 (R1) 
, H4 422.17 (R2) 
434.07 (R3) W4 
0 .5 1 1.5 2 2.5 
Figure 6.6 Binding (ELISA OD) of three core -type -specific 





SZ 43 3.4.8 (R1) 
H4 361.23 (R2) 


















0 .5 1 1.5 2 2.5 
f I 
Figure 6.7 Binding (ELISA OD) of three core -type- specific 
MAbs (batch 2) to E. coli rough mutants and selected E. 
coli strains from urine cultures. 
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confirmed to be E. coli. Strain U44 was unfortunately no longer 
viable, but the original heat -killed cell preparation was however 
available for repeat testing in ELISA. The binding of a range of 
concentrations of SZ 27 150.3 to U36, U44 and some other E. coli from 
urine culture was examined (figure 6.8), and confirmed that there was 
much less binding to U36 and U44. The binding that is seen is at 
much higher MAb concentration. 
The reactivity of U36 and U44 with the three different R1- specific 
MAbs showed some inconsistencies. In the original ELISA screen, SZ 
43 27.11.2 bound to both these strains while SZ 43 3.4.8 bound only 
to U36, and VN2 423.10 bound to neither strain. This was in contrast 
to the trend for these MAbs to bind to an equivalent degree to "Rl" 
strains. In a repeat assay (not shown) under standard ELISA 
conditions results were as above, except that VN2 423.10 now bound to 
U36, although more weakly than the other two R1- specific MAbs. A 
quantitative assay of the ability of these MAbs to bind to these two 
organisms and some other E. coli from urine was therefore performed. 
This confirmed (figure 6.9) that SZ 43 3.4.8 and VN2 423.10 did not 
bind to U44, even at high MAb concentration. SZ 43 3.4.8 and VN2 
423.10 did bind to U36, though in neither case did binding to U36 
equal the binding to the R1 strain U21. U36 bound SZ 43 3.4.8 more 
than it bound VN2 423.10. This was true across the range of 
concentrations, both for absolute OD values and for comparison with 
binding to the R1 strain. SZ 43 27.11.2 is shown in figure 6.9 to be 
less specific in its binding, producing, at higher concentrations, 
measurable OD values with all the E. coli strains tested in this 
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Figure 6.8 Binding (ELISA OD) of a range of dilutions of 
MAb SZ 27 150.3 (purified preparation) to heat -killed cells 
of six different E. coli isolates from urine. The MAb 
preparation had a nominal concentration of 2.5 mg /ml. Arrow 
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-0- U44 
Vi (RNC) 
-111- U21 (R1) 
- 6- U29 (R2) 
-E- U39 (R3) 
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-0- U44 
-0- U1 (RNC) 
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-6- U29 (R2) 
-F U34 (R3) 
Log2 (dilution/10) 
SZ 43 3.4.8 
VN2 423.10 
SZ 43 27.11.2 
Figure 6.9 Binding (ELISA OD) of a range of dilutions of three 
R1- specific MAbs (culture supernatants) to heat -killed cells of 
six different E. coli isolates from urine. Arrows indicate 
dilution equivalent to that used in core -typing experiments. 
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which has shown that, in some assays, it is less Ri- specific than SZ 
43 3.4.8. The binding of SZ 43 27.11.2 to U36 is slightly less than 
its binding to the R1 strain, while its binding to U44 is lower 
still, and not distinguishable in this assay from its binding to the 
RNC strain. The differences observed in the initial ELISA assay do 
therefore appear to represent real differences in the abilities of 
the three R1- specific MAbs to bind to strains U36 and U44. 
rim oblotting with is MAbs 
The specificity of batch 2 core- type -specific MAbs SZ 43 3.4.8, S2 43 
27.11.2, VN2 423.1 (all R1 specific), H4 361.23 (R2 specific), W4 
434.07 (R3 specific), SZ 27 150.3 ( "all E. coli "), and WN1 222.5 
( "all E. coli") for LPS core was confirmed by i.mmundblotting against 
LPS (proteinase K extracts) from E. coli R1, R2, R3, R4, K12, 0:12, 
0:15, and 0:18K1. The strains of R1, R2, R3, R4 and K12 used were 
those supplied by Dr H. Brade The 0:12, 0:15, and 0:18 strains were 
chosen as they seemed, from the ELISA data above, to represent smooth 
strains with R2, R3, and R1 core types respectively. The immunoblots 
(figure 6.10) showed reactivity of each MAb with a band corresponding 
to the LPS core of each of the organisms with which it reacted in 
ELISA. With the rough mutants a band was seen whi.ch.corresponded to 
the single band seen in the silver stain. With the smooth strains 
the R3- specific MAb W4 434.07 and the R1- specific MAID SZ 43 3.4.8 
again reacted with a single band corresponding to the fastest moving 
band seen in the silver stain, which consists of unsubstituted LPS 
core. MAb SZ 43 3.4.8 reacted in the same way in blots with the 0:1, 




























































































































































































































27.11.2 and VN2 423.10) produced identical results . The R2- specific 
MAb H4 361.23 and the all E. coli MAb SZ 27 150.3 reacted with the 
unsubstituted core band and also with the "ladder" pattern of bands 
corresponding to 0- substituted LPS core. A further imnunoblot was 
carried out later with the R2 specific MAb H4 361.23, using 
additional strains identified (see below) as a) R2 and 0:75 b) R1 and 
0:75 and c) R2 of unknown 0 type. The result, shown on figure 6.11, 
confirms that the "ladder" pattern observed with MAb H4 361.23 is 
restricted to the R2 core type, and is not related to the 0:12 
antigen or to the 0:75 antigen. 
MAb SZ 27 150.3 reacted in the blot shown in figure 6.10 with bands 
in the R1 and R4 LPS preparations which are not visible in the silver 
stain. These bands may represent either non -covalent polymers of 
rough LPS [21] or the production, due to a leaky mutation, of small 
quantities of 0- substituted LPS. Alternatively they may represent 
LPS core substituted with enterobacterial common antigen [121]. The 
failure to observe these bands in the silver stain may be due to 
inadequate staining. Material in this region was detected on the 
silver -stain of similar preparations on some occasions, eg figure 
5.14. 
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1 2 3 4 5 6 7 8 9 10 11 
Figure 6.11 Silver stain (top) and immunoblot with R2 specific MAb 
H4 361.23 (bottom) of polyacrylamide gel of proteinase K preparations 
of E. coli. Lanes 1 -8 respectively represent strains R1, R2, R3, R4, 
K -12, 012, 015, 018. Lanes 9 -11 represent blood culture isolates: 
lane 9: 10b145 (R2, not 0 typed); lane 10: 10b149 (R2, 0:75); 
lane 11: 9b25 (R1, 0:75). 
190 
Frequencies of LPS -core types among clinical isolates of E. coli 
The numbers of wild -type strains falling into the four MAb- defined 
groups are given in table 6.2. U36 and U44, the two strains which 
did not bind the "all E. coil" MAbs, have been included in the RNC 
group. Rl strains were the most common overall (123/181, 68 %), and 
were more common among the strains from urine (62/80, 78 %) than among 
those from blood -culture (48/79, 61 %, p = .017) or faeces (11/21, 
52 %, p = .030). 
Relationship between MAb- defined core type and sensitivity to rough- 
specific phage and K- specific phage. 
This is summarized in table 6.3. The collection of wild -type E. call 
was tested for sensitivity to the rough -specific phages which have 
been used to distinguish between the different R types of E. coil 
[208], since it was thought that the pattern of reactivity might 
support the MAb- defined R typing scheme. Fifty of the 180 strains 
tested were sensitive to one or more of the rough -specific phage. 
They were found among each of the R -types defined with MAbs. C21 
sensitivity, a marker for the R1 rough mutant, was found in 19 
strains, 17 of which were R1 and 2 RNC strains. FO sensitivity is a 
marker for R2 rough mutants, but no strains were found to be FO 
sensitive. There was no other discernible relationship between R type 
and sensitivity to particular rough -specific phages. 
Forty -six of the 180 strains were sensitive to one of the two K- 
specific phages. The R1 strains accounted for 19 of the 22 K1 strains 
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Table 6.2 Frequency of core types in wild -type isolates of E. coli 
determined by binding of core- type -specific MAbs in ELISA. 
Number( %) of strains assigned to 
MAb- defined core types 
Source R1 R2 R3 RNCa Total 
Blood culture 48(61) 6(7) 12(15) 13(16) 79 
Urine 64(81) 4(5) 4(5) 8(10) 80 
Faeces 11(52) 4(19) 2(10) 4(19) 21 
Total 123(68) 14(8) 18(10) 25(14) 180 
aNC = Not Classified. 
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Table 6.3. Sensitivity of 180 E. coli of different core types to 
rough -specific, K1- specific, and K5- specific phage. 
Number of strains sensitive to each phage 
Core type (n) FO BR10 C21 6SR T4 Total R +a K1 K5 
R1 (123) 0 8 17 5 28 40 19 20 
R2 (14) 0 2 0 1 3 3 0 1 
R3 (18) 0 0 0 0 2 2 0 1 
RNCb (25) 0 3 2 2 3 5 3 2 
Total (180) 0 13 19 8 36 50 22 24 
a Total R+ = number of strains sensitive to one or more of the rough - 
specific phage. 
bNC = Not Classified. 
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and 20 out of the 24 K5 strains found. This was not a statistically 
significant association, however, because of the overall 
preponderance of R1 strains. 
Relationship between MAb- defined core type and 0 type among the urine 
and blood -culture isolates. 
The urine and blood -culture isolates of E. coli were tested for 12 0 
antigens found commonly among E. coli from blood -culture [52,177] or 
urinary infection [89], as described in the Note at the end of this 
chapter. The relationship between 0 types and core types is shown in 
table 6.4. The proportion of strains which belonged to one of the 0- 
types tested for was higher among those of R1 core type (66/112, 58 %) 
than among the other core types (11/47, 23 %, p = .0005). Some 
constant associations between 0 type and core type are apparent, eg 
all 26 0:6 strains are R1, and all three 0:15 strains were R3. In 
contrast, 0:75 strains were found among both the R1 and the R2 core 
types. 
The proportion of the R1 strains which belonged to one of the common 
0 types was greater among the blood -culture isolates (32 0 typed 
strains among 48 R1 strains, 67 %) than among the urine culture 
isolates (34/64, 53 %). This difference is not statistically 
significant (p = .177), but the number of R1 strains not belonging to 
the common 0 types could account for the greater proportion of R1 
strains among the isolates from urine. 
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Table 6.4 0 type of E. col./ of different core types from blood 
and urine cultures. 
Number of each core type associated with 
the 0 -type given 
Core type(n) 01 02 04 05 06 07 08 015 018 075 NTa 
R1 (112) 11 0 6 1 26 3 3 0 10 6 46 
R2 (10) 0 0 0 0 0 0 0 0 0 3 7 
R3 (16) 0 0 0 0 0 0 0 3 0 0 13 
RNCb ( 21) 1 2 0 0 0 2 0 0 0 0 16 
Total (159) 12 2 6 1 26 5 3 3 10 9 82 
a NT = Not Typed by the available 0- specific sera. 
b NC = Not Classified 
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Relationship between R type, serum resistance, and LPS dhemotype 
among blood -culture strains. 
Serum resistance, which is a property of most invasive strains of E. 
coli [52] was determined for all the blood -culture isolates. Of the 
79 strains, 21 (26 %) were serum sensitive. Serum sensitive strains 
were present in all the core types but were slightly less common 
among the R1 strains (9/48, 19 %) than among the other R types (10/31, 
32 %). This difference may have been due to the association of R1 
core with K1 and K5 capsule, since all of the 11 K1 strains and all 
but one of the 10 K5 strains from blood -cultures were serum 
resistant. 
Seventy of the 79 blood- culture strains produced a typical "ladder" 
pattern LPS in silver stains of polyacrylamide gels of proteinase K 
digests. Typical "ladder" patterns were produced by some of the 
strains which were sensitive to one or more rough -specific phage, as 
was found by Cross et al [52]. The other nine strains showed only 
one or a few fast -moving bands, one corresponding to the 
unsubstituted core. Seven of these strains, together with some 
strains producing typical "ladder" patterns are shown in figure 6.12. 
All these 9 strains were sensitive to one or more of the rough - 
specific phage. Three of the nine were R1, three were R2, two were 
R3 and one was RNC. One was 0 typeable, an 0:1 Kl strain. Two were 
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Figure 6.12 Silver stains of polyacrylamide gel of LPS (proteinase K 
digests) from some blood -culture isolates of E. coil. The strains in 
lanes 5, 6, 8, 11, 12, 13, and 16 were considered to show an atypical 
pattern lacking the usual "ladder" of high molecular weight bands, 
and were all sensitive to one or more rough -specific phage. The 
strains represented by lanes 1, 3, 4, 9, and 15 were also sensitive 
to rough -specific phage. The strain in lane 10 is 10b149 which shows 
a unique ladder pattern dominated by low molecular weight bands. This 
strain is also seen in figure 6.11. 
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Binding of anti -LPS core MAbs to Rnteropathogenic E. toil and 
Shigella spp. 
The "all E. coli" MAb SZ 27 150.3, and individual core -specific MAbs 
from batch 2 (R1: VN 2 423.10, R2: H4 361.23, and R3: W4 434.07) were 
used to test Shigella and enteropathogenic E. coli strains. These 
experiments were carried out in two separate batches, each including 
E. coli rough mutants R1, R2, R3 and R4 as controls. Table 6.5 
summarises the results. The OD results have been classified as 
positive or negative, with a positive taken as more than 60% of the 
result obtained with the appropriate rough control organism. In most 
cases the wild -type strains gave OD results close to or higher than 
those obtained with the rough strain. 
Both of the Shigella sonnei strains reacted with the R1- specific MAb, 
while the two Shigella flexneri strains reacted with the R3- specific 
MAb. These strains also reacted with the "all E. coli" MAb. These 
results are consistent with previous studies of LPS core in these 
species [78,101,145]. The two Shigella dysenteriae type 2 strains 
also reacted with the R3- specific MAb, but they failed to react with 
the all E. coli MAb SZ 27 150.3, implying that they probably have a 
different core structure. Enteropathogenic E. coli strains 
classified as R1, R2, R3 and RNC were found, though there was a 
predominance of R3 strains among the group of strains tested. The 
finding of two different core types among the two available strains 
of E. coli 0:127 was surprising in view of the suggested "clonal" 
nature of enteropathogenic E. coli [178], but may reflect the 
suggestion that many sporadic isolates of enteropathogenic 
serotypes 
of E. coli are not true enteropathogenic strains [117]. 
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Table 6.5 Core- typing of Shigella spp. and enteropathogenic E. coli 
strains with MAbs in ELISA. 
Strain Reactiona with MAbsb 
specific for 
E. coli core types 




Shigella sonnei 4/2 + + 
S. sonnei 2/1 + + 
S. flexneri 3/1 + - 
S. flexneri 1A + 
S. dysenteriae type 2c - - 
E. coli 0125d + + 
E. coli 0126d + - 
E. coli 0127d + - 
E. coli 0127e + - 
E. coli 0128f + - 
E. coli 0157g + - 
- - R1 
- + R3 
- + R3 
- + RNC 
- - R1 
- + R3 
+ - R2 
- - RNC 
- + R3 
- + R3 
Notes. a " +" indictates an OD > 60% of that obtained with the 
appropriate R type control organism; " -" indicates an OD of < 10 % of 
the appropriate control. b The MAbs used were SZ 27 150.3 (reactive 
with all E. coli core types) VN2 423.10 (R1 specific) H4 361.23 (R2 
specific) and W4 434.07 (R3 specific). c Two stock strains. d Stock 
culture. e Recent sporadic clinical isolate. f One stock strain and 
three clinical isolates. g Six clinical isolates. 
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Binding of MAbs to Gram -negative bacilli other than E. coli or 
Shigella spp. 
Blood -culture isolates of other Gram-negative genera (Acinetobacter, 
7; Citrobacter, 5; Enterobacter, 18; Klebsiella, 14; Proteus, 9; 
Providencia, 1; Pseudomonas, 8; and Salmonella, 2; Serratia, 5) were 
also tested in ELISA with the full panel of batch 2 MAbs. The only 
positive reaction observed with the "all E. coli" MAbs or core -type- 
specific MAbs was between the two Salmonella strains and the "all E. 
coli" MAbs. As indicated above, some other MAbs were identified 
which reacted with E. coli R2 and Salmonella or with E. coli K12 
and Salmonella. Three MAbs were identified which did apparently 
cross -react with a wider range of bacterial species, and these are 
discussed further in chapter 7. 
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DISCUSSION 
I have described a group of MAbs that bind to the LPS core of E. coli 
in polymyxin -LPS ELISA (data not shown) and in immunoblots, and 
studied their binding to a wide range of heat -killed Gram -negative 
bacteria in ELISA. Some of the MAbs bind to Salmonella and Shigella 
strains which share E. coli core structures. The MAbs do not bind to 
a range of other Gram -negative bacilli, confirming that the binding 
observed is specific. 
MAbs which bind to rough E. coli of one core type and which also bind 
to some smooth E. coli have been used to identify three mutually 
exclusive groups among E. coli isolates. These groups have been 
named Rl, R2, and R3 after the corresponding rough mutants. A fourth 
group, which could not be assigned to a particular core type, has 
been referred to as RNC, and is probably of heterogeneous core type. 
I have included in the RNC group the strains which did react with one 
or more of the Ri- specific antibody but which did not react with the 
"all E. coli" MAb. If these strains had been of Rl core type then a 
reaction with the "all E. coli" MAb would have been expected. 
E. coli strains assigned to the groups R1, R2 and R3 defined with 
MAbs may have the core structure of the named rough strain, though 
this has not been confirmed by chemical analysis. 
Results reported in chapter 5 suggested that there may be some 
heterogeneity within the R1 group. All five E. coli strains used in 
chapter 5 were subsequently assigned to the R1 group on the basis of 
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experiments with the MAbs described in the current chapter (data not 
shown). MAbs H4 351.18 and H7 41.76 (table 5.3) failed to bind (or 
bound very weakly) to E. coli strain 8b317 in immunoblots, but did 
bind to the other four E. coli strains tested. It was this 
observation which led to the idea of looking for core- type -specific 
MAbs, but which now suggests some heterogeneity in the R1 group. 
There are other possible explanations however, including differences 
in the amount of LPS present in the preparations used in chapter 5, 
and problems with transfer of LPS to nitrocellulose at one end of the 
blotting tank. The whole -cell ELISA experiments in chapter 5 
(figures 5.2 and 5.3) did not clearly demonstrate a difference 
between E. coli strain 8b317 and the other E. coli strains with 
respect their binding of MAbs H4 351.18 and H7 41.76. 
The presence of C21 sensitivity (a marker for R1 rough mutants) among 
wild -type strains of MAb- defined R1 rather than R2 or R3 core 
type supports the view that the MAb- defined core types are the same 
as the reference rough strains. Two RNC strains were also C21 
sensitive, but the specificity of these phages for particular core 
types is not based on an independent knowledge of their receptor 
sites, and it is not known how they might react with as yet 
unidentified core types of E. coli. Phage typing is of little value 
in determining the core type of wild -type strains since most wild - 
type strains are resistant to all of the phage used. 
No st:air. of R4 or 7'2 core type have been positively identified. 
This may be explained by the lack of suitable specific MAbs. We did 
have MAbs reactive with K12, but these also reacted with R2, and did 
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not bind to a clearly defined group of wild type strains other than 
those which reacted with the R2- specific MAbs. The RNC group may 
include strains with R4 or K12 core, but probably also contains other 
as yet unidentified core types. The RNC group is heterogeneous, as 
seen from the variable reactivity with those MAbs that react with 
K12, and the lack of reactivity with the "all -E. coif" MAb observed 
with urine strains U36 and U44. 
MAbs reactive with complete core structures have been reported by 
others. Tsang and colleagues reported MAb T6 [235] which reacts with 
the LPS core of Salmonella and the E. coli R2 rough mutant, and MAb 
105 [236] which reacts with the core of Salmonella only. Luk et al 
[133] described two other MAbs (Ty1 and Ty2) which recognise the 
complete core of Salmonella. Ty1 reacted only with unsubstituted 
core, and did not react with any of the E. coli core types. Ty2 
reacted with 0- substituted core of Salmonella and also reacted with 
the E. coli R2 rough mutant. It was not tested against smooth E. 
coli other than 0111, which is of R3 core type [207]. Nnalue et al 
[170] described MAb MM3 which also reacted with Salmonella and with 
E. coli R2 core but not with other E. coli core types. MM3 also 
reacted with 10 of 68 clinical isolates of E. ccolí, and reacted with 
0- substituted Salmonella core in immunoblots. 
Viret et al [245] described MAb Sh9R which binds E. coli R1 core but 
not other E. coli cores. It does not bind to Salmonella, but does 
bind to Shigella sonnei and to other Shigella species which are 
reported to have R1 core. It does not bind to 0- substituted core in 
immunoblots. Attempts to define its epitope by competition studies 
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were unsuccessful. 
Comparison of the structural formulae (figure 1.4) with the 
specificities of the core- type -specific and "all E. coli" MAbs could 
suggest binding of the MAbs to particular sugar residues. R1 and R3 
cores each have a unique terminal branching hexosyl unit (ß1 -3 linked 
glucose and al -3 linked N- acetyl glucosamine respectively) which may 
be the epitope for the R1 and R3 MAbs. Viret et al [245] also 
concluded that MAb Sh9R recognised the terminal glucose residue. E. 
coli R2 and Salmonella core share a terminal al -2 linked N- acetyl 
glucosamine, while R2 and K12 have in common the next three sugar 
residues. These may therefore be the epitopes for the MAbs which 
bound to these combinations of strains. Competition studies have 
shown however that the epitope of the R2 /Salmonella MAb Ty2 [133] was 
in the Glucose- Galactose -Glucose backbone of the core, and that the 
epitope of the apparently similar MAb MM3 [170] was in the heptose 
region, where there are no differences in the accepted structural 
formulae. 
A unique binding site for the R2- specific antibody is not obvious 
from the structural formulae but, as is apparent from the results of 
competition studies discussed above the structural formulae probably 
give an incomplete picture of the structure of LPS -core. From the 
calculated three -dimensional structure of the different core types 
[103] however it appears that the branch -terminating al -6 galactose 
present in R2, Salmonella and K12 may be in a different orientation 
in R2, and may therefore be the R2- specific epitope. It is of note 
that, while most of the core -specific MAbs reacted in immunoblot only 
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with unsubstituted core, the R2- specific MAb also reacted with 0- 
substituted core, giving a ladder pattern in inmiunoblots. This 
implies that the R2- specific epitope is the only one not altered or 
masked by the attachment of the 0 polysaccharide. Further study of 
the binding site of these antibodies may therefore be useful in 
elucidating the three- dimensional structure of LPS core, and in 
attempts to define the attachment site of the 0 polysaccharide. 
The observation that the urine strains U36 and U44 showed 
differential binding of the three "R1- specific" MAbs implies that 
these three R1- specific MAbs have different specificities, indicating 
that the R1- specific region of E. coli R1 -type LPS -core contains 
three distinct, though perhaps overlapping, epitopes. All three 
epitopes are apparently present on the R1 group of organisms, and all 
are lost in 0- substituted LPS. U36 strongly expresses the epitopes 
recognised by SZ 43 3.4.8 and SZ 43 27.11.2. U44 and some other E. 
coli strains bind SZ 43 27.11.2 to a lesser extent, suggesting the 
presence of an epitope which is similar to but not identical with the 
epitope recognised by this MAb on E. coli Rl. U36 binds VN2 423.10 
only at high MAb concentration, again suggesting the presence of an 
epitope similar to but not identical with the epitope recognised on 
E. coli Rl. 
U36 and 44 would be an interesting starting point for further study 
of the detailed structure of E. coli R1 core, and it is unfortunate 
that U44 is no longer viable. Some doubt must remain over whether 
U44 is really an E. coli, since it was not possible to recheck its 
identification. As far as the interpretation above of the 
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differential binding of the three R1- specific MAbs is concerned, it 
does not matter if the organism is not an E. colí. 
It is likely that the R2- and R3- specific regions are of similar 
complexity to the R1- specific region, and possibly as complex as the 
region or regions common to E. colí R2 and Salmonella [133,170]. 
Demonstrating the presence of multiple epitopes requires a suitable 
collection of MAbs with subtly different specificities. We did not 
appear to have such a collection of MAbs, but MAbs of interest in 
this regard may have been overlooked because of problems in 
production and labelling of some of the R2- and R3- specific MAbs. In 
order to demonstrate multiple epitopes by the methods employed here 
one would also require a collection of organisms which express 
suitable variants of the core region. Such strains may be very rare 
or non -existent. Alternative and more systematic approaches would 
be to synthetic 
to test for competitive inhibition between the different MAbs. 
The binding of the "all E. coli" MAb SZ 27 150.3 to almost all of the 
E. coli strains and to the Salmonella and Shigella strains, together 
with the pattern of binding of the core -specific MAbs, supports the 
view that these organisms share closely related LPS cores. The lack 
of binding of any of the antibodies to other genera suggests that 
these core structures are not distributed more widely. The 
structure of LPS core has not been determined for all the other 
genera, but it has been shown that the LPS cores of Citrobacter 
[197,198] Proteus [192] and Pseudomonas [200] are different from 
that of E. colí. 
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R2 core type accounted for 8% of the collection of E.coli strains 
reported here. A similar overall frequency of R2 core type is 
suggested by Nnalue et al [170] who reported that MAb MM3 (which 
reacted with Salmonella and E. coli R2 core) bound to 10 (14.7 %) of 
68 clinical isolates of E. coli. The overall figure reported by 
Nnalue et al [170] masks a major difference between faecal and blood - 
culture isolates of E. coli however, since 10 of 36 faecal isolates 
reacted with MM3, while none of 32 blood culture isolates reacted. 
It is not clear from this report whether the faecal isolates were 
enteropathogenic serotypes of E. coli or simply commensal strains. 
MAb T6, which also recognises the R2 core of E. coli and the core of 
Salmonella spp, did not react with 25 clinical isolates of E. coli in 
Hong Kong [235]. These differences in the apparent frequency of R2 
core may represent differences in the specificity of the MAbs as well 
as geographical and temporal differences in the true frequency of R2 
core. A capture ELISA using MAb T6 which is intended to detect 
Salmonella in clinical samples has been described [41]. This assay 
may yield a significant number of false positives if E. coli of R2 
core type is as common as is suggested by the data reported here. 
The tendency for certain apparently distinct properties of E. coli to 
occur together [178] seems to apply to the relationship between core 
types and 0 and K types. The association between core type and 0 
type reported here is largely in agreement with the results of Viret 
et al [245] who found that the R1- specific MAb Sh9R reacted with E. 
coli serotypes 0:1, 0:6, 0:7, 0:18 and 0:75 but not with 0:12 or 
0:15. It may be that there are chemical or structural factors 
limiting the ability of E. coli to express certain combinations of 0 
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types and core type (eg 0:15 and R1), or it may be that some such 
combinations have a selective advantage in the host. The finding 
that there was greater proportion of R1 core type among the urine 
strains, and in particular that there was a greater proportion of R1 
strains not belonging to one of the common 0 types, may indicate some 
relationship between R1 core type and unusual 0 types and 
pathogenicity in the urinary tract. Further studies are needed before 
firm conclusions can be drawn on this point. 
Core typing with MAbs may be a useful addition to current typing 
methods for E. coli. The number of possible types is small, and the 
core type does not usually discriminate among strains of a given 0 
and K type, but core typing may be useful in recognising relatedness 
between groups of E. coli. It would be of interest to use the MAbs 
described here to investigate the LPS -core type of a wider range 
Shigella and E. coli from a variety of sources. 
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NOTE ON THE 0- TYPING METHOD USED. 
Small amounts of Difco absorbed antisera to E. coli 0 antigens 0:1, 
0:2, 0:4, 0:6, 0:7, 0:12, 0:15, 0:18, 0:22, 0:75 and 0:86 were a gift 
from Dr CC Blackwell, of the Department of Medical Microbiology, 
Edinburgh University. Using these antisera the standard method of 0 
typing E. coli strains was adapted, by including an ELISA based 
initial screening stage, to reduce the workload and amount of serum 
required. 
An initial experiment was devised to determine the feasibility of 
this approach, and to determine the appropriate dilution of serum to 
use. NUNC polysorb strips were coated with heat -killed E. coli 
strains 0:4, 0:12 and 0:15 and post coated as described in materials 
and methods, and an ELISA assay was performed using varying dilutions 
of absorbed rabbit antisera(Difco) to E. coli 0 antigens 4, 12 and 
15. On the basis of these results (figure 6.13) a serum dilution of 
1 in 1000 was chosen for the assay of the full panel of organisms, 
since this seemed to give a minimal OD with the heterologous strains 
tested while maintaining a reasonably high homologous OD. If 
necessary the incubation of the substrate could be continued for a 
longer period to achieve a higher specific OD. 
The full panel of 79 blood culture E. coli and standard strains was 
tested in ELISA with a 1 in 1000 dilution of the available Difco 
absorbed 0 typing sera. ODs were recorded at 60 min and 90 min 
incubation. The 60 min readings were used for all antisera except 
0:18. In the case of the 0:18 antiserum a printer fault caused the 
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Figure 6.13 Binding (ELISA OD) of absorbed rabbit 
anti -0 antisera to E. coli 0:4, 0:12, and 0:15. 
41= homologous strain, C)= heterologous strains. 
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loss of most of the 60 min data for the blood -culture isolates, and 
the 90 min data were therefore used. 
Results were first examined for the standard 0 type strains, as an 
index of the discriminatory power of the test. Table 6.6 shows the 
OD obtained for each antibody with its homologous strain, and the 
highest OD obtained with any of the heterologous strains. The 
homologous strain gave an OD of at least twice the maximum obtained 
with any heterologous strain for all but the 0:86 antiserum. 
Among the wild -type strains, most of the antisera reacted strongly 
with a small number of strains, and the strains which reacted 
strongly with one antiserum did not react strongly with any other. 
In the case of 0:6, for example, 10 strains gave OD values above 
0.978, compared to an OD obtained with the standard 0:6 strain of 
0.937. The next lowest OD obtained with any wild -type strain was 
0.360, compared to a maximum OD obtained with any heterologous 
standard strain of 0.299. The 10 strains with the highest OD values 
were therefore provisionally assigned as 0:6. Other antisera behaved 
in a similar way, reacting with a clearly identifiable group of 
strains. The 0:7 antiserum, for which no homologous strain was 
available, gave an OD of >- 0.908 with two strains, compared to a 
maximum OD from the heterologous standard strains of 0.512, and a 
maximum for other wild -type strains of 0.420. These two strains were 
therefore provisionally assigned to 0:7. 
Conventional tube agglutination was carried out to confirm the 
identification of all the provisionally identified 0:18 and 0:7 
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Table 6.6 ELISA results obtained with Difco absorbed anti -0 sera 
tested at a dilution of 1 in 1000 against a panel of standard smooth 
strains of E. coli of known 0 typea. 
OD obtained with 
Homologous Heterologous strains 
strain Discriminatory 
Antiserum Maximum Minimum ratiob 
0:1 0.803 0.269 0.137 2.99 
0:2 0.978 0.222 0.094 4.41 
0:4 0.826 0.152 0.036 5.43 
0:6 0.937 0.299 0.122 3.25 
0:7 N/Ac 0.512 0.210 N/A 
0:12 0.396 0.161 0.056 2.46 
0:15 0.837 0.365 0.047 2.29 
0:18 0.837d 0.416 0.110 2.01 
0:22 N/A 0.122 0.037 N/A 
0:75 0.893 0.331 0.126 7.09 
0:86 0.258 0.273 0.090 0.95 
Notes a The standard strains used were 0:1, 0:2, 0:4, 0:6, 0:8, 
0:12, 0:15, 0:18, 0:75, and 0:86. b The discriminatory ratio was 
defined as (OD obtained with homologous strain) /(Maximum OD obtained 
with any heterologous strain). c N/A = not available. d The lowest 
result obtained with any of the 0:18 strains is given. 
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strains, and on the strain with the lowest OD from each of the other 
provisionally identified 0 types. 
Absorbed 0:8 and 0:9 antisera were not available, and no commercial 
source of antisera to the E. co1i 0 antigens found commonly in blood 
and urine cultures could be found. Unabsorbed antisera to 0:8 and 
0:9 was subsequently obtained from the Statens Seruminstitut, 
Copenhagen. However, these antisera were not able to distinguish 
between homologous and heterologous 0 -types of E. coli in ELISA as 
the absorbed sera had done. Figure 6.14 shows an example of the 
results obtained. Attempts were made to absorb out cross - 
reactivity, but without success. It was therefore decided to screen 
the organisms with these sera by conventional tube agglutination 
using a final serum dilution of 1 in 80, and confirm by determining 
the highest titre of antiserum which would agglutinate the organism 
suspension. Four of the blood- culture isolates of E. coli were 
agglutinated by the 0:8 antiserum at i in 80, of which 3 were 
agglutinated at 1 in 1280, the same titre as the control organism. 
None of the blood -culture isolates were agglutinated by the 0:9 
antiserum. 
E. coli strains from urine cultures were 0 -typed in the same way as 
the blood -culture isolates had been. The results of 0 typing are 
shown in tables 6.4, 6.7, and 6.8. Grüneberg et al [89] noted that 
there were statistically significant differences between the numbers 
of strains of particular 0 types reported in different series of 
urinary infections, even from different centres within a few miles of 












Figure 6.14 Binding (ELISA OD) of absorbed and unabsorbed 
anti -O antisera to E. coli 0:8 and 0:18. = homologous 
strain; O = heterologous strain; A = binding to ELISA 
wells which had not been coated with E. coli but which had 
been post- coated. 
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Table 6.7 Frequency of common 0 types among isolates of E. coli from 
blood cultures. 


















(N = 219) 
Meand 
(n = 1179) 
This thesis 
(n = 79) 
2.8 6.4 8.2 5.0 8.9 
10.8 4.9 3.2 7.2 1.3 
10.6 5.2 8.2 8.2 3.8 
8.2 10.5 13.7 10 12.7 
3.2 4.5 NSf 3.0 2.5 
4.0 NS 4.6 2.7 3.8 
4.2 NS NS 2.0 0 
NS NS 1.8 0.3 0 
NS NS 2.7 0.5 1.3 
3.3 13.1 6.4 7.5 6.3 
3.0 1.2 NS 0.4 0 
7.2 4.7 7.2 5.9 7.6 
Notes a OKskov and Orskov [177]. b Cheasty et al [39]. c Cross et 
al [52]. Mean = mean of results from the three published series 
shown. For the purposes of this calculation it has been assumed that 
no strains of a given 0 type were identified in a series where the 
number is not stated (NS) in the publication. e The total given in 
the paper is 411, but the numbers given add up to 421. NS = not 
stated in the publication. In the series of Cheasty et al [39] and 
Orskov and Orskov [177] NS means less than five strains of a 
particular serotype. 
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Table 6.8 Frequency of common 0 types among isolates of B. coli from 
urine cultures 
0 type Frequency ( %) reported by: 
Grünberg et al [89] 
(n = 1771) 
This thesis 
(n = 80) 
0:1 7.7 6.3 
0:2 4.5 1.3 
0:4 11.8 3.8 
0:6 11.8 20.0 
0:7 5.0 3.8 
0:9 1.0 0 
0:12 1.1 0 
0:15 NSa 2.5 
0:18 2.9 6.3 
0:75 7.6 3.8 
a NS = Not Stated. 
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limited range of types (notably 0:1, 0:2, 0:4, 0:6, 0:18, and 0:75) 
were frequent in all series of urinary infection, as they are in 
series of blood culture E. coli. Within these broad limits, the 
relative numbers of strains in each of the common 0 groups reported 
here is in agreement with that reported by others. 
The use of ELISA screening to determine the 0 types of E. coli 
appeared to work very well, and could probably be used without the 
need to confirm any 0 types by tube agglutination. It did however 
require appropriate absorbed sera. Since these sera are no longer 
commercially available however it is unlikely that this method will 
be widely applied. 
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CHAPTER 7 
CROSS- REACTIVE MONOCLONAL ANTIBODIES 
WHICH DO NOT REACT WITH LPS-CORE. 
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INTRODUG'TION 
During the Sandoz project some MAbs were produced which were widely 
cross reactive in ELISA with Gram -negative bacteria, but which did 
not react with LPS -core in ELISA. These were considered therefore to 
be reactive with some bacterial antigen other than LPS -core. Three 
of these MAbs (WN1 16.1, H7 2.1.5, and H4 250.7) were selected for 
further study. The MAbs preparations used were all from batch 2. 
Experiments with HA -1A (Centoxin) are also considered in this 
chapter. 
219 
MATERIALS AND METHODS 
ELISA 
ELISA with heat -killed bacteria was carried out as described in 
chapter 6. ELISA with whole bacteria was carried out in the same 
way, except that the heating of bacteria was omitted. 
Outer membrane protein (OMP) preparations 
Bacteria were grown up overnight in 100 ml nutrient broth in a 
shaking incubator. Broth was then centrifuged at 10,000 g for 10 
min. The pellet was suspended in distilled water, re- centrifuged 
resuspended in 5 ml of distilled water, and 0.55 ml of 7% w/v 
Sarkosyl (Sigma) added. The suspension was then sonicated (Microson 
ultrasonic cell disrupter, Heat Systems -Ultrasonics Inc., NY, USA) 
for six 1 min bursts at an amplitude of 10 pm on iced water with 
intervals of 30 s. The suspension was then centrifuged at 10,000 g 
for 10 min to remove unbroken cells. The remaining supernatant was 
centrifuged at 80,000 g for 1 h at 4 °C to harvest insoluble outer 
membranes. The pellet was resuspended (by aspiration into a syringe 
through a 26 -gauge needle) in 4 ml of distilled water, centrifuged 
again at 80,000 g for 1 h at 4 °C. The pellet was then resuspended in 
2 ml of distilled water. The protein concentration was measured by 
the method of Lowry [132]. The preparation was stored at -20 °C. 
Samples containing 25 pg of protein were mixed with an equal volume 
of double- strength sample buffer and heated to 100 °C for 2 min before 
electrophoresis. 
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preparation of LPS by the Triton method [239] 
Freeze -dried bacteria (100 mg) were suspended in 2.2 ml distilled 
water. The following were successively added and mixed: 0.4 ml 
100mM Tris HC1 pH 8.0, 0.4 ml 0.5 M Mg C12, and 1.0 ml 8% Triton X- 
100. Finally lml ethanol was added, the mixture tightly capped and 
placed at 100 °C for 10 min. After cooling the mixture was 
centrifuged at 100,000 g for 90 min at room temperature and the 
precipitate washed once in 4 ml 10 mM Tris HC1 pH 8.0 containing 10 
mM MgC12. The precipitate was suspended in 1 ml distilled water, lml 
0.2 M EDTA pH 8.0, 1 ml 2M NaCl, and 1 ml 8% Triton X -100. The 
suspension was mixed and incubated with shaking at 37 °C for 60 min 
and then centrifuged at 15,000 g for 15 min at room temperature. The 
supernatant from this step (3.6 - 4.0 ml) was mixed with 0.4 ml 1M 
MgC12, and incubated at 37 °C for 60 min. The resultant opaque 
solution was then centrifuged at 100,000 90 min at 15 °C, and 
the resulting precipitate washed once in 4.0 ml 10 mM Tris HC1 pH 8.0 




Figures 7.1 - 7.3 show the results of the ELISA screen of the 
collection of 69 non -E. coli strains from blood cultures with the 
three selected MAbs. H4 250.7 and H7 2.15 produced very similar 
patterns of reactivity, and were placed together by the correlation - 
sorting analysis of the results. WN1 16.1 produced a different 
pattern. Neither MAb H4 250.7 nor H7 2.15 bound to the Proteus 
strains, for example, whereas WN1 16.1 did bind to most of these 
strains. There were some similarities in the patterns of reactivity 
of the three MAbs however. For example, all bound to all of the E. 
coli strains, and none bound to any of the Acinetobacter strains. 
From the strains in the original screen, a panel of bacteria was 
selected to include organisms from a variety of genera which bound 
strongly to each MAb. I decided to compare the binding of these 
MAbs to heat- killed and "whole" (not heat -killed) bacteria in ELISA. 
The results of the initial experiment are shown in figure 7.4. The 
reactivity with heat -killed bacteria confirmed the pattern observed 
previously. MAbs H4 250.7 and H7 2.15 gave almost identical patterns 
of reactivity. As before, neither reacted with the Proteus strains. 
MAb WN1 16.1 reacted with all of the selected strains. MAb SZ 27 
150.3 reacted only with the E. coli strain. None of the MAbs reacted 
with either of two Acinetobacter sp. (10b335 and 10b348) or with two 
Pseudomonas spp. (10b411 and 10b224) (not shown). The reactivity 
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Figure 7.1 Binding (ELISA OD) of MAb H4 250.7 (culture 
supernatant diluted 1 in 250) to heat -killed cells of 68 
blood culture isolates of bacteria other than E. coli and 




































.3 .6 .9 1.2 1.5 
Figure 7.2 Binding (ELISA OD) of MAb H7 2.15 (culture 
supernatant diluted 1 in 250) to heat -killed cells of 68 
blood culture isolates of bacteria other than E. coli and 
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Figure 7.3 Binding (ELISA OD) of MAb WN1 16.1 (culture 
supernatant diluted 1 in 250) to heat -killed cells of 69 
blood culture isolates of bacteria other than E. coli and 


















































































































































































































































































































































































































































































































250.7 and H7 2.15, and a reduction in the binding of WN1 16.1 to some 
of the strains. There appear therefore to be differences in the 
accessibility of the epitopes recognised by these MAbs, and these 
seem to be related to strain differences as well as to differences 
caused by heating the cells. 
In order to confirm that the MAbs did not bind LPS -core I next 
reacted a series of dilutions of each MAb with polymyxin -LPS -core 
cocktail plates (figure 7.5). This confirmed that neither H4 250.7 
nor H7 2.15 bound to this preparation. MAb WN1 16.1 did however 
bind to the polymyxin -LPS -core plates, producing higher OD values 
than the core -specific MAb SZ 27 150.3 which was used as a positive 
control. 
Immunoblots of the MAbs against proteinase K preparations of the 
selected strains was then performed. H4 250.7 and H7 2.15 
no bands. WN1 16.1 did produce a set of bands in the immunoblot with 
the proteinase K preparation of each of the selected isolates with 
which it reacted in ELISA (figure 7.6). The sets of bands from the 
different isolates all had the same mobility, and did not coincide 
with the LPS bands seen on the equivalent silver -stained gel. These 
bands were similar to those seen when human IgG preparations were 
blotted against a range of blood -culture isolates, and were thought 
likely to represent enterobacterial common antigen (ECA). 
This would 
be consistent with the pattern observed of reactivity with many 
Enterobacteriaceae but not with Acinetobacter or Pseudomonas. 
Attempts were subsequently made to prepare pure ECA [146] 
to test 
this hypothesis, but without success. 
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OD 
f SZ 27 150.3 
-A- WN1 16.1 
HO- H4 250.7 
-4-H7 2.15 
80 320 1280 
Reciprocal dilution 
5120 
Figure 7.5 Binding (ELISA OD) of 4 
MAbe to 
polymyxin -LPS -core cocktail. 
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41110190, 
a b c d e f g 
Figure 7.6 Silver stain (top) and immunoblot with MAb WN1 16.1 
(bottom) of polyacrylamide gel of proteinase K digest of 
Enterobacteriaceae. Lanes a = E. coli 018 (10b281); b = Proteus sp. 
(10b54); c = Serratia sp. (10b85); d = Enterobacter sp. (10b271); e = 
Proteus sp. (10b282); f Klebsiella sp. (10b322); g = Citrobacter sp. 
(10b347). 
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Immunoblots were then performed with outer membrane protein (OMP) 
preparations from four of the selected strains. The initial blot 
was performed using 10% polyacrylamide in the separating gel. MAb 
WN1 16.1 gave a negative result in this experiment. 
H4 250.7 and H7 2.15 reacted with a narrow band at the gel front in 
the tracks containing OMP from the E. coli, Citrobacter and 
Serratia strains, but produced no band in the track containing OMP 
from the Proteus strain. This was consistent with the pattern of 
reactivity observed with heat -killed bacteria in ELISA. The bands 
seen in the immunoblot corresponded to bands seen on the Coomassie- 
blue stained preparation. This suggested that the MAbs were 
reacting with an OMP of low molecular weight, possibly the 
lipoprotein described by Braun [35]. The result obtained with H4 
250.7 is shown in figure 7.7. It is of note that the Coomassie -blue 
stained gel shows an equivalent low molecular weight OMP in the 
Proteus preparation, although this is not seen in the immunoblot. 
In an attempt to resolve the low molecular weight protein more 
precisely the immunoblots were repeated using 14% acrylamide in the 
separating gel, as shown in figure 7.8. Under these conditions the 
narrow band seen in the Coomassie -blue stained gel was replaced by 
a 
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Figure 7.7 Immunoblot of H4 250.7 against outer -membrane protein 
preparations separated on a 10% polyacrylamide gel. Left: Coomassie 
blue stained polyacrylamide gel. Right: Immunoblot. Lanes 1 & 5 = 
E. coli 018 (8b281); 2 = Serratia sp. (10b85); 3 = Proteus sp. 
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Figure 7.8 Immunoblot of H4 250.7 against outer -membrane protein 
preparations separated on a 14% polyacrylamide gel. Left: Coomassie 
blue stained polyacrylamide gel. Right: Immunoblot. Lanes 1 = E. 
coli 018 (8b281); 2 = Serratia sp. (10b85); 3 = proteus sp. (10b282); 
4 = Citrobacter sp. (10b347). 
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HA-1A ICentoxìn) 
A small supply of HA -1A was obtained by salvaging material from 
"empty" bottles from the pharmacy at the Royal Infirmary of Edinburgh 
after this MAb became commercially available. These bottles 
typically contained 100 pl of a 5 mg /ml solution of HA -1A. Bottles 
were stored at 4 °C. The first sample obtained was used for an ELISA 
experiment using heat -killed E. coli R3 as antigen. As seen in 
figure 7.9 the MAb bound to the E. coli but not to control wells 
which had been coated with albumin. Similar results for binding to 
polymyxin -LPS -core were obtained with this same sample of HA -1A by Dr 
GR Barclay (not shown). 
From the data in figure 7.9, 20pg /ml was selected as a reasonable 
concentration of HA -1A to use to assess its ability to bind to other 
bacterial preparations in ELISA, and this concentration to 
assess the binding of HA -1A to a range of other organisms in ELISA. 
Initially a range of Gram -negative organisms was used. Figure 7.10 
shows the results expressed net of the blank reading obtained from 
wells with no HA -1A. In this assay there was a measurable amount of 
non -specific binding of the MAb to wells which contained no antigen 
but which had been post -coated compared to wells which had no HA -1A. 
HA -1A showed some degree of binding to all of the Gram -negatives 
tested. The binding was greatest with heat -killed cells rather 
than 
whole cells, and in some cases the binding to whole cells 
was little 
higher than that obtained with no added bacterium. 
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Figure 7.9 Binding (ELISA OD) of Centoxin to 
heat -killed E coli R3 post- coated with albumin 
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Figure 7.10 Binding (ELISA OD) of HA-1A (20 yg /ml) 
to 
whole and heat -killed Gram- negative bacteria 
post- coated with albumin and to albumin alone. 




Subsequent experiments were planned to examine the binding of HA -1A 
to Gram -positive bacteria and to other organisms in ELISA. These 
experiments were hampered by the problem of "non- specific" binding of 
HA -1A to control wells, which seemed to become worse as experiments 
were repeated. New batches of buffers were made with pyrogen free 
water and compared with the previous batches, and the problem shown 
to be relate at least in part to the older coating buffer and to the 
albumin post -coat. The albumin sock solution, which was stabilised 
with sodium azide was found to contain Aerococcus viridans, an 
organism which is not susceptible to azide. Organisms were grown up 
in tissue culture media (RPMI 1640, Gibco) to avoid the possibility 
that binding observed was due to LPS contamination of the culture 
media. Post -coating overnight with solutions containing albumin from 
this stock was found to increase the background binding to wells with 
no added bacteria, but post- coating for 2 hours was found to reduce 
background binding. These experiments did show some binding of HA- 
1A to some Gram -positive bacteria in ELISA. Figure 7.11 presents the 
results of one such experiment using heat -killed Gram -positive 
bacteria and E. coli 0:18. Figure 7.i1a shows the reduction in 
background by post- coating. It also shows binding of HA -1A to a 
strain of Bacillus cereus which was greater than that obtained with 
the E. coli 0:18 control, and some binding to the two strains 
of 
coagulase- negative staphylococcus. No binding of conjugate 
was 
obtained in the absence of HA -1A, confirming that the binding 
observed is not due to direct binding of the conjugate 
to the 
organisms. Whole Staphylococcus aureus cells did bind 
the conjugate 
under these conditions (not shown). Figure 7.11b 
shows results 
obtained in a parallel experiment using pooled 
human IgG. This 
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Enterococcus faecium 
Coagulase- negative Staphylococcus 
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Enterococcus faecium 
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0 .3 .6 .9 1.2 
b) Pooled human IqG 
Figure 7.11 Binding (ELISA OD) of a) HA-1A (20 
mg /ml), and b) pooled human IgG (100 }ig /ml), to 
heat -killed E. coli 018 and heat -killed Gram -positive 
bacteria. 
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experiment was intended as a positive control, since it was expected 
that pooled human IgG would contain antibody to all of the organisms 
tested. The low OD results obtained with the two Enterococcus spp. 
may indicate that these organisms have not adhered to the ELISA 
wells, and therefore that the low readings obtained with HA -1A cannot 
be regarded as clear evidence of failure to bind. The relatively 
low binding of human IgG to the Bacillus cereus suggests that the 
high binding obtained with HA -1A was significant. 
Further ELISA experiments were carried out with other organisms, but 
interpretation was hampered by high background readings in many 
cases. The high level of binding to Bacillus cereus was however 
observed consistently. In addition, consistently low readings 
(similar to background) were obtained with a strain of Candida 
albicans. Figure 7.12 shows an experiment with a range of 
concentrations of HA -1A and pooled human IgG which supports these 
conclusions. 
Immunoblotting of HA -1A against LPS preparations was also attempted, 
with largely negative results. An initial experiment used a single 
wide blot of a proteinase K preparation of E. coli 0:18 LPS cut into 
strips. HA -1A at concentrations of 250pg /ml, 50pg /ml, and 17pg 
/ml of 
HA -1A were used, and produced a diffuse darkening of the blot 
which 
was not related to the LPS bands, but which did decrease 
in intensity 
with decreasing HA -1A concentration. This indicated 
non -specific 
binding of the HA -1A to the blot, and also indicated 
that the 
peroxidase anti -human-IgM conjugate was functioning. 
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zn7 E coli R3 
-D- Candida albicans 
-0- Bacillus cereus 
-O- No Antigen 
b) Pooled human IIG 
Figure 7.12 Binding (ELISA OD) of a) HA -1A, and b) pooled 
human IgG, to heat -killed microorganisms. 
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A further immunoblot was carried out using LPS from E. soli 0:18 and 
from a Citrobacter sp. prepared by three different methods (figure 
7.13). This experiment confirmed the essentially negative result 
obtained with the proteinase K preparation of LPS, and gave a 
similarly negative result with the conventional phenol -water 
extracted LPS. However, LPS extracted by the Triton method (prepared 
by two honours students as part of a practical exercise) gave rise to 
two bands which were not apparently related to any of the bands seen 
on the silver -stained gel. These two bands were seen with both the E. 
coli and the Citrobacter. The lower line in the E. coli track is not 
visible in figure 7.13, but was seen in a repeat experiment (not 
shown). 
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Figure 7.13 Immunoblot of HA -1A (25 pg /ml) against LPS, prepared by 
three different methods, from E. coil 8b281 (lanes 1,2,3) and 
Citrobacter sp. 12b274 (lanes 4,5,6). Left: Silver -stained 
polyacrylamide gel; Right: Immunoblot. Lanes 1 & 4 = proteinase K 
digest, 2 & 5 = phenol -water extract, 3 & 6 = Triton extract. 
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DISCUSSION 
Three distinct types of MAb are described in this chapter. 
MAb H4 250.7 and H7 2.15 
MAb H4 250.7 and H7 2.15 bind to an outer membrane protein of E. coli 
and some other Enterobacteriaceae, with the notable exception of 
Proteus spp. This protein is probably the lipoprotein described in 
E. coli by Braun [35] which has a molecular weight of 7300. 
Lipoproteins from E. coli, Proteus mirabilis, Morganella morganii, 
Erwinia amylovora and Serratia marcescens have been sequenced [263]. 
Of the 58 amino acids in E. coli free lipoprotein, 29 are the same in 
all these organisms, and the rest show some variation. The greatest 
differences are between E. coli and Proteus mirabilis, which have 
only 33 amino acids in common. E. coli and Serratia marcescens, in 
contrast, have 54 of the 58 amino acids in common. 
Earlier serological studies (reviewed by Braun [35]) have shown that 
antibodies to E. coli lipoprotein do not react with Proteus but do 
react with some other Enterobacteriaceae. Interpretation of these 
serological studies is however complicated by the different methods 
used to prepare lipoprotein. " Lysozyme- lipoprotein" was prepared 
by 
lysozyme, which left two repeating units of peptidoglycan attached 
to 
the C- terminal of lipoprotein. Alternatively "sugar -free 
lipoprotein" was prepared with trypsin, but this lacked 
the C- 
terminal lysine residue. Antisera to these preparations 
of 
lipoprotein from E. coli did not cross -react with 
one another, 
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indicating that the C- terminal end was the dominant epitope of 
lipoprotein. These antisera also showed differing degrees of cross - 
reactivity with equivalent lipoprotein preparations from other 
Enterobacteriaceae. 
The lipoprotein present in the OMP preparations described in this 
thesis is expected to be the "free" form which can be extracted 
without enzyme treatment. An antiserum to free lipoprotein from E. 
coli was shown by Halegoua et al [91] to react with lipoprotein from 
Salmonella and Serratia but not Proteus in precipitation experiments. 
However, Henricksen et al [92] found that antiserum to E. coli free 
lipoprotein did react with Proteus lipoprotein in inumuvoblots. It is 
likely that the cross- reactive antiserum described by Henricksen et 
al [92] included antibodies to epitopes shared by E. coli and 
Proteus. It is clear from the sequence data that such regions do 
exist. 
The finding of two MAbs which react with lipoproteins from several 
enterobacterial genera other than Proteus is therefore consistent 
with the available data on lipoproteins. 
The two MAbs show such similar patterns of reactivity with the range 
of bacteria tested that they are likely to share the same epitope. 
In view of the difference in specificity between MAb H4 250.7 
from 
batch 1 (E. coli R3 specific) and MAb H4 250.7 from batch 
2 described 
here it is clear that some mistake in labelling has 
occurred. It is 
Possible that one clone has been given two different 
labels and 
therefore that the two MAbs may be identical. 
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These MAbs might be of value in studies of the structure of Gram - 
negative bacterial cell envelopes. The epitope recognised appears to 
be relatively inaccessible in standard broth -grown smooth organisms. 
It may be more accessible in rough strains [35] or in bacteria grown 
under non- standard conditions. 
MAb WIId1 16.1 
This MAb is thought to react with ECA, for the following reasons: a) 
it reacts with Enterobacteriaceae, but not with other Gram- negative 
bacteria; b) it reacts in immuzoblots with proteinase K- resistant 
material which is not detectable on silver stained gels; c) the bands 
seen in the immunoblot are identical between different 
enterobacterial species; and d) the bands are similar to those found 
others in imnunoblots of ECA [121,183]. Confirmation of the 
specificity of this MAb would require purified ECA with which to test 
its reactivity. 
The binding of this MAb to polymyxin -LPS -core cocktail ELISA was 
unexpected as it had been found not to bind to a range of smooth LPS 
in ELISA (data not shown). A likely explanation for this result 
is 
the presence of ECA as an unexpected component of the LPS -core 
cocktail. This is most likely to be in the form of ECALPS 
[121], 
which consists of ECA covalently bound to LPS -core. 
ECALPS is found 
in the LPS -core fraction when the aqueous phenol, 
chloroform, 
Petroleum ether method used to prepare rough LPS. 
ECALPS is found in 
some enterobacterial rough mutants, in particular 
E. coli K12 ([120], 
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cited by [1211) which is a component of the polymyxin -LPS -core 
cocktail. This observation is important for the interpretation of 
antibody measurements made with polymyxin -LPS -core cocktail ELISA 
plates, since antibodies to ECA may be detected. 
Other anti -ECA MAbs have been described, and a possible application 
of such MAbs is the detection of Enterobacteriaceae in drinking water 
[98,129,183]. It might also be possible to use these MAbs in the 
study of Gram -negative bacterial cell envelopes under different 
conditions, as described above. WN1 16.1 could also be used to 
detect ECA contamination of rough LPS preparations. 
HA-1A 
A surprising limited amount of information is available on the in- 
vitro activity of HA -1A. In the original of this MAb 
[230] culture supernatants with an antibody content of 8 -20 pg /ml 
reacted with a variety of Gram -negative bacteria in ELISA at a 
dilution of between 1 in 16 and 1 in 128 for most organisms tested. 
The minimum MAb concentration showing activity in ELISA must 
therefore be 0.06 -1.25 pg /ml. Binding to lipid A in ELISA was 
reported in the product monograph [3] to be just above background 
at 
a similar range of concentrations. The OD rose steeply with 
rising 
MAb concentration up to 20pg /ml. Similar findings are reported 
in 
less detail in two abstracts [20,22]. Lipid A was 
said to inhibit 
competitively this binding in the original report [230]. 
Binding was 
also reported to LPS in immunoblots, and to chitin 
which is a polymer 
of N- acetylglucosamine. No negative control studies, 
such as failure 
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of HA -1A to bind to Gram -positive bacteria or other biological 
materials, were reported. An affinity constant for Re LPS of 1071 
was claimed [265]. 
Baumgartner et al [16] have challenged the specificity of the MAb for 
lipid A, reporting that HA -1A binds to a wide range of Gram -positive 
bacteria, to fungi, and to lipids unrelated to lipid A. This group 
reported an affinity constant for lipid A of 104 M-1, and suggested 
that the binding observed represented non -specific interactions with 
hydrophobic substances. 
The results reported in this chapter support the idea that HA -1A is 
not specific for lipid A, but rather that it interacts with a variety 
of substances. The concentrations used in ELISA experiments was 
similar to those discussed above, suggesting that the binding 
observed was not simply a result of using excessive amounts of MAb. 
These experiments are unsatisfactory however, because of the 
considerable and variable background binding that was observed. This 
could be taken as evidence of non -specific binding. The background 
binding might however be due to the presence of contaminating LPS 
somewhere in the system. Efforts were made to avoid LPS 
contamination by using endotoxin -free water, and by growing organisms 
up in tissue -culture media, but the possibility cannot be absolutely 
excluded. Alternatively, the quality of the HA -1A preparations 
used 
might be questioned because of the way they were obtained. 
However, 




The reaction of HA -1A with two bands of uncertain nature in LPS 
prepared by the relatively new Triton method serves to confirm that 
the immunoblotting reagents were working. The nature of these bands 
is obscure, but it appears that they are something which bind HA -1A 
more strongly than does LPS. 
The lack of a clear definition of the in vitro activity of HA -1A was 
one of the criticisms made of this MAb following the clinical trial 
[249]. If the MAb is really not lipid A specific then there is no 
rational basis for its use. It is clearly of enormous importance to 
potential users of HA -1A to establish this basic point. It may not 





Seeing is believing, but, if you're not careful, 
believing is seeing 
JI-i Collins 
The concept of cross -reactive antibodies to LPS as a mechanism of 
natural immunity began with a paper by Chedid et al in 1968 [40]. 
The protective element described was however heat- labile and seemed 
to require an "enzymatic process capable of ... unmasking R antigenic 
structures [of bacteria]" for its activity, which was bactericidal. 
The concept has moved on considerably since then but still suffers 
from the lack of a clear theoretical basis defining the epitope to 
which such antibodies should be directed, and the mechanism by which 
they might work. 
Antibodies to complete LPS -core, or to Rc core which may share the 
cross -reactive epitopes [10] may occur naturally, and may well have a 
protective role [188]. Measuring such antibodies is a problem, 
however, and no standard method has emerged. The difficulties 
include the detection of highly specific antibodies, for example to 
E. coli J5 LPS [14,17], though this type of antibody may only be 
found after immunisation. 
The main method used to detect naturally- occurring cross -reactive 
antibodies in this thesis has been polymyxin -LPS -core 
cocktail ELISA. 
This method is certainly open to the criticism that 
it may be 
detecting a number of specific antibodies to LPS -core 
(antibodies 
equivalent to the J5- specific antibodies) rather 
than truly cross - 
reactive antibodies. This may not be important 
when the assay is 
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used for its original purpose of selecting donor sera for the 
manufacture of an "anti -LPS" immune globulin, since infusion of a 
range of specific antibodies may have a useful therapeutic effect. It 
would be important however when using the assay to show the existence 
of truly cross -reactive antibodies. The method has two other 
problems: the presence of polymyxin and the possible presence of 
antigens than LPS -core, notably ECA. Polymyxin has been shown to 
compete with some cross -reactive MAbs in binding to the lipid A -inner 
core region [7,163,189], and therefore the assay will probably fail 
to detect equivalent naturally- occurring antibodies. ECA seems 
likely to be present in the LPS -core cocktail as a component of the 
E. coil K12 component ([120], cited by [121]), and was apparently 
detected by the ECA- specific MAb WN1 16.1. Antibodies to ECA do 
occur naturally, but are not apparently protective in Gram -negative 
bacteraemia [150]. 
Despite these limitations, the polymyxin -LPS -core assay was suitable 
for the purposes for which it was used in this thesis. In the 
studies of typhoid vaccinees the original question raised was whether 
typhoid vaccination might have induced the production of antibodies 
which had been detected by the polymyxin -LPS -core ELISA. If more 
positive results had been obtained it would have been important to 
investigate the antibodies by other methods, but the generally 
negative results obtained were sufficient to answer the question 
posed. 
The studies on antibodies in urine serve as an example 
of the danger 
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of seeing what you believe to be present. McKenzie and Young [156] 
looked for antibodies to bacteria causing urinary infection, and 
found them. I looked for antibodies to LPS -core (as defined by the 
polymyxin -LPS -core cocktail ELISA) and found them. The likelihood is 
however that the antigen used was irrelevant to these studies, and 
that any antigen to which humans are commonly exposed would do. 
Similar considerations may relate to other studies of naturally 
occurring antibodies. Thus the finding that antibodies to E. coli J5 
[188] or Salmonella Re [152] LPS are associated with improved outcome 
from bacteraemia may be explained simply by cross -protective activity 
of the antibody measured, but it is possible that the measured 
antibody was associated with some other defensive mechanism, such as 
the presence of a variety of specific protective antibodies. 
There has been growing interest in monoclonal antibodies to LPS in 
years. In the first 50 weeks the Science Citation 
Index listed 127 papers with "monoclonal" and "lipopolysaccharide(s)" 
in the title or as key words. With the growth of interest in 
monoclonal antibodies to LPS has come increasing sophistication in 
their assessment. The original description of HA -1A [230], 
for 
example, would surely not be acceptable to a peer- reviewed 
journal 
now, only eight years later. HA -1A is, in my opinion, 
another 
example of the danger of seeing what was believed 
to be present. 
The MAbs described in this thesis have not been 
subjected to the most 
detailed of the analyses now available. The 
epitopes which they 
recognise could be characterised by competition 
studies with 
synthetic partial structures. It would be 
impractical to do this for 
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all the MAbs mentioned in this thesis, but it would be of interest to 
study some particularly those core- type -specific MAbs, and the "all - 
E. coli" MAbs. Such studies would be a major undertaking, and would 
ideally include comparisons with core - type -specific MAbs from other 
sources [133,170,235,245] and determination of affinity constants for 
the defined epitopes. The ability of the MAbs to bind to whole 
bacteria, as distinct from isolated LPS, has not been systematically 
studied, but it is apparent from other work that this question 
depends crucially on the way in which bacteria are grown [153], and 
cannot therefore lead to practical conclusions until the phenotype of 
bacteria causing infection is better understood. The effect of the 
MAbs studied here on the biological activities of LPS have not been 
discussed. Such studies are being undertaken by others, and show 
promise [58], but it is not possible to draw simple conclusions about 
their possible benefit in human infections. 
Useful conclusions can be drawn from the studies in this thesis 
however. Many of the MAbs produced have been found to react withE. 
coli and Salmonella LPS, but not with LPS from other Gram -negatives. 
The nature of the MAbs obtained was presumably determined by the 
predominance of E. coli and Salmonella LPSs in immunisation and 
selection procedures. 
MAbs have been described which react with complete LPS molecules from 
nearly all E. coli and Salmonella strains tested. This 
sort of 
relatively specific antibody seems likely to be of benefit 
in illness 
caused by E. coli or Salmonella LPS, assuming that 
the binding of 
antibody results in either reduced toxicity or enhanced 
clearance of 
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LPS. In contrast, MAbs capable of binding only to free lipid A [122] 
or incomplete core structures [130] seem unlikely to of benefit [28]. 
Although lipid A and incomplete core structures are more conserved 
among Gram -negative bacterial species they are probably not found in 
infections, except as part of complete LPS -core or 0- substituted LPS 
molecules. To guide the use of relatively specific MAbs (such as the 
"all -E. coli" MAbs) it would be necessary to have a more precise 
knowledge of the types of LPS involved in human disease. It might 
be, for example, that an "all -E. coli" MAb together with an 
equivalent anti- Pseudomonas aeruginosa MAb [167] and an anti- 
Kiebsiella and Enterobacter MAb would prove to be a powerful 
combination. Alternatively, it may be that an antibody to 
Bacteroides LPS is required, or it may be that an "all -E. coli" MAb 
will react with enough clinically significant LPS to be useful by 
itself. It appears to me unrealistic to expect to find a single 
antibody which will bind to complete LPS molecules from all these 
species. 
The core - type -specific MAbs seem unlikely to be of therapeutic use 
simply because of their failure to react with a sufficiently wide 
group of organisms. Some do however show protective activity in 
some 
animal models (unpublished data) and might be useful in improving 
our 
understanding of these animal models. They could for example 
be used 
to study the relationship between suppression of TNF 
production and 
protection in whole animal systems. 
The anti -ECA and anti -lipoprotein MAbs seem unlikely 
to be of 
therapeutic value either, because they do not 
recognise the 
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appropriate toxic molecule. There is also evidence that antibodies 
to ECA are not protective in humans [150] or in animal models [149]. 
Negative results in such experiments by one investigator do not 
however absolutely rule out the possibility of beneficial effects 
[264]. Anti -ECA or anti -lipoprotein antibodies might play some part 
in the protective effects of immunisation with rough bacteria [37] or 
transfer of sera from immunised donors [106,267], and might go some 
way to explain the failure to find the expected anti -LPS antibodies 
in sera from these studies [14], and the observation that these sera 
are more protective against live infection than against endotoxin 
challenge [264]. Immunisation with rough bacteria does lead to the 
production of antibody to lipoprotein ([144] cited by [35]) and ECA 
[121], while immunisation with smooth bacteria does not. It would 
therefore be interesting to investigate the bactericidal activity of 
these MAbs. 
Cross -reactive antibodies to LPS still have considerable potential 
for therapeutic use, although the initial wave of enthusiasm may 
have 
passed. The continuing challenge is to decide which antibodies 
and 
which investigations deserve an investment of time and money, 
and to 
achieve the scientific imperative of openness and objectivity 
despite 
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Abstract 
Aims: To determine whether antibody 
to lipopolysaccharide -core(LPS -core) 
antigen is an important component of the 
antibody, detected by mixed heat -killed 
coliform antigen, in urine from patients 
with suspected urinary tract infection. 
Methods: LPS -core antigen and mixed 
heat -killed coliform antigen were used in 
an enzyme linked immunosorbent assay 
(ELISA) to measure IgG antibody in mid- 
stream urine samples. Seventy two 
samples from students attending their 
general practitioner with symptoms sug- 
gestive of urinary tract infection, six 
samples from which a Gram positive 
organism was isolated, and 16 asymp- 
tomatic controls were tested. Plates 
coated with LPS -core antigen were also 
used to absorb out the antibody detected 
by the mixed heat -killed coliform 
antigen. 
Results: Antibody to either antigen was 
associated with a positive culture, but 
neither was a useful predictor of a 
positive culture. There was a significant 
correlation between the results of the two 
assays (r = 0.7633; p < 0.001), and absor- 
ption with LPS -core antigen did reduce 
the level of antibody to the mixed heat - 
killed coliform antigen. Antibody to both 
preparations was found in patients with 
Gram positive urinary tract infection. 
Conclusions: Antibody to LPS -core 
antigen forms a substantial part of the 
antibody detected by mixed heat -killed 
coliform ELISA. The antibodies detected 
by these assays are probably the result 
of non -specific leakage of antibody into 
the urine, rather than a specific immune 
response. 
Studies of antibacterial antibody in urine dur- 
ing urinary tract infection have mainly focused 
on specific responses to organisms isolated 
from individual patients,'-` and have been 
mainly directed towards distinguishing bet- 
ween pyelonephritis and cystitis." An alter- 
native approach has been to look for urinary 
antibody to a wide range of likely pathogens, 
and to use this as a tool for the primary 
diagnosis of urinary tract infection.' 6 A test 
based on this concept (Uristat, Shield Diagnos- 
tics, Dundee) has been marketed in the United 
Kingdom. This approach to the diagnosis of 
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urinary tract infection has the theoretical 
advantage that urinary antibody would not be 
prone to the problems of contamination and 
overgrowth associated with quantitative bac- 
terial culture, and would be more stable than 
pus cells. It has the disadvantage, however, that 
there is a dearth of basic information about the 
clinical importance of this kind of antibody in 
urinary tract infection. 
The aim of this study was to investigate the 
nature and clinical relevance of the antibody 
detected by the mixed heat -killed coliform 
ELISA (MHCE) described by Mackenzie and 
Young.' It was decided to concentrate on IgG 
because this was the main antibody class that 
had been detected in that assay. Secretory IgA 
was considered but rejected on the grounds 
that it has not been found consistently in urine 
in urinary tract infection.' The core region of 
LPS (LPS -core) was thought likely to be an 
important antigen in the assay for two reasons. 
First, LPS -core is a heat stable antigen which is 
present in all Gram negative bacteria. It would 
thus be present in the MHCE antigen prepara- 
tion used. Second, LPS -core antibody is found 
frequently in serum from the normal human 
populations,' confirming that this antibody is 
part of the human immunological repertoire. A 
urinary antibody response to urinary tract 
infection might therefore be expected to 
include antibody to LPS -core antigen, and this 
antibody would be detected by the MHCE 
assay. 
Methods 
Seventy two urine specimens were collected 
from students with suspected urinary tract 
infection attending general practitioners at the 
University of Edinburgh Students' Health 
Centre. None of these patients was thought to 
have pyelonephritis. One patient who was 
known to be taking antibiotics was excluded. 
Most were subsequently treated with 
antibiotics, and none returned because of pers- 
isting symptoms. These specimens were collec- 
ted under the supervision of an experienced 
nurse and were then brought directly to the 
diagnostic laboratory by the patient. Urine 
specimens from patients with Gram positive 
urinary infection were selected after culture 
from among all specimens sent to the diagnos- 
tic laboratory by general practitioners. Control 
samples were obtained from 16 asymptomatic 
students. 
Microscopy was performed using an inver- 
ted microscope. Ten pus cells per field 
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(equivalent to 20 per mm3) was scored positive. 
Cultures (standard loop) containing > 105 
colony forming units (cfu) ml of a single 
bacterial species were considered positive, and 
specimens containing 10" -105 cfu /ml were 
reported as doubtful. 
Urine samples were centrifuged at 4000 x g 
for 10 minutes and the supernatant stored in 1 
ml volumes at - 20° C before analysis for 
antibody. 
ELISA PLATES 
For MHCE assay, plates were coated with a 
mixture of six coliform organisms (four E coli, 
one Klebsiella, one Proteus) isolated from urine 
specimens. The coating suspension was 
prepared as follows: each organism was grown 
overnight in nutrient broth at 37° C, washed, 
and resuspended in phosphate buffered saline 
(PBS). The concentration was adjusted so that 
a 1 in 10 dilution had an extinction level of 0.25 
at 540 nm. The suspension was then heated to 
100 °C for 30 minutes. The six preparations 
were mixed together in equal parts and the 
mixture diluted 1 in 10 with 0.05M carbonate- 
bicarbonate coating buffer (pH 9.6). Nunclon 
polysorb strips were coated with 100 Ed of 
antigen preparation in each well and incubated 
at room temperature overnight. Each well was 
then washed four times with wash buffer (PBS 
with 0-05% sodium azide and 0.1% Tween- 
20). Plates coated with LPS -core were donated 
by Dr GR Barclay, Blood Transfusion Service, 
Edinburgh.' These were prepared using LPS 
purified by phenol /chloroform /petroleum 
extraction from four rough mutant bacteria, 
Salmonella typhimurium Rc878, Escherichia 
coli K12, Klebsiella aerogenes M10B, and 
Pseudomonas aeruginosa PAC605. Each was 
made up to a concentration of 0.2 mM in water 
and complexed with 0.4 mM polymixin B. 
Equal volumes of each antigen were mixed to 
give a final LP S-core concentration of 0.1 mM 
and 100 µl per well was dispensed into Nuclon 
maxisorb plates, incubated overnight at room 
temperature, and washed as above. PBS con- 
taining 5% bovine serum albumin (100 Etl) was 
then added to each well, incubated overnight at 
room temperature, and washed as above. Plates 
were stored at -20 °C. 
URINE ANTIBODY ASSAYS 
Urine samples (100 Eel) were added in duplicate 
to microplate wells, incubated at 37 °C for 
one hour, and washed four times. Alkaline 
phosphatase labelled anti -human IgG (ICN 
Immunologicals) was diluted 1 in 500 in 
ELISA diluent (PBS containing 0.05% 
Tween -20, 0.5% bovine serum albumin, 4% 
(w /v) polyethylene glycol 6000, and 0.05% 
sodium azide), and 100 Etl added to each well, 
incubated for one hour at 37 °C, and washed 
four times. P- nitrophenyl phosphate (100 pi of 
a 1 mg /ml solution: Sigma) in 0.05M sodium 
carbonate, 1mM magnesium chloride, pH 9.8, 
was added and the colour measured at 405 nm 
after 30 minutes at room temperature. Each 
assay included duplicate blank wells with no 
urine added, and duplicate reference wells 
containing standard human IgG (IgG from 
pooled blood donor sera, donated by Dr GR 
Barclay, diluted to 50 Etg /ml in ELISA diluent 
and stored at - 20°C). Wells without antigen 
but washed and post- coated as above were also 
used as negative controls. 
ABSORPTION ASSAY 
Samples (100 Etl) of antibody positive urine 
were added in duplicate to wells coated with 
LPS -core antigen and incubated at 37 °C for 
one hour. The samples were then transferred to 
Wells freshly coated with LPS -core antigen. 
Incubation and transfer were repated twice so 
that each sample had been incubated for a total 
of three hours in three separate wells. Antibody 
was then measured using MHCE coated plates. 
Antibody results were compared with those for 
unabsorbed urine and urine that had been 
absorbed in control wells (wells containing no 
LPS -core antigen but washed and post- coated 
with albumin in the same way as LPS -core 
coated wells). 
STATISTICAL ANALYSES 
Data were analysed using the Statistical Pack- 
age for Social Sciences (SPSS -PC) (Informa- 
tion Analysis Systems). 
Results 
For all but one of the asymptomatic controls, 
antibody results (OD405) were <0.1 with both 
MHCE and LPS -core antigens. One male 
asymptomatic control did have consistently 
high titres of urinary antibody to both antigens 
(OD,o5 >1.0). He did not have covert urinary 
tract infection, haematuria, proteinuria, hyper- 
tension, or any other evidence of renal or other 
disease. 
Of the 72 specimens from symptomatic 
patients, 19 were culture positive (> 105 cfu/ 
ml, all with coliforms), and the remaining 53 
were culture negative ( < 104 cfu /ml). Pus cells 
were seen in 17 of the 19 culture positive 
specimens, and in one of the 53 culture negative 
specimens. 
IgG antibody was detected by both LPS - 
core ELISA and MHCE in the urine samples 

















0 05 1'0 
Mixed heat -killed Coliform antigen 
15 
Figure 1 Correlation of IgG antibody (OD) with 
mixed, heat -killed col:form and LPS -core antigens in 72 
urine samples from symptomatic patients = culture 
positive; O = culture negative. 
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Figure 2 Reduction in 
IgG antibody (OD) to 
mixed heat -killed coliform 
antigen following 
absorption with LPS -core 
antigen or mock absorption 
on blank plates. 
Table 1 IgG antibody (OD) to individual and mixed LPS -core antigens in eight positive urine samples 
Sample No Mixed 
Antibody titres (OD,,,,) detected by LPS-core from 
Klebsiella aerogenes Pseudomonas aeruginosa E coli Salmonella typhimurium 
1 1.346 0.393 0.435 0.440 0.535 
2 1.310 1.087 1.135 1.077 1.012 
3 0.293 0.154 0.135 0.140 0.205 
4 0.992 0758 0.719 0.587 0.722 
5 0.969 0340 0.452 0.400 0.528 
6 0.888 0.507 0.480 0.513 0.473 
7 0.995 0.463 0.478 0.514 0.672 
8 1.302 0.358 0.256 0.300 0.676 
Antibody positive specimens from symp- 
tomatic patients had detectable titres of 
antibody against all of the individual bacteria 
which went to make up the MHCE antigen, as 
found by McKenzie and Young.' Similarly, the 
individual LPS -core antigens permitted the 
detection of antibody (table 1). 
For the symptomatic patients there was a 
significant correlation between antibody to 
LPS -core antigen and antibody to MHCE 
antigen (r = 0.7633, p < 0.001). Within this 
group there was also a significant association 
between antibody titre and positive culture for 
both LPS -core antigen (t = 3.65; p < 0.001) 
and MHCE antigen (t = 3.55; p < 0.001). 
The predictive value of the antibody tests for 
positive culture was, however, low. For LPS - 
core antigen, an OD value of > 0.6 OD predic- 
ted positive culture with a sensitivity of 15/19 
(79 %) and a specificity of 15/30 (50 %). For the 
MHCE antigen an OD of > 0.4 predicted 
positive culture with a sensitivity of 13/19 
(68 %) and a specificity of 13/21 (62 %). 
The correlation between the two assays sug- 
gested that they were measuring the same 
antibody. This was supported by the demon- 
stration that the antibody detected by the 
MHCE antigen was reduced following absorp- 
tion by LPS -core antigen in coated wells (fig 2). 
Because LPS -core antigen is present only in 
Gram negative bacteria it might be predicted 
that this antibody would not be found in 
urinary tract infection caused by Gram positive 
organisms. Antibody to both antigens, 
however, was found in all six urine samples 
from symptomatic patients from which > 10' 
Gram positive organisms were grown in pure 














The results presented here show that the 
presence of urinary IgG antibody detected in 
the MHCE assay is correlated with the 
presence of anti -LPS -core IgG. The assays 
could be measuring two quite separate 
antibodies which happen to occur together, or 
they could be measuring the same antibody. 
The demonstration that the coliform antibody 
can be reduced by absorption with LPS -core 
antigen suggests that antibody to LPS -core 
antigen makes up a sizeable proportion of the 
antibody detected by the MHCE antigen. This 
in part reflects the fact that other antigens in the 
MHCE assay will have been denatured by heat 
(in the case of proteins) or will be highly strain 
specific (in the case of 0 antigens). It may also 
indicate that antibody to LPS -core is an impor- 
tant part of the host immune response in 
urinary tract infection, as it is thought to be in 
septic shock.' 
The simplest explanation for the presence of 
IgG core and coliform antibody in urine during 
urinary tract infection would be that inflamma- 
tion and leakage of plasma proteins results in 
the presence in urine of unselected IgG 
antibodies from serum, as is thought to occur in 
pyelonephritis.4 This would explain why the 
antibody is present early in the course of 
infection, when patients are presenting to their 
GP with symptoms. A specific immune res- 
ponse to infecting organisms would not be 
expected to result in an antibody response at 
this stage. It would also explain why the 
antibody is not a specific response to the 
infecting organisms, as is seen in the Gram 
positive infections. Such antibody would 
probably also be found in gonococcal or 
chlamydial urethritis, conditions which should 
be differentiated from simple urinary tract 
infection and managed differently. 
Urinary IgG antibody to both antigen 
preparations was found in many of the symp- 
tomatic but culture negative patients as well as 
in those with positive cultures. Similar results 
were obtained by McKenzie and Young.' 
Antibacterial substances in urine could account 
for some false negative cultures, but we have 
found such substances in less than 1% of urine 
samples from the students' health centre in 
previous studies (unpublished). Undiagnosed 
urethritis, or urinary tract infection with < 104 
cfu /ml, might be present in some cases, but the 
absence of large numbers of pus cells in all but 
one of the culture negative specimens militates 
against this.' There is no satisfactory explana- 
tion for the presence of acute urinary symp- 
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Table 2 IgG antibody (OD) to mixed heat -killed coliform and LPS -core antigen in 





Antibody titre (OD,) detected by 
MHCE antigen LPS -core antigen 
Enterococcus 0.256 0.571 
Etterococcus 0.589 1.054 
3 Staphylococcus saprophyricus 0.265 0584 
4 Staphylococcus saprophyticus 0.100 0.227 
5 Staphylococcus saprophyticus 0.688 1235 
8 Group G Streptococcus 0.528 1.091 
toms in many patients, however,910 and it is 
therefore impossible to relate these findings to 
established underlying mechanisms. The 
presence of antibody does suggest that the 
symptoms have a physiological basis. 
The purpose of measuring urinary antibody 
to a mixture of common urinary pathogens' was 
that it would permit rapid detection of urinary 
tract infection and would be less sensitive to 
contamination or overgrowth than is conven- 
tional bacteriology. In our hands IgG coliform 
or core antibody did not predict positive cul- 
ture in fresh, carefully taken specimens to any 
useful extent. Such antibody tests are therefore 
not likely to be useful in examining contamin- 
ated specimens or specimens which have been 
delayed, or where the patients have been on 
antibiotics. Other workers have found that 
measuring lipopolysaccharide antibodies in 
urine is not a useful way of screening urine 
samples before culture.' 
It is clear that urinary antibodies can be 
measured in association with symptoms sug- 
gestive of urinary tract infection. It may be 
possible to define particular classes or 
specificities of urinary antibody which are of 
predictive value in the diagnosis of urinary 
tract infection. There is, however, much to be 
learned about the relation between urinary 
tract infection and urinary antibodies before 
such a test can be devised. 
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Mouse monoclonal antibodies (MAbs) specific for the lipopolysaccharide (LPS) core types R1, 
R2, and R3 of Escherichia coli and a cross -reactive MAb that binds to the LPS core of almost all 
E. coli were used in ELISA to determine the frequency of cores resembling R1, R2, and R3 in 
strains of E. coli isolated from clinical samples (blood and urine specimens) and from the feces of 
asymptomatic individuals. Of the 180 wild -type isolates, 123 were assigned to RI core type, 14 to 
R2, and 18 to R3. Twenty -five wild -type E. coli isolates could not be assigned to a particular core 
type and may have either an R4 or K12 core or a previously unrecognized core type. R1 core type 
was associated with O types 1, 4, 6, 8, and 18 and with Kl or K5 capsules. R3 was associated with 
015. 075 isolates could be of either R1 or R2 core type. 
The lipopolysaccharide (LPS) core region of Escherichia 
coli has a conserved overall structure, with an inner 2- keto -3- 
deoxy- octonate -heptose region and an outer hexose region. 
Most of the variation that does occur is in the outer part of 
the core, furthest from lipid A. In wild -type smooth E. coli, 
the core region can occur in at least four different forms, 
known as R1, R2, R3, and R4 [1 -3]. The naturally rough 
strain K12 has a different core region [4]. 
The O antigen of smooth LPS may mask some of the epi- 
topes and phage attachment sites in the core region. The 
chemical, serologic, and phage typing methods that have 
been used to define the different core types of E. coli are 
therefore not directly applicable to wild -type smooth strains. 
The frequency with which these different core types occur in 
wild -type E. coli is therefore not known. 
Little is known about the association between core types 
and O serotypes of E. coli, except that the original R I and R2 
rough mutants were both derived from 08 strains [ 1 ] and 
that the original R3 mutant was derived from an O 11 I strain 
[2]. There is no published evidence on the relationship of 
LPS core types to capsular types or to virulence. Information 
about the distribution of O and K antigens has proved to be 
useful, for example in identifying and understanding entero- 
pathogenic strains [5] and in suggesting novel therapeutic 
approaches to bacteremia [6]. Information about core types 
might be equally interesting. 
We therefore set out to produce a panel of mouse monoclo- 
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nal antibodies (MAbs) that would react with specific LPS 
core types of E. coli and other gram- negative bacilli with 
related core structures. We wished to use these MAbs as a 
means of determining the LPS core types of a collection of 
wild -type E. coli. 
Materials and Methods 
Bacteria and bacteriophages. E. coli R1 (F470), R2 (F576), 
R3 (F653), R4 (2513) and K12 (2131) and rough- specific 
phages FO, Br10, C21, 6SR, and T4 were obtained from G. 
Schmidt (Forschunginstitut, Borstel, Germany). E. coli O1, 02, 
04, 06, 012, 015, 018, and 075 were obtained from A. S. 
Cross (Walter Reed Army Institute, Washington, DC). Phages 
specific for E. coli capsular types K 1 (OK 1 GS) and K5 
(4K5DG) were obtained from A. P. Roberts (Charing Cross and 
Westminster Medical School, London). Blood culture and urine 
isolates were obtained from the Clinical Bacteriology Labora- 
tory, Department of Medical Microbiology, Edinburgh Univer- 
sity, from routine clinical specimens. The blood culture isolates 
were all of the gram- negative organisms isolated in a 1 -year pe- 
riod. Twenty -one fecal isolates of E. coli were obtained, each 
from a separate healthy volunteer. Rough mutants of Salmo- 
nella minnesota (R60), Salmonella lyphimurium (1 542), Kleb- 
siella pneuntoniae (M l OB), and Pseudomonas aeruginosa 
(PAC608) and wild -type smooth Shigella sonnei (colicin types 
4/2 and 2/1) and Shigella flexneri (serotypes 1 a and 3) were 
freeze -dried stock cultures held in our laboratory. 
MAbs. MAbs were produced by standard methods [7]. The 
details of immunization schedules and selection procedures are 
to be published elsewhere. All were reactive in ELISA with poly - 
myxin- complexed rough LPS [8]. All MAb preparations were 
supernatants of hybridoma cell cultures grown in RPMI 1640 
supplemented with 5% fetal calf serum. Antibody concentration 
was in the range of 10 -50 µg /mL. 
ELISA. Overnight nutrient broth cultures of bacteria were 
washed and resuspended in saline to give an OD of 0.5 at 525 
nm and heated for 30 min at 100 °C. Cells were then diluted 
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1/20 in coating buffer (sodium carbonate -bicarbonate, pH 9.6, 
with 0.05% sodium azide) and 100 µL /well was added to Nunc 
(Roskilde, Denmark) Polysorb strips. After overnight incuba- 
tion at room temperature, plates were washed three times with 
wash buffer (0.05% Tween 20 and 0.05% sodium azide in PBS, 
pH 7.4) and postcoated with 5% (wt /vol) bovine serum albumin 
(BSA) in coating buffer overnight at room temperature. Plates 
were then washed and stored at -20 °C. 
MAbs were diluted 1/250 in dilution buffer (4% [wt /vol] poly- 
ethylene glycol, 0.05% sodium azide, and 0.05% tween 20 in 
PBS, pH 7.4). Diluted MAb (100 µL) was added to wells and 
incubated for 90 min at 37 °C. Plates were washed three times, 
and urease- conjugated anti -mouse immunoglobulin (Zymed, 
Cambridge, UK; diluted 1 /500 in dilution buffer with 0.5% 
BSA, 100 AL /well) was added and incubated for a further 90 
min. Plates were then washed three times in wash buffer and 
three times in distilled water; urease substrate solution (Seralab, 
Crawley Down, UK; 100 tL /well) was added and plates were 
incubated for 90 min at room temperature and read at 590 nm. 
An OD of >0.8 was considered positive. 
PAGE and immunoblotting. LPS was prepared by proteinase 
K (protease type XI; Sigma, Poole, UK) digestion of lysed bacte- 
ria [9] and separated on 14% polyacrylamide gels [ 10] with SDS 
omitted from stacking and separating buffers. Gels were then 
silver stained [9] or blotted to nitrocellulose membrane (0.2 -Am 
pore size) [ 1 l ]. Blots were blocked with 3% (wt /vol) gelatin in 
TRIS- buffered saline, pH 7.5 (TBS), incubated for 3 h in a 1 /10 
dilution of MAb in 1% gelatin in TBS followed by a 1 -h incuba- 
tion with horseradish peroxidase anti -mouse IgG conjugate 
(ICN, High Wycombe, UK; diluted 1 /1000), and developed 
with horseradish peroxidase color reagent (Bio -Rad, Hemel 
Hempstead, UK). 
Serum sensitivity of bacteria. Serum from one donor was 
stored at -70 °C. This serum had IgG antibodies to LPS core at a 
level equal to the 65th centile of the normal population [8]. 
Overnight broth cultures were washed and resuspended in com- 
plement fixation test (CFT) buffer (Oxoid, Basingstoke, UK) at 
room temperature to an OD of 0.5 at 525 nm. This suspension 
was then diluted 1 /5000 in CFT buffer, and 10µL was added to 
70 µL of CFT buffer and 20 µL of freshly thawed serum or 
heated (56 °C, 30 min) serum. After 1 h at 37 °C, duplicate 20- 
µL samples were spread on the surface of nutrient agar plates, 
and colonies were counted after overnight incubation. If the 
number of colony-forming units in the fresh serum was <10% of 
the number in the heated serum, the organism was considered to 
be serum sensitive. 
0 typing. E. coli isolates from blood and urine cultures were 
screened for common O antigens, by ELISA with absorbed O 
typing sera (Difco, Detroit) to 01, 02, 04, 06, 07, 012, 015, 
018, 022, and 075 (diluted 1 /1000) and by tube agglutination 
at a final dilution of 1/80 with unabsorbed sera to 08 and 09 
(Statens Seruminstitut, Copenhagen). O types were confirmed 
by conventional tube agglutination [12]. 
Phage typing. Nutrient agar plates were surface inoculated 
by flooding with overnight broth culture and allowed to dry. 
Phage suspension (10µL) was dropped onto the agar and incu- 
bated overnight. A clear zone of lysis was scored as sensitive. 
Table 1. Reactivity of selected monoclonal antibodies (MAbs) in 
ELISA. 
Reactivity with E. coli strain 
MAb RI R2 R3 R4 K12 012 015 018 
SZ 43 3.4.8 + 
H4 361.23 - 
W4 434.07 - 
SZ 27 150.3 + 
NOTE. +, strong reactivity (OD >0.8); -, no or weak reactivity (OD 
<0.15). 
Statistics. All P values are two -tailed results calculated by 
Fisher's exact test. 
Results 
Selection of core -specific MAbs. A preselected panel of 
LPS- reactive MAbs was tested by ELISA against heat -killed 
E. coli rough strains R1, R2, R3, R4, and K12; E. coli 
smooth strains 01, 02, 04, 06, 012, 015, 018, and 075; 
and the rough mutants of K. pneumoniae, P. aeruginosa, S. 
minnesota, and S. typhimurium. MAbs that reacted with a 
restricted range of R types and also with some smooth strains 
of E. coli were thought likely to be useful in core typing 
wild -type smooth strains. Four such distinct patterns of reac- 
tivity were observed with more than one antibody. R 1 -spe- 
cific MAbs (e.g., SZ 43 3.4.8) reacted with R1 and with E. 
coli 01, 02, 04, 06, 018, and 075; R2- specific MAbs (e.g., 
H4 361.23) reacted with R2 and 012; R3- specific MAbs 
(e.g., W4 434.07) reacted with R3 and 015; cross -reactive 
MAb SZ 27 150.3 reacted with all the E. coli rough and 
smooth strains and with the Salmonella rough mutants but 
not with the Klebsiella or Pseudomonas rough mutants 
(table 1). 
Other patterns were observed, including a group of MAbs 
that reacted with R2 and K12, with R2 and the Salmonella 
rough mutants, or with all of these strains. However, no 
MAb reacted with K12 or R4 but not with other rough mu- 
tants. None of the MAbs used in this study reacted with the 
Klebsiella or Pseudomonas rough mutants tested. 
The specificity of MAbs for LPS core was confirmed, for 
the MAbs given as examples above, by immunoblotting 
against LPS (proteinase K extracts) from E. coli R1, R2, R3, 
R4, K12, 0 12, 0 15, and 01 8. The 0 12, 015, and 018 
strains were chosen as they seemed, from the ELISA data, to 
represent smooth strains with R2, R3, and R1 core types, 
respectively. As seen in figure 1, the immunoblots showed 
reactivity of each MAb with a band corresponding to the LPS 
core of each of the organisms with which it reacted in ELISA. 
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Figure 1. Proteinase K prepara- 
tions of LPS from E. coli. Lanes 1 -8: 
Strains R 1, R2, R3, R4, K12, 012, 
015, and 018. A: Silver stain; B -D, 
respectively: Immunoblots obtained 
with SZ 43 3.4.8 (R1- specific), H4 
361.23 (R2 specific), W4 434.07 
(R3 specific), and SZ 27 150.3 
(cross- reactive). 
7 8 
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With the rough mutants, a band was seen that corresponded 
to the single band seen in the silver stain. With the smooth 
strains, the R I and R3 MAbs again reacted with a single 
band corresponding to the fastest -moving band seen in the 
silver stain. This band consists of LPS core that has not been 
substituted with O antigen [ 13]. The R I antibody reacted in 
the same way in blots with the 01, 02, 04, 06, and 075 
strains (not shown). The R2- specific MAb H4 361.23 and 
the cross -reactive MAb SZ 27 150.3 reacted with the unsub- 
stituted core band and also with the "ladder" pattern of 
bands corresponding to 0- substituted LPS core. MAb SZ 27 
150.3 reacted weakly in the blot with bands in the R I and 
R4 LPS preparations that were not visible in the silver stain. 
We believe these bands represent production, due to a leaky 
mutation, of small quantities of 0- substituted LPS that are 
not detected by the silver stain but are detected by immuno- 
blot. 
Binding of anti -LPS core MAbs to gram- negative bacilli 
other than E. coli. Four Shigella strains were tested in 
ELISA, and all reacted with the cross -reactive MAb. In addi- 
tion, both S. sonnei strains reacted with the R I -specific MAID, 
while the S. flexneri strains reacted with the R3- specific 
MAb. This is in agreement with previous studies of LPS core 
in these species [14 -16]. Blood culture isolates of other 
gram- negative genera (Acinetobacter, 7; Citrobacter, 5; En- 
terobacter, 1 8; Klebsiella, 14; Proteus, 9; Providencia, 1; Pseu- 
domonas, 8; Salmonella, 2; and Serratia, 5) were also tested 
5 6 7 8 
1 2 3 4 5 6 7 8 
in ELISA with the core type- specific and cross -reactive 
MAbs. The only positive reaction observed was between the 
two Salmonella isolates and the cross -reactive MAb. The 
cross -reactive MAb SZ 27 150.3 was tested in an immuno- 
blot against LPS (proteinase K extracts) from single blood 
culture isolates of K. pneumoniae, Proteus mirabilis, P. aeru- 
ginosa, Enterobacter cloacae, and Citrobacter freundii. No re- 
action was observed with any of these isolates, confirming 
the lack of reactivity seen in ELISA. 
Frequency of MAb -defined core types in wild -type isolates of 
E. coli. E. coli isolates from blood cultures (n = 79), urine 
cultures (n = 80), and fecal specimens from asymptomatic 
volunteers (n = 21) were tested in ELISA with core type - 
specific and cross -reactive MAbs. The cross -reactive MAb 
reacted with all of the isolates tested except for two of the 
urine isolates. When the strains reacting with the cross -reac- 
tive MAb were tested with the R 1 -, R2 -, and R3- specific 
MAbs, each MAID reacted with a mutually exclusive group of 
isolates, which were classified as R 1, R2, and R3, respec- 
tively. Figure 2 illustrates these results for the fecal isolates. 
Of the two urine isolates that did not react with the cross - 
reactive antibody, one reacted with the R 1 antibody. These 
and the isolates that did not react with any of the core- speci- 
fic antibodies are referred to as RNC (not classified). The 
numbers of wild -type isolates in the four categories are given 
in table 2. R 1 was the most common classification overall 
(123/181, 68 %) and was more common among isolates from 
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urine (62/80, 78 %) than among those from blood culture 
(48/79, 61 %, P = .017) or feces (11/21, 52%, P = .030). 
Those MAbs that had reacted with R2, K12, and Salmo- 
nella rough mutants reacted with all of the R2 group of wild - 
type isolates but also reacted with variable numbers of the 
RNC isolates. This showed that the RNC group was heteroge- 
neous but did not permit clear subdivision of this group. 
Relationship between MAb -defined core type and sensitivity 
Table 2. Frequency of core types in wild -type isolates of E. coli 
determined by binding of core -type- specific monoclonal antibod- 
ies (MAbs) in ELISA. 
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Figure 2. Reactivity (ELISA optical den- 
sity) of antibodies with 21 fecal E. coli show- 
ing mutually exclusive reactions. Shading in- 
dicates core type to which each strain was 
assigned. 
to rough- specific and K- specific phages (table 3). The collec- 
tion of wild -type E. coli was tested for sensitivity to the 
rough- specific phages that have been used to distinguish be- 
tween the different R types of E. coli [3], since it was thought 
that the pattern of reactivity might support the MAb- defined 
R typing scheme. Fifty of the 180 isolates tested were sensi- 
tive to one or more of the rough- specific phages. They were 
found among each of the R types defined with MAbs. They 
included isolates that were O typeable and produced a ladder 
Table 3. Sensitivity of 180 E. coli of different core types to rough - 
specific, K1- specific, and K5- specific phages. 
No. ( %) of strains assigned to MAb -defined No. of strains sensitive to phage 
core type Core type 
(n) FO Br10 C21 6SR T4 Any R+ Kl K5 
RNC Total 
Rl (123) 0 8 17 5 28 40 19 20 
13 (16) 79 R2 (l4) 0 2 0 I 3 3 0 1 
8 (10) 80 R3 (18) 0 0 0 0 2 2 0 1 
4 (19) 21 RNC (25) 0 3 2 2 3 5 3 2 
25 (14) 180 Total (180) 0 13 19 8 36 50 22 24 
Source RI R2 R3 
Blood culture 48 (61) 6 (7) 12 (15) 
Urine 64 (81) 4 (5) 4 (5) 
Feces 11 (52) 4 (19) 2 (10) 
Total 123 (68) 14 (8) 18 (10) 
NOTE. NC, not classified. NOTE. Any R +, any rough- specific phage; NC, not classified. 
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Table 4. 0 type of E. coli of different core types from blood and 
urine cultures. 
No. of each core type associated with O type 
Core type 
(n) 01 02 04 05 06 07 08 015 018 075 NT 
RI (112) II 0 6 I 26 3 3 0 10 6 46 
R2(I0) 0 0 0 0 0 0 0 0 0 3 7 
R3 ( I6) 0 0 0 0 0 0 0 3 0 0 13 
RNC (21) 1 2 0 0 0 2 0 0 0 0 16 
Total (159) 12 2 6 I 26 5 3 3 10 9 82 
NOTE. NT, not typed by available 0- specific sera; NC, not classified. 
pattern on silver stain of LPS, as was found by Cross et al. 
[6]. C21 sensitivity, a marker for the R 1 rough mutant, was 
found in 19 isolates (17 R1 and 2 RNC). FO sensitivity is a 
marker for R2 rough mutants, but no isolate was FO sensi- 
tive. There was no other discernible relationship between R 
type and sensitivity to particular rough- specific phages. 
Forty -six of the 180 isolates were sensitive to one of the 
two K- specific phages. The R 1 isolates accounted for 19 of 
the 22 K1 isolates and 20 of the 24 K5 isolates found. 
Relationship between MAb- defined core type and O type 
among the urine and blood culture isolates. The urine and 
blood culture isolates of E. coli were tested for 12 0 types 
found commonly among E. coli from blood culture [6, 12] or 
urinary tract infection [ 17] (table 4). The overall proportion 
of isolates that belonged to one of these O types was much 
higher among those of R1 core type (66/112, 58 %) than 
among the other core types (11/47, 23 %, P = .0005). Some 
constant associations between O type and core type were 
apparent: all 26 06 isolates were R1, and all 3 015 isolates 
were R3. In contrast, 075 isolates were found among both 
the R 1 and the R2 core types. The proportion of the R 1 
isolates that belonged to one of the common O types was 
greater among the blood culture isolates (32/48, 67 %) than 
among the urine culture isolates (34/64, 53 %). This differ- 
ence is not statistically significant (P = .177), but the num- 
ber of R l isolates not belonging to the common O types 
could account for the greater proportion of R 1 isolates 
among the isolates from urine. 
Relationship between R type, serum resistance, and LPS 
chemotype among blood culture isolates. Serum resistance, 
which is a property of most invasive strains of E. coli [6], was 
determined for all the blood culture isolates; 21 (26 %) of 79 
were serum sensitive. There were serum -sensitive isolates of 
all the core types, but serum sensitivity was slightly less com- 
mon among the R 1 isolates (9/48, 19 %) than among the 
other R types (10/31, 32 %). This difference may have been 
due to the association of R 1 core with K l and K5 capsule, 
since all of the 11 K1 isolates and all but 1 of the 10 K5 
isolates from blood cultures were serum resistant. 
Seventy of the 79 blood culture isolates produced a typical 
ladder pattern of LPS in silver stains of proteinase K digests 
(data not shown). The other 9 showed only one or a few 
fast -moving bands, one corresponding to the unsubstituted 
core. Three isolates were R 1, 3 were R2, 2 were R3, and I 
was RNC. 
Discussion 
We have described a group of MAbs that are selective for 
the LPS core of E. coli. Some of the MAbs also bind to Salmo- 
nella and Shigella strains that share E. coli core structures. 
The MAbs do not bind to a range of other gram- negative 
bacilli, confirming that the binding observed was specific. 
We have shown that the binding of these antibodies in 
ELISA to bacterial cells heated at 100 °C corresponds to 
their binding to unsubstituted (and in some cases 0- substi- 
tuted) LPS core in immunoblots. 
Unsubstituted LPS core is present in smooth bacterial cells 
but may not be readily accessible to MAbs in standard labora- 
tory cultures [ 18, 19]. Core epitopes are, however, much 
more accessible on bacterial cells grown in serum or in a 
magnesium -depleted medium, which is thought to mimic the 
conditions in the infected host [20]. Core epitopes also be- 
come more accessible in bacterial preparations heated at 
100 °C [21, 22]. The expression and accessibility of core epi- 
topes and the possible existence of cross -reactive epitopes 
have important implications for immunotherapy of gram - 
negative sepsis [23]. 
We have examined the binding of selected MAbs to 
heated bacterial cells in ELISA. We could recognize three 
mutually exclusive groups among E. coli isolates and labeled 
them R1, R2, and R3 after the corresponding rough mu- 
tants. A fourth group, which could not be assigned to a partic- 
ular core type, was referred to as RNC and is probably of 
heterogeneous core type. We included in the RNC group the 
strain that reacted with the R 1- specific antibody but not with 
the cross -reactive MAb. If this strain had been of R 1 core 
type, a reaction with the cross -reactive MAb would have 
been expected. 
We anticipate that each of the groups R1, R2, and R3 
defined with MAbs probably has the core structure of the 
named rough strain, though this has not been confirmed by 
chemical analysis. The presence of C21 sensitivity (a marker 
for R1 rough mutants) among the wild -type isolates of MAb - 
defined R 1 rather than R2 or R3 core type supports our view 
that the MAb- defined core types are the same as the refer- 
ence rough strains. Two RNC isolates were also C2I sensi- 
tive, but the specificity of these phages for particular core 
types is not based on an independent knowledge of their 
receptor sites, and it is not known how they might react with 
as -yet- unidentified core types of E. coli. Phage typing is of 
little value in determining the core type of wild -type isolates 
since most are resistant to all of the phages used. 
No isolates of R4 or K 1 2 core type were positively identi- 
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fled. This may be explained by the lack of suitable specific 
MAbs. We did have MAbs reactive with K12, but these also 
reacted with R2 and did not bind to a clearly defined group 
of wild -type isolates other than those that reacted with the 
R2- specific MAbs. The RNC group may include isolates 
with R4 or K12 core but probably also contains one or more 
as -yet- unidentified core types. 
Comparison of the structural formulas [ 15] with the speci- 
ficities of our MAbs could suggest binding of the MAbs to 
particular sugar residues. R 1 and R3 each have a unique 
terminal branching hexosyl unit (ßl -3- linked glucose and 
al -3- linked N- acetylglucosamine, respectively) that may be 
the epitope for the R1 and R3 antibodies. R2 and Salmonella 
core share a terminal al -2- linked N- acetylglucosamine, 
while R2 and K 12 have in common the next three sugar 
residues. These may therefore be the epitopes for the MAbs 
that bound to these combinations of strains. A unique bind- 
ing site for the R2- specific antibody is not obvious from the 
structural formulas. From the calculated three -dimensional 
structure of the different core types [24], however, it appears 
that the branch -terminating a 1 -6 galactose present in R2, 
Salmonella core, and K12 may be in a different orientation 
in R2 and may therefore be the R2- specific epitope. It is of 
note that while most of the core -specific MAbs reacted in 
immunoblot only with unsubstituted core, the R2- specific 
MAb also reacted with 0-substituted core, giving a ladder 
pattern in immunoblots. This implies that the R2- specific 
epitope is the only one not altered or masked by the attach- 
ment of the O polysaccharide. Further study of the binding 
site of these antibodies may therefore be useful in elucidating 
the three -dimensional structure of LPS core and in attempts 
to define the attachment site of the O polysaccharide. 
The binding of the cross- reactive MAb SZ 27 150.3 to 
almost all of the E. coli isolates and to the Salmonella and 
Shigella strains, together with the pattern of binding of the 
core -specific MAbs, supports the view that these organisms 
share closely related LPS cores. The lack of binding of any of 
the antibodies to other genera suggests that these core struc- 
tures are not distributed more widely. The structure of LPS 
core has not been determined for all the other genera, but it 
has been shown that the LPS cores of Citrobacter [25, 26] 
Proteus [27], and Pseudomonas [28] species are different 
from that of E. coli. 
A MAb designated T6, which recognized the R2 core ofE. 
coli and the core of Salmonella species, did not react with 25 
clinical isolates of E. coli in Hong Kong [29], suggesting that 
the R2 core type was rare. We have found, however, that R2 
accounted for 8% of our collection of E. coli isolates. This 
suggests that attempts to use MAb T6 in a capture ELISA 
[22] to detect Salmonella organisms in clinical samples may 
yield a significant number of false -positives because of the 
presence of E. coli of R2 core type. 
The tendency for certain apparently distinct properties of 
E. coli to occur together [5] seems to apply to the relationship 
between core types and O and K types. It may be that there 
are chemical or structural factors limiting the ability ofE. coli 
to express certain combinations of O and core types (e.g., 
015 and R 1) or it may be that some such combinations have 
a selective advantage in the host. The finding that there was 
greater proportion of RI core type among the urine isolates 
and in particular that there was a greater proportion of R I 
isolates not belonging to one of the common O types may 
indicate some relationship between R 1 core type and un- 
usual O types and pathogenicity in the urinary tract. Further 
studies are needed before firm conclusions can be drawn on 
this point. 
Core typing with MAbs may be a useful addition to 
current typing methods for E. coli. The number of possible 
types is small, and the core type does not usually discrimi- 
nate among strains of a given O and K type, but core typing 
may be useful in recognizing relatedness between groups of 
E. coli. We hope to use these antibodies to investigate the 
LPS core type of a wider range of Shigella and E. coli isolates 
from a variety of sources. 
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REVIEWS IN MEDICAL MICROBIOLOGY 
The role of bacteria in sepsis syndrome 
A.P. Gibb 
Department of Medical Microbiology, The University of Edinburgh Medical School, 
Teviot Place, Edinburgh EH8 9AG, UK 
Summary. The name `sepsis syndrome' has been suggested for a precisely defined severe 
generalized illness in which underlying infection is suspected. Endotoxin is thought to play a key 
part in its pathogenesis. The syndrome has a high mortality despite antibiotics and intensive care. A 
range of new therapies aimed at endotoxin, and the cytokines which it induces, is being developed 
and tested. Among patients with sepsis syndrome the group with bacteraemia do not have a worse 
outcome, probably because this is the group which obtains most benefit from antibiotics. 
Anti -endotoxin antibody treatments tested so far seem to be of benefit mainly or exclusively to 
those patients with Gram -negative bacteraemia, implying that the role of endotoxin is greatest in 
these patients. Protein toxins and peptidoglycan fragments could produce the features of sepsis 
syndrome in some patients, but this possibility has not been explored because there are no suitable 
a substantial number of patients neither endotoxin nor bacterial infection can be shown 
to be involved in the pathogenesis of sepsis syndrome. 
Introduction 
Clinical definitions 
The term `sepsis syndrome' has been used1 -3 to 
describe a condition of fever or hypothermia asso- 
ciated with tachypnoea, tachycardia and evidence of 
inadequate tissue perfusion in a patient with clinical 
evidence of infection. `Septic shock' is used to refer to 
a more severely ill group of patients who, in addition 
to the features noted above, have signs of shock. 
These definitions could apply to a very wide range of 
patients, but are usually applied to patients in 
intensive care units in developed countries. Most 
such patients are suffering primarily from trauma, or 
from intra- abdominal infection which has not been 
eradicated surgically. Classical infectious diseases 
which might produce similar clinical effects (and 
which might share similar underlying mechanisms of 
pathogenesis) are excluded, either explicitly (in the 
case of tuberculosis4), or implicitly because of the 
clinical setting in which this term is applied. 
The definition of sepsis syndrome is by no means 
standardized. Terms such as septicaemia,5.6 systemic 
sepsis' and sepsiss9 have been used to describe the 
condition in broadly similar groups of patients. 
Others have used `sepsis' applied only to those 
patients with pus10 or microbiological evidence of 
infection .8'11 The argument is far from settled.8.'2 
The fundamental problem with this example of 
clinical taxonomy, as in some areas of microbiological 
taxonomy, is that definitions have been based on 
empirical observations and not supported by a com- 
plete understanding of the underlying processes. 
Sepsis syndrome certainly includes many patients 
with classical Gram -negative sepsis13 but also 
includes patients with a similar clinical presentation 
in whom bacterial infection is not the apparent cause. 
Despite its difficulties and necessarily arbitrary 
nature, classification of patients based on features 
which can be determined quickly and easily is neces- 
sary in sepsis syndrome if rapid therapeutic action is 
to be taken. Until recently, treatment of these 
patients has consisted of surgery, physiological 
support and antibiotics. Antibiotic treatment is often 
given to patients in whom infection is not subsequen- 
tly confirmed microbiologically, but this is accepted 
because of the expected benefit from antibiotics in 
patients with Gram -negative bacteraemia,'4.15 
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Table Organisms isolated from blood cultures from 223 
patients with sepsis syndrome' 












Other Gram -positive spp. 
Candida spp. 














sais in or on intensive care patients (Table). These 
patients are often colonized by organisms such as 
Pseudomonas, which are uncommon in healthy indi- 
viduals, and are often colonized in sites such as the 
upper respiratory tract by organisms normally restric- 
ted to the colon.18 These organisms may go on to 
cause infection, but it is not possible to conclude that 
they are acting as pathogens simply because they have 
been isolated from a sick patient. It is necessary to 
consider whether the organism has invaded a 
normally sterile site, or whether bacterial products 
(notably endotoxin) may be having deleterious 
effects without invasion. 
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coupled with the time required to make a definite 
microbiological diagnosis and the lack of evidence 
that antibiotics could be harmful. When new treat- 
ments aimed at controlling the deleterious aspects of 
the host response are ? 9 1' '16'17 it is necessary to 
review their effect on all patients who would receive 
such treatments. Many more such treatments aimed 
at different aspects of the host response are being 
developed,3 and will also need to be tested in this 
way. The concepts of sepsis syndrome and septic 
shock are therefore set to remain with us, despite 
their limitations. 
Aims of this review _ 
My purpose in this article is to review the role of 
bacteria in sepsis syndrome and septic shock. I have 
used the term `sepsis syndrome' to refer to the 
generalized illness outlined above. Because no 
standard definition is in use, it is inevitable that the 
meaning of the term will vary according to the study 
under discussion. I have also used the term `septic 
shock' to refer to the more severely ill group of 
patients who have developed shock, but again the 
definition is not standardized. Following the sug- 
gestion of Bone,' I have not used the term 'septicae- 
mia' because of the confusion over its meaning. As 
well as series of patients with sepsis syndrome, I have 
drawn on series of patients who have been selected 
because they have bacteraemia. The nature of the 
clinical illness in these patients is even more variable, 
and is not always clearly defined. These differences 
create real problems and uncertainties in analysis of 
the data, but until a large body of data using standard 
case -definitions is produced these problems are una- 
voidable. 
Interpretation of bacteriological results 
The organisms generally thought to be involved in 
sepsis syndrome may all be found living as commen- 
Bacteraemia is the most easily interpreted bacteriolo- 
gical finding in sepsis syndrome patients. Blood can 
be sampled easily and aseptically in every patient, 
and any organisms cultured from the blood have 
clearly invaded the host, though the problem of 
contamination of specimens must always be remem- 
bered. The only other similar specimen is cerebrospi- 
nal fluid (CSF), which is unlikely to be invaded in 
most patients with sepsis syndrome. 
In some patients there may be organisms from 
other sites, such as abscess cavities or the perito- 
neum, which can be regarded as clear evidence of 
invasion. Cases where such isolates are made are 
relatively few, however. These cases are not easily 
comparable with one another and are therefore 
difficult to analyse in large series of patients with 
sepsis syndrome. In the case of peritonitis there is also 
the potential for confusion between faecal contamin- 
ation from the initial perforation and the organisms 
which go on to cause infection. 19 Infection at other 
sites, notably the respiratory tract, undoubtedly 
occurs in intensive care patients and is associated with 
high mortality, but diagnosis is very imprecise, and 
has not been related to the aetiology of sepsis 
syndrome .2" 
Attention has therefore focussed on bacteraemia 
as the most readily understood way of documenting 
infection in these patients. This does not mean that 
bacteria must be in the blood to cause sepsis 
syndrome; it is simply more difficult to be sure of the 
role of organisms from other sites. 
Endotoxaemia 
As well as detecting whole bacteria, it may be 
possible to infer microbial involvement in an illness 
by detecting bacterial toxins, notably endotoxin, in 
the blood. Endotoxin is certainly capable of produc- 
ing the features of sepsis syndrome, and a great deal 
of research has focussed on this area.3,21.22 Endotoxin 
assays based on Limulus amoebocyte lysate (LAL) 
were originally developed as a way of detecting 
rapidly the presence of Gram -negative bacteria, and 
positive results in the absence of bacteria were 
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initially regarded as false- positives.23 More recently it 
has been noted that endotoxaemia is an independent 
prognostic indicator, and indeed a better indicator for 
the development of shocks or death24 than bacterae- 
mia. Endotoxin may be absorbed from the gut25 
rather than being derived from organisms in the 
blood or other sites of infection. Endotoxaemia is 
therefore not necessarily evidence of bacterial 
infection. 
Antibody response as evidence of infection 
Another general approach to the diagnosis of infec- 
tion is to show a rising titre of antibody to the 
infecting organism. This approach is complicated in 
sepsis syndrome. The organisms involved form part 
of the normal commensal flora, and therefore many 
patients have high levels of antibody prior to the 
septic episode. High levels of pre- existing antibody 
do not confer complete immunity, but are associated 
with a good outcome in Gram -negative bacterae- 
mia.26 Many patients die before a detectable antibody 
response would be expected. Looking for a rising 
antibody titre has been found to be of no value in 
diagnosis of Escherichia coli bacteraemia.27 
Bacterial invasion in sepsis syndrome 
There have been four major prospective studies 
of patients with clinically defined sepsis 
syndrome .' 1.17.28 and one of septic shock.24 Studies 
of sub -groups of three of the sepsis syndrome series 
have been published separately, duplicating some of 
the data.47.29 Two other studies' 6'3() were prospective 
in design but appear to have included Gram -negative 
bacteraemia as one of the possible entry criteria and 
cannot therefore be used to determine the frequency 
of bacteraemia in sepsis syndrome. 
Bacteraemia 
In prospective series of sepsis syndrome patients, 
bacteraemia was found in 40-47 %17.28 and Gram - 
negative bacteraemia was found in 21 -37 %.9.11.17.28 
In the prospective study of septic shock, 39% had 
bacteraemia, and 19% had Gram -negative bacterae- 
mia.24 Full detail of the blood culturing protocol is not 
given in any of these studies, and there may be false 
negatives in some series if inadequate volumes of 
blood were cultured before antibiotics were given.3' 
Bacteraemia (Gram -positive or Gram- negative) was 
associated with the development of septic shock in 
one series of febrile patients5 and in one series of 
sepsis syndrome patients,4 but not in the other series. 
Bacteraemia was not associated with a worse out- 
come in any of these series. 
Since bacteraemia is not associated with a worse 
outcome in sepsis syndrome, one is forced to question 
its significance. Studies of patients with bacteraemia, 
particularly Gram -negative bacteraemia, have shown 
high mortality rates,'5'32 but the bacteraemia in these 
patients might just be an epiphenomenon, with the 
real harm coming from gut- derived endotoxin or 
some other stimulus to the cytokine release. What 
evidence is there that bacterial invasion is harmful? 
Evidence that bacterial invasion is harmful 
There is evidence derived from clinical studies of the 
effect of antibiotics to support the idea that bacterial 
invasion is harmful. Since the demonstration that 
early antibiotic treatment led to greatly reduced 
mortality in Pseudomonas bacteraemia,14 antibiotics 
have been used empirically for patients in whom 
bacteraemia is suspected. It would be considered 
unethical now to withhold antibiotics as part of a 
double -blind study to show their benefit, and there- 
fore such definitive studies have not been done. More 
oblique approaches have been used, however, includ- 
ing comparisons of different antibiotic regimes and 
retrospective studies of the outcomes of individual 
patients. 
Comparison of antibiotic regimens 
Large studies in febrile neutropenic patients have 
compared different empirical antibiotic regimens'3'33 
and have shown differences between outcome for the 
different regimens. These studies have also shown 
that in -vitro sensitivity tests on blood- culture isolates 
are good predictors of the effectiveness of treatment 
regimens. This implies that the differences in out- 
come observed are due to the antibiotic action of the 
drugs, and therefore that the living bacteria detected 
in the blood were important. However, in these 
patients, unlike sepsis syndrome patients, bacterae- 
mia itself is a predictor of a worse outcome.33 This 
difference is probably related to the much lower 
clinical threshold for admission of these patients to 
trials. These results therefore confirm that bacterae- 
mia can be a cause of illness, but they are not 
necessarily applicable to sepsis syndrome patients in 
whom other more powerful insults may be respon- 
sible for the illness observed. 
Retrospective series of bacteraemic patients 
Retrospective studies have looked at the difference in 
outcome for patients treated with appropriate anti- 
biotics (antibiotics to which the isolated organism was 
sensitive) and those treated with inappropriate anti- 
biotics (to which the organism was not sensitive). 
Significantly lower mortality rates in patients receiv- 
ing appropriate antibiotics were found in three large 
series of bacteraemic patients'53234 and in several 
smaller series of patients bacteraemic with individual 
organisms such as Enterobacter, 35 Klebsiella, 36, E. 
coli37 and enterococci.38 The clinical state of these 
patients was not defined, however, so that, as in the 
comparative studies above, they would not all have 
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had `sepsis syndrome'. The relationship between 
appropriate antibiotic and outcome has been con- 
sidered in one small study of sepsis syndrome 
patients,39 which confirmed that inappropriate anti- 
biotics were associated with a significantly worse 
outcome. Delay in introduction of the appropriate 
antibiotic was also associated with a significant 
increase in hospital stay and with the development of 
acute organ failure, though not with increased morta- 
lity. This study considered appropriateness in rela- 
tion to `the cultured pathogen', which presumably 
means isolates from abscesses and other sites as well 
as blood cultures, but nevertheless supports the view 
that antibiotics can be effective in sepsis syndrome 
patients, and therefore that invading organisms, such 
as blood -culture isolates, are important. 
Do antibiotics completely neutralize the deleterious 
effect of bacterial invasion? 
The apparent effectiveness of antibiotic treatment 
offers an explanation for the failure to observe a 
worse outcome in sepsis syndrome patients who have 
bacteraemia. Among sepsis syndrome patients, 90.5- 
98 %9.11.16 of those with Gram -negative bacteraemia, 
or 86-91% of all patients with significant positive 
cultures,739 received appropriate therapy. The lack 
of difference between bacteraemic and non- bacterae- 
mic patients with sepsis syndrome could therefore be 
because the deleterious effect of bacteraemia is 
largely neutralized by effective antibiotics. 
There does, however, seem to be room for further 
improvement in the outcome of sepsis syndrome 
patients, despite adéquate antibiotics. Ziegler et al9 
showed that the human monoclonal IgM antibody 
HA-1A reduced the mortality rate from 49% to 30% 
in patients with sepsis syndrome who had Gram - 
negative bacteraemia, although the mortality rate 
rose from 40% to 45 %40 in those patients who did not 
have Gram -negative bacteraemia. The benefit was 
greatest in patients who had Gram -negative bacterae- 
mia and shock. No benefit was reported in the group 
of patients who had Gram -negative infection (defined 
by culture from the site of infection) but no bacterae- 
mia. There is some doubt about how exactly HA-1A 
might work,4142 but the demonstration that it is only 
active in patients with Gram- negative bacteraemia 
suggests that these patients are different in an impor- 
tant respect from other sepsis syndrome patients. 
This is true even after the beneficial effect of anti- 
biotics has been taken into account. 
Slightly different results have been obtained in 
studies with two other antibody treatments' 1.16 in 
patients with sepsis syndrome, both of which showed 
benefit in patients with Gram -negative infection. 
Most of these patients had bacteraemia, but a propor- 
tion ranging from 10 %16 to 46 %" had infection 
defined only by isolates from the site of infection. The 
patients with non -bacteraemic Gram -negative infec- 
tion appeared to benefit from the antibodies used in 
these studies, although the results do not reach 
statistical significance for the non -bacteraemic sub- 
group because of the small numbers involved. In the 
first of these studies,16 using polyclonal human anti -J5 
serum, patients with Gram -negative infection con- 
firmed by isolates from specimens other than blood 
were only included in the analysis if the negative 
blood culture could be `explained' by the fact that 
appropriate antibiotics were given before blood cul- 
tures were taken. Other patients who did not have 
Gram -negative bacteraemia were excluded from the 
analysis, and presumably did not benefit. In the 
second study, using the murine monoclonal IgM 
anti -endotoxin antibody E5," patients with Gram - 
negative infection, whether bacteraemic or not, 
appeared to benefit from antibody treatment if they 
were not in septic shock. The relationship between 
negative blood -cultures and prior antibiotic treat- 
ment is not discussed in this study. No benefit was 
found in the patients without Gram -negative infec- 
tion in the E5 study. 
The role of shock in these studies is interesting. 
Both of the studies by the Ziegler group9,16 showed 
greatest benefit from antibody treatment in patients 
with shock, consistent with the idea that the antibody 
is neutralizing endotoxin and therefore favouring 
reversal of shock. In contrast, the E5 study' found no 
benefit in shock patients. These differences may be 
explained by differences in the action of the anti- 
bodies, or by differences in the exact definitions of 
shock, or by other unrecognised differences in the 
types of patient studied. 
The conclusions of these studies also differ in 
respect to the non -bacteraemic patients, as discussed 
above, but they share some conclusions that are 
relevant to this review. They all show that there is 
potential for improved outcome in sepsis syndrome 
patients with Gram -negative infection in addition to 
what is achieved by appropriate antibiotics and other 
conventional therapies. They also support the idea 
that there are important differences between sepsis 
syndrome patients with bacterial infection and those 
without. Other studies that show no benefit from 
antibody treatment3° do not detract from these 
conclusions. 
Endotoxaemia in sepsis syndrome 
It is remarkable, in view of the central role which 
endotoxin is thought to play in sepsis syndrome,3 how 
few of the large studies of sepsis syndrome have 
reported the results of endotoxin assays. This is a 
reflection of the major practical difficulties in actually 
performing the assays,43 particularly in the multi -cen- 
tre type of studies which have been required to collect 
large numbers of sepsis syndrome patients. Danner et 
aí24 measured endotoxaemia in septic shock and 
showed that it was associated with a poorer prog- 
nosis. They also found that 57 of 100 patients with 
septic shock did not have endotoxaemia, despite 
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performing an average of 9.6 endotoxin assays per 
patient. Either the assays were missing transient 
episodes of endotoxaemia, or some other mechanism 
is involved in these patients. This implies that endo- 
toxaemia cannot be confidently regarded as the sine 
qua non of septic shock. 
Antibiotics and endotoxin release 
The finding that antibiotics are of benefit in bacterae- 
mia runs contrary to the suggestion that antibiotic 
treatment might lead to release of endotoxin and 
therefore to worsening of clinical progress.44 The 
evidence that significant endotoxin release happens 
in vivo, however, is weak. 
Experiments in rabbits have shown an increase in 
the ratio of endotoxin to bacteria in the blood 
following therapy with moxalactam45 or gentami- 
cin.44 In these experiments bacteraemia was induced 
by injecting 20 ml of overnight broth culture of E. 
coli, with mucin, into the peritoneum. The reported 
rise in endotoxin:bacteria ratio in the treated animals 
can be explained largely by the fact that antibiotic 
caused a reduction in the number of viable bacteria in 
the blood, rather than any marked difference in the 
amount of endotoxin in the blood. The endotoxin 
level did continue to rise after antibiotic treatment, 
but was no greater in the treated animals than in the 
controls. Endotoxin may well have continued to be 
absorbed from the very large inoculum (109 -101) 
c.f.u.) in the peritoneum. 
In humans, it has been clearly shown in meningo- 
coccal infection that endotoxin levels in the blood 
decline consistently and rapidly following the intro- 
duction of antibiotic therapy.46 Rising levels of 
endotoxaemia have been observed during the first 
few hours of antibiotic therapy in some patients with 
septic shock24 or Gram -negative bacteraemia,47 but 
these rising levels have not been consistently asso- 
ciated with poor outcome. 
How does bacterial invasion lead to disease? 
The triggering of cytokine release by endotoxin 
derived from the invading organisms is the best - 
known mechanism by which bacterial invasion may 
lead to clinical sepsis syndrome,; but is only relevant 
to Gram -negative infections. 
Endotoxin in the blood is not necessarily derived 
from invading bacteria, but may in many cases be 
absorbed or `translocated' from the gut.25 This is 
presumably the mechanism which leads to endotox- 
aemia in Gram -positive infection,5.47 but begs the 
question of how bacterial invasion leads to endotoxin 
translocation. Mechanisms other than the effects of 
endotoxin must be involved in sepsis caused by 
Gram -positive infection, and may well be involved in 
Gram -negative infections. 
A group of protein toxins produced by Staphylo- 
coccus aureus, Streptococcus pyogenes and some 
other organisms are now recognized as `super 
antigens' which can stimulate T -cells via the Vp 
element of the T -cell receptor.4x This stimulation 
triggers release of tumour necrosis factor (TNF) and 
interleukin -1 (IL -1), and can produce systemic illness 
in animal models. Toxic shock syndrome is a well - 
recognized manifestation of this effect in humans and 
would, in many cases satisfy the clinical criteria for 
sepsis syndrome. 
Other bacterial components are able to induce the 
features of sepsis syndrome, though with relatively 
low specific activity. Cell walls of Gram -positive 
bacteria are pyrogenic,49 and low molecular weight 
peptidoglycan is probably the active component. 
Muramyl dipeptide (MDP) is a synthetic molecule 
which appears to be the minimum structure required 
to mimic the effect of low- molecular- weight peptido- 
glycan, and its activity has been studied in some 
detail.50 MDP induced the production of endogenous 
pyrogen (IL -1) from rabbit white blood cells or 
human mononuclear cells in vitro. The action of 
MDP did not appear to be due to endotoxin con- 
tamination of the material, since LAL assays were 
negative, and cross -tolerance experiments suggest 
that the mechanism of action of MDP is different 
from that of endotoxin. 
Neither ̀ super antigen' protein toxins nor peptido- 
glycan fragments can be readily detected in clinical 
samples. The importance of these factors in sepsis 
syndrome has therefore not been explored, but this 
does not mean that they are unimportant. 
Conclusions 
There is no doubt that live bacteria and bacterial 
products, particularly endotoxin, can be, and some- 
times are, responsible for the features of sepsis 
syndrome. What is much less clear is the relative 
importance of live bacteria, endotoxin and other 
bacterial products in these patients. To answer the 
fundamental questions, and to guide the wide range 
of new therapies being developed, we need methods 
as sensitive as LAL to recognize other microbial 
products and methods to recognize bacteraemia more 
quickly. Equally important is the identification of 
non -microbial causes of sepsis syndrome, together 
with rapid methods to recognize them. 
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